Non-naturally occurring melanocortin analogs with various lactam cyclization types and associated uses

Abstract

The present technology comprises non-naturally occurring melanocortin analogs or pharmaceutically acceptable salts, solvates, or stereoisomers thereof and compositions comprising the same. The non-naturally occurring melanocortin analogs may exhibit (i) full MC4R antagonism and full, partial, or no MC3R agonism; (ii) partial MC4R antagonism and no MC3R activity; or (iii) full MC4R agonism and full MC3R antagonism with sub-micromolar or low-nanomolar binding activity.

Description

Docket No.: 183B-416027-WO NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH VARIOUS LACTAM CYCLIZATION TYPES AND ASSOCIATED USES CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 683,671, filed August 15, 2024; U.S. Provisional Patent Application No.63 / 683,676, filed August 15, 2024; and U.S. Provisional Patent Application No.63 / 683,679, filed August 15, 2024, all of which are incorporated herein by reference in their entirety. INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0002] This application contains an ST.26 compliant Sequence Listing, which is submitted concurrently in xml format and is hereby incorporated by reference in its entirety. The .xml copy, created on August 14, 2025 is titled “183B-416027-WO_SL.xml” and is 3,027,185 bytes in size. BACKGROUND

[0003] Melanocortins are a group of small peptides that bind to a family of five known melanocortin receptors (MC1R through MC5R). They are derived from a common precursor protein, pro-opiomelanocortin (POMC), which is expressed in the neurons of the central and peripheral nervous system, and in the pituitary gland. The proteolytic cleavage of POMC results in α-, β- and γ-melanocortin and adrenocorticotrophic hormone (ACTH), in addition to several other biologically important peptides.

[0004] Melanocortin analogs have been synthesized for the potential regulation and treatment of many conditions, including weight regulation (e.g., obesity, anorexia, and cachexia), hormonal secretion, and hyposecretion of many exocrine glands. However, in regulating these physiological effects, melanocortin analogs have also been shown to cause certain side effects, such as, for example hypertension and cardiac arrhythmias.

[0005] Despite recent attempts to reduce melanocortin peptide side effects or enhance melanocortin in vivo activity, there still exists a need for highly stable and selectiveDocket No.: 183B-416027-WO melanocortin analogs in the treatment and prevention of various melanocortin-related diseases. SUMMARY

[0006] The present technology comprises non-naturally occurring melanocortin receptor analogs comprising a sequence of Formula (I), X1-R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IA), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab;Docket No.: 183B-416027-WO Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is absent, Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when Y3is Lys, then R1is Glu, R4is dNal(2’), and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R4is p(Cl)dPhe, then either (i) X1is dVal, R1is dPro, and R2is Orn, Dab, or Aad, or (ii) R1is Nle, Y1is dVal, and (a) R3is Mamb, and R2is not Aad; (b) R3is absent and R2is Asp; (c) R3is Trp-Pro and R2is Dab or Orn; (d) R3is Pro and either R7is dOrn or R7is Glu and R5is Pro; (e) R3is β-Ala, and R2is Asp or Dab; or (f) R3is Pro-Pro and R2is Asp; when Y1is Nle, then Y2is Nle and (i) R4is p(Cl)dPhe and R2is Orn, Dab, or Aad, (ii) R4is dNal(2’) and R2is Aad, or (iii) R4is p(F)dPhe, and R2is Glu; when R4is dNal(2’), then R5is Arg or Pro, and (i) R1is dAsn, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; (ii) R1is dGln, R2is Asp and R3is dAla, His, or dHis; (iii) R1is Glu,Docket No.: 183B-416027-WO Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; (iv) R1is absent, and either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; (v) R1is dPro, and R2is Aad; or (vi) R1is Nle, and (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is dPro, X1is dVal, and R2is Glu, (iv) R1is Dmt and R3is Pro; or (v) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn; when R4is dTrp, then R3is Pro-Pro; and when R4is dNal(1’), then R3is Pro-Pro. DETAILED DESCRIPTION

[0007] The present technology provides non-naturally occurring melanocortin analogs and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, referred to herein collectively as melanocortin analogs. The melanocortin analogs of the present technology may selectively bind the melanocortin 3 receptor and / or the melanocortin 4 receptor over the melanocortin 1, melanocortin 2, and melanocortin 5 receptors. Some of the melanocortin analogs bind the melanocortin 3 receptor with greater affinity than the melanocortin 4 receptor, whereas other melanocortin agonists can bind the melanocortin 4 receptor with greater affinity than the melanocortin 3 receptor. Certain melanocortin agonists bind the melanocortin 3 receptor with the same or generally similar affinity as the melanocortin 4 receptor.Docket No.: 183B-416027-WO

[0008]

[0009] Each of the non-naturally occurring melanocortin analogs may have one or more beta hairpin (β-hairpin) and / or beta turn (β-turn) structures. In general, cyclization such as, for example, via a disulfide or lactam bond, may stabilize beta-turns, structurally rigid amino acids, such as, for example, proline, and / or the presence of D-amino acids may induce and / or stabilize beta-turns.

[0010] The non-naturally occurring melanocortin analogs of the present technology include one or more of the following features: an N-terminus that stabilizes the non-naturally occurring melanocortin analogs; a pharmacophoric region that binds to one or more melanocortin receptor; and a C-terminus that provides enhanced transport and / or resistance to degradation. The non-naturally occurring melanocortin analogs may be linear or cyclized.

[0011] The following description is merely exemplary in nature and is not intended to limit the present technology, its applications, or its uses. The description of specific examples indicated in various embodiments of the present technology are intended for purposes of illustration only and are not intended to limit the scope of the present technology disclosed herein. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features or other embodiments incorporating different combinations of the stated features.

[0012] While the embodiments are described in sufficient detail to enable those skilled in the art to practice the present technology, it should be understood that other embodiments may be realized, and that logical changes may be made without departing from the spirit and scope of the present technology. Thus, the detailed description herein is presented for purposes of illustration only and not of limitation. For example, steps or functions recited in any method or process may be executed in any order and are not limited to the order presented. Moreover, any of the steps thereof may be outsourced to or performed by one or more third parties. Definitions

[0013] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which theDocket No.: 183B-416027-WO present technology belongs. For the purposes of the present technology, the following terms are defined below.

[0014] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0015] The term “about” means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by acceptable levels in the art. Typically, such variation may be as much 10% above and below a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length and such variation may be influenced by standard applicable measurement practices. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth.

[0016] As used herein, a “composition” or a “pharmaceutical composition” refers to a mixture of the active ingredient with other chemical components, such as pharmaceutically acceptable carriers and / or excipients.

[0017] As used herein, a “pharmaceutically acceptable carrier” of the first or the second pharmaceutical composition refers to a carrier or diluent that does not cause significant irritation to an organism, does not abrogate the biological activity and properties of the administered active ingredient, and / or does not interact in a deleterious manner with the other components of the composition in which it is contained. The term “carrier” encompasses any excipient, binder, diluent, filler, salt, buffer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005, which is incorporated herein by reference in its entirety). Some examples of physiologically acceptable carriers include antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;Docket No.: 183B-416027-WO amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN® (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol (PEG), and PLURONICS™ (BASF; Florham Park, N.J.). An “excipient” of the first or the second pharmaceutical composition refers to an inert substance added to a composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[0018] “Melanocortin analogs,” “melanocortin peptides,” or “melanocortins,” are used interchangeably and refer to melanocortin-receptor ligands, which are macromolecules containing at least one melanocortin pharmacophore. Melanocortin analogs are typically peptides that bind melanocortin receptors under physiological conditions. Melanocortin analogs include non-naturally occurring melanocortin peptides and truncated and / or modified versions of melanocortin full-length protein or peptides. For example, the full-length pro-opiomelanocortin protein (POMC), prior to proteolytic cleavage of “sub-peptides,” consists of 241 amino acids. Tissue-specific proteolytic cleavage of POMC yields peptides ranging in size from 13 amino acids to 76 amino acids. See Bicknell and Lawry, Encyclopedia of Stress, vol.3, 257-265, Academic Press (2000). Synthesized, non-naturally occurring melanocortin analogs having increased melanocortin receptor activity as discussed herein are approximately 7-12 amino acids in size. Melanocortin analogs exhibit binding functionality with melanocortin receptors. The binding to the melanocortin receptor may activating (i.e., agonist activity). In addition to peptides, the non-naturally occurring melanocortin analogs include small molecule analogs of melanocortin or portions thereof comprised of organic compounds, inorganic compounds, or combinations of peptide and small molecule—i.e., peptide mimetics, or various combinations thereof. “Melanocortin peptides” can be structurally similar and / or functionally similar to biological melanocortin proteins in their ability to bind melanocortin receptors. Further, the non-naturally occurring melanocortin analogs generally contain the pharmacophore: His-Phe-Arg-Trp (SEQ ID NO: 1) or a modified version thereof, or a structural or functional peptide mimetic thereof.Docket No.: 183B-416027-WO

[0019] A “pharmacophore” is the minimum set of amino acid residues necessary to achieve a physiological effect; or a small molecule that is (with respect to a receptor) a structural mimic of the amino acid residues required for binding to and activation of a receptor. His-Phe-Arg-Trp (SEQ ID NO: 1) and their analogs are the pharmacophore of melanocortin for the regulated physiological effect. Therefore, non-naturally occurring melanocortin pharmacophore analogs can be small peptides or organic molecules designed to mimic the appearance or function (including activation or deactivation of receptor activity) of the melanocortin pharmacophore core sequence peptide.

[0020] A “melanocortin receptor agonist” or “melanocortin agonist” is a naturally occurring substance or manufactured drug substance or composition that can interact with a melanocortin receptor and initiate a pharmacological response characteristic of the melanocortin receptor.

[0021] A melanocortin receptor “antagonist” or “melanocortin antagonist” is a naturally occurring substance or manufactured drug substance (e.g., a non-naturally occurring substance) or composition that opposes the melanocortin receptor-associated responses normally induced by a melanocortin receptor agonist agent.

[0022] The terms “bind,” “binding,” “complex,” and “complexing,” refer to all types of physical and chemical binding, reactions, complexing, attraction, chelating and the like.

[0023] The “peptides” described herein can be (a) naturally occurring, (b) produced by chemical synthesis, (c) produced by recombinant DNA technology, (d) produced by biochemical or enzymatic fragmentation of larger molecules, (e) produced by methods resulting from a combination of methods (a) through (d) listed above, or (f) produced by any other means for producing peptides.

[0024] The term “peptide” as used herein includes any structure comprised of two or more amino acids, including chemical modifications and derivatives of amino acids. The amino acids forming all or a part of a peptide may be naturally occurring amino acids, stereoisomers and modifications of such amino acids, non-protein amino acids, post- translationally modified amino acids, enzymatically modified amino acids, constructs or structures designed to mimic amino acids, and the like, so that the term “peptide” includesDocket No.: 183B-416027-WO pseudopeptides and peptidomimetics, including structures which have a non-peptidic backbone. The term “peptide” also includes dimers or multimers of peptides. A “manufactured” peptide includes a peptide produced by chemical synthesis, recombinant DNA technology, biochemical, or enzymatic fragmentation of larger molecules, combinations of the foregoing or, in general, made by any other method. The term “peptide” includes peptides containing a variable number of amino acid residues, optionally with non- amino acid residue groups at the N- and C-termini, such groups including acyl, acetyl, alkenyl, alkyl, N-alkyl, amine, or amide groups, among others.

[0025] By employing chemical synthesis, a useful means of production, it is possible to introduce various amino acids which do not naturally occur along the chain, modify the N- or C-terminus, and the like, thereby providing for improved stability and formulation, resistance to protease degradation, and the like.

[0026] “Amino acids” are molecules containing an amine group, a carboxylic acid group, and a side-chain that is specific to each amino acid. The key elements of an amino acid are carbon, hydrogen, oxygen, and nitrogen and have the generic formula H2N—CHR— COOH, wherein R represents a side chain group. The various α-amino acids differ in the side-chain moiety that is attached to the α-carbon. The “amino acids” of the present technology include the known naturally occurring protein amino acids, which are referred to by both their common three letter abbreviation and single letter abbreviation. See generally Synthetic Peptides: A User’s Guide, G. A. Grant, editor, W.H. Freeman & Co., New York (1992), the teachings of which are incorporated herein by reference, including the text and table set forth at pages 11 through 24. As set forth above, the term “amino acid” also includes stereoisomers and modifications of naturally occurring protein amino acids, non- protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, and the like. Modified and unusual amino acids are described generally in Synthetic Peptides: A User’s Guide, supra; Hruby et al., Biochem. J.268:249-262 (1990); and Toniolo, Int. J. Peptide Protein Res.35:287-300 (1990); the teachings of all of which are incorporated herein by reference.Docket No.: 183B-416027-WO

[0027] The phrase “amino acid side chain moiety” used herein, including as used in the specification and claims, includes any side chain of any amino acid, as the term “amino acid” is defined herein. This thus includes the side chain moiety present in naturally occurring amino acids. It further includes side chain moieties in modified naturally occurring amino acids, such as glycosylated amino acids. It further includes side chain moieties in stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs, or structures designed to mimic amino acids, and the like. For example, the side chain moiety of any amino acid disclosed herein is included within the definition. A “derivative” of an amino acid side chain moiety is included within the definition of an amino acid side chain moiety.

[0028] The “derivative” of an amino acid side chain moiety includes any modification to or variation in any amino acid side chain moieties, including a modification of naturally occurring amino acid side chain moieties. By way of example, derivatives of amino acid side chain moieties include straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated, alkyl, aryl or aralkyl moieties.

[0029] In the non-naturally occurring melanocortin analogs of the present technology, conventional amino acid residues have their conventional meaning as given in Chapter 2400, of the Manual of Patent Examining Procedure, 8th Ed. Thus, “Ala” is alanine; “Arg” is arginine; “Asn” is asparagine; “Asp” is aspartic acid; “Cys” is cysteine; “Gln” is glutamine; “Glu” is glutamic acid; “His” is histidine; “Ile” is isoleucine; “Leu” is leucine; “Lys” is lysine; “Met” is methionine; “Phe” is phenylalanine; “Pro” is proline; “Ser” is serine; Thr is threonine; “Trp” is tryptophan; “Tyr” is tryosine; and “Val” is valine. Unless otherwise indicated, all amino acids abbreviations represent either isomer, i.e., the L-isomer, the D-isomer, or combinations thereof can be used. Thus, for example, “L-Phe” or “lPhe” is L-phenylalanine; “D-Phe” or “dPhe” is D-phenylalanine; dVal is D-valine; dPro is D-proline; “D- / L-Phe” or “d / lPhe” is D-phenylalanine, L-phenylalanine, or combinations thereof; “Phe” is also D- phenylalanine, L-phenylalanine, or combinations thereof, and so on.

[0030] An alpha (α)-amino acid has the generic formula H2N—CαHR—COOH, where R is a side chain moiety and the amino group is attached to the carbon atom immediatelyDocket No.: 183B-416027-WO adjacent to the carboxylate group (i.e., the α-carbon). Other types of amino acids exist when the amino group is attached to a different carbon atom.

[0031] When β-amino acids are incorporated into peptides, two main types of β- peptides exist: those with the side chain residue, R, on the carbon next to the amine are called β3peptides and those with the side chain residue on the carbon next to the carbonyl group are called β2amino acids. Further, β-amino acids may adopt L- or D- stereochemistry. Unless otherwise indicated, all β-amino acid abbreviations represent either isomer, i.e., the L-isomer, the D-isomer, or combinations thereof.

[0032] Gamma (γ)-amino acids are amino acids with the carbon atom to which the amino group attaches is separated from the carboxylate moiety by two carbon atoms.

[0033] For additional modified and unusual amino acids, see §2422 of the MPEP, particularly Table 4 at 2400-24. Additionally, “Ac” indicates N-acetyl and “cyclo” and “c” refers to a cyclic structure. “NH2” indicates an amine group, typically added on the C- terminus of a polypeptide. Accordingly, as used herein, an —NH2 moiety on the C-terminus of a peptide indicates an amidated C-terminus.

[0034] Additional abbreviations are used as follows: Orn is ornithine; dOrn is D- ornithine; Dab is 2,4-diaminobutyric acid; dDab is 2,4-D-diaminobutyric acid; Dap is 2,3- diaminopropionic acid; dDap is 2,3-D-diaminopropionic acid; Aad is aminoadipic acid; Phg is phenylglycine; dPhg is D-phenylglycine; Pen is Penicillamine; dPen is D-Penicillamine; and 2’-D-naphthylalanine (dNal(2’)).

[0035] The term “acyl” includes a group RCO—, where R is an organic group. An example is the acetyl group CH3CO—, referred to herein as “Ac.”

[0036] A peptide or aliphatic moiety is “acylated” when an alkyl or substituted alkyl group as defined above is bonded through one or more carbonyl {—(C═O)—} groups. A peptide is most usually acylated at the N-terminus.

[0037] An “amine” includes compounds that contain an amine group (—NH2).

[0038] An “amide” includes compounds that have a trivalent nitrogen attached to a carbonyl group (i.e., —CO—NH2), such as for example methylamide, ethylamide,Docket No.: 183B-416027-WO propylamide, and the like. A peptide is most usually amidated at the C-terminus by the addition of an amine (—NH2) moiety to the C-terminal carboxyl group.

[0039] Amino acids, including stereoisomers and modifications of naturally occurring amino acids, protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs, or structures designed to mimic amino acids (peptide mimetics), and the like, including all of the foregoing, are sometimes referred to herein as “residues.”

[0040] “Substantial degradation” refers to the degradation of the N-terminal extension, the C-terminal extension, both N- and C-terminal degradation or degradation to other regions of the melanocortin peptide by physiological enzymes and other factors, in such a manner or to a degree that side effects appear. According to one aspect, a melanocortin analog having a C-terminal extension that resists substantial degradation is one where no more than 50% of the administered peptide causes side effects and / or displays a low half-life. In some embodiments, no more than 25% of the administered peptide causes side effects and / or displays a low half-life. More preferably, in some embodiments, less than 10% of the administered peptide causes side effects and / or displays a low half-life, as compared to a melanocortin analog that lacks a C-terminal extension.

[0041] The disclosure of all publications, patents, and published patent applications listed herein are hereby incorporated by reference in their entireties, including but not limited to U.S. Patent Nos.8,541,545 and 9,534,018. Non-naturally Occurring Melanocortin Analogs

[0042] Non-naturally occurring melanocortin analogs described herein may be selective for the melanocortin 4 receptor and / or melanocortin 3 receptor over other melanocortin receptors, i.e., the melanocortin 1, melanocortin 2, and melanocortin 5 receptors. Some of the melanocortin analogs bind only the melanocortin 3 receptor or the melanocortin 4 receptor. Alternatively, some of the melanocortin analogs bind the melanocortin 3 receptor with greater affinity than the melanocortin 4 receptor, whereas other melanocortin analogs can bind the melanocortin 4 receptor with greater affinity than theDocket No.: 183B-416027-WO melanocortin 3 receptor. Certain melanocortin analogs bind the melanocortin 3 receptor with the same or generally similar affinity as the melanocortin 4 receptor.

[0043] The non-naturally occurring melanocortin analogs of the present technology may be full antagonists or full agonists for one or more melanocortin receptors. A full antagonist may comprise a non-naturally occurring melanocortin analog having a maximum effect (Emax) antagonist value of greater than or equal to 80%. Likewise, a full agonist may comprise a non-naturally occurring melanocortin analog having a maximum effect (Emax) agonist value of greater than or equal to 80%.

[0044] The non-naturally occurring melanocortin analogs of the present technology may be partial agonists of one or more melanocortin receptor. A partial agonist may comprise a non-naturally occurring melanocortin analog having a maximum effect Emax agonist value of less than 80%.

[0045] If a non-naturally occurring melanocortin analog’s Emax antagonist value is greater than it’s Emax agonist value, then the non-naturally occurring melanocortin analog may be classified as an agonist (e.g., a full agonist or a partial agonist). Similarly, if a non- naturally occurring melanocortin analog’s Emaxagonist value is greater than it’s Emaxantagonist value, then the non-naturally occurring melanocortin analog may be classified as an antagonist (e.g., a full antagonist or a partial antagonist).

[0046] The non-naturally occurring melanocortin analogs of the present technology may be one or more of (i) a full MC4R antagonist and a full MC3R agonist; (ii) a full MC4R antagonist and a partial MC3R agonist; (iii) a full MC4R antagonist having no MC3R agonist or antagonist activity; (iv) a partial MC4R antagonist having no MC3R agonist or antagonist activity; or (v) a full MC4R agonist and a full MC3R antagonist.

[0047] The non-naturally occurring melanocortin analogs in accordance with the present technology may have structural features that impart specific properties on the analogs, such as, for example, degradation resistance, enhanced epithelial, gastrointestinal, and / or blood brain barrier transport, and binding affinity for the MC4R and / or MC3R. For example, in some embodiments, the non-naturally occurring melanocortin analogs comprise one or more of (i) blood brain barrier passage capabilities, (ii) enhanced epithelial and / orDocket No.: 183B-416027-WO gastrointestinal transport; (iii) degradation resistance; or (iv) equipotency on MC3R and MC4R activity. In some embodiments, the non-naturally occurring melanocortin analogs comprise two or more of (i)-(v). In some embodiments, the non-naturally occurring melanocortin analogs comprise each of (i)-(iv). Accordingly, in some embodiments, the melanocortin analogs include a stabilizing N-terminus, and / or a C-terminus that provides enhanced transport of the analog. In some embodiments, melanocortin analogs include a D-valine-D-proline (dVal-dPro) chain as their C-terminus, which may provide enhanced transport and resistance to degradation Additionally, in some embodiments, the melanocortin analogs have one or more beta hairpin (β-hairpin) and / or beta turn (β-turn) structures. In general, cyclization and D-amino acids may induce and / or stabilize beta-turns.

[0048] In some embodiments, the non-naturally occurring melanocortin agonist comprises a sequence according to Formula (I): X1-R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(I), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’));Docket No.: 183B-416027-WO R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is absent or is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is absent, Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is absent and Y1is absent, (d) R1is Ala and R2is Orn or Aad, or (e) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when Y3is Lys, then R1is Glu, R4is dNal(2’), and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp;Docket No.: 183B-416027-WO when R4is p(Cl)dPhe, then either (i) X1is dVal, R1is dPro, and R2is Orn, Dab, or Aad, or (ii) R1is Nle, Y1is dVal, and (a) R3is Mamb, and R2is not Aad; (b) R3is absent and R2is Asp; (c) R3is Trp-Pro and R2is Dab or Orn; (d) R3is Pro and either R7is dOrn or R7is Glu and R5is Pro; (e) R3is β-Ala, and R2is Asp or Dab; or (f) R3is Pro-Pro and R2is Asp; when Y1is Nle, then Y2is Nle and (i) R4is p(Cl)dPhe and R2is Orn, Dab, or Aad, (ii) R4is dNal(2’) and R2is Aad, or (iii) R4is p(F)dPhe, and R2is Glu; when R4is dNal(2’), then R5is Arg or Pro, and (i) R1is dAsn, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; (ii) R1is dGln, R2is Asp and R3is dAla, His, or dHis; (iii) R1is Glu, Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; (iv) R1is absent, and either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then either R7is Lys and Y1is absent, or R7is Dab and Y1-Y2is dVal-dPro; (v) R1is dPro, and R2is Aad; or (vi) R1is Nle, and (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and either R2is Aad, or R2is Asp and Y1is absent; (c) R3is His, R2is Asp, and R7is dOrn; (d) R3is Mamb, and R2is Asp, Glu, Lys, Orn or Dab, wherein when R2is Asp, then Y1is absent, or (e) R3is β-Ala, R2is Asp, and Y1is absent; when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is dPro, X1is dVal, and R2is Glu, (iv) R1is Dmt and R3is Pro; or (v) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn; when R4is dTrp, then R3is Pro-Pro; and when R4is dNal(1’), then R3is Pro-Pro.

[0049] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (I), wherein: X1is absent or D-valine (dVal);Docket No.: 183B-416027-WO R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is absent or is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab;Docket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4) Ac-Nle-c[Asp-His-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5) Ac-Nle-c[Asp-Pro-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 6) Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 7) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 8) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 9) Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 10) Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 11) Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 13) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 16) Ac-Nle-c[Asp-dHis-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 17) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 18) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 19)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 20) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 22) Ac-Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 23) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24) Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 25) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 26) Ac-Glu-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 27) Ac-Nle-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28) Ac-Nle-c[Asp-dAla-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29) Ac-dVal-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 30) Ac-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 31) Ac-Nle-c[Glu-Trp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 32) Ac-Nle-c[Lys-Trp-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 33) Ac-Nle-c[Orn-Trp-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 34) Ac-Nle-c[Dab-Trp-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 35) Ac-Nle-c[Aad-Trp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 36) Ac-Nle-c[Glu-Pro-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 37) Ac-Nle-c[Lys-Pro-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 38) Ac-Nle-c[Dab-Pro-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 39) Ac-Nle-c[Asp-His-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 40) Ac-Nle-c[Glu-His-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 41) Ac-Nle-c[Lys-His-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 42)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-His-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 43) Ac-Nle-c[Dab-His-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 44) Ac-Nle-c[Aad-His-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 45) Ac-dAsn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 46) Ac-dAsn-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 47) Ac-dAsn-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 48) Ac-dAsn-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 49) Ac-dAsn-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 50) Ac-dAsn-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 51) Ac-dAsn-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 52) Ac-dAsn-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 53) Ac-dAsn-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 54) Ac-dAsn-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 55) Ac-dAsn-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 56) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 57) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 58) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 59) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 60) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 61) Ac-Nle-c[Asp-β-Ala-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 62) Ac-Nle-c[Asp-β-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 63) Ac-Nle-c[Glu-β-Ala-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64) Ac-Nle-c[Lys-β-Ala-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 65) Ac-Nle-c[Orn-β-Ala-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 66)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-β-Ala-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 67) Ac-Nle-c[Aad-β-Ala-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 68) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 69) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 70) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 71) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 72) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 73) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 74) Ac-Nle-c[Glu-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 75) Ac-Nle-c[Lys-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 76) Ac-Nle-c[Orn-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 77) Ac-Nle-c[Dab-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 78) Ac-Nle-c[Aad-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 79) Ac-Nle-c[Glu-Mamb-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 80) Ac-Nle-c[Lys-Mamb-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 81) Ac-Nle-c[Orn-Mamb-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 82) Ac-Nle-c[Dab-Mamb-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 83) Ac-Nle-c[Aad-Mamb-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 84) Ac-Ala-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 85) Ac-Ala-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 86) Ac-Ala-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 87) Ac-Ala-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 88) Ac-Ala-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 89) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 90)Docket No.: 183B-416027-WO Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 91) Ac-Ala-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 92) Ac-Nle-c[Asp-His-dPhe-Pro-Trp-Lys]-NH2 (SEQ ID NO: 93) Ac-Nle-c[Glu-His-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 94) Ac-Nle-c[Lys-His-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 95) Ac-Nle-c[Orn-His-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 96) Ac-Nle-c[Dab-His-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 97) Ac-Nle-c[Aad-His-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 98) Ac-Nle-c[Glu-Pro-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 99) Ac-Nle-c[Lys-Pro-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 100) Ac-Nle-c[Orn-Pro-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 101) Ac-Nle-c[Dab-Pro-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 102) Ac-Nle-c[Aad-Pro-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 103) Ac-Nle-c[Asp-His-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 104) Ac-Nle-c[Glu-His-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 105) Ac-Nle-c[Lys-His-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 106) Ac-Nle-c[Orn-His-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 107) Ac-Nle-c[Dab-His-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 108) Ac-Nle-c[Aad-His-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 109) Ac-Nle-c[Asp-Pro-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 110) Ac-Nle-c[Glu-Pro-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 111) Ac-Nle-c[Orn-Pro-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 112) Ac-Nle-c[Dab-Pro-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 113) Ac-Nle-c[Asp-His-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 114)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-His-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 115) Ac-Nle-c[Lys-His-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 116) Ac-Nle-c[Orn-His-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 117) Ac-Nle-c[Dab-His-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 118) Ac-Nle-c[Aad-His-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 119) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 120) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 121) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 122) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 123) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 124) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 125) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 126) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 127) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 128) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 129) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 130) Ac-dVal-dPro-c[Lys-Trp-Arg-dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 131) Ac-dVal-dPro-c[Orn-Trp-Arg-dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 132) Ac-dVal-dPro-c[Dab-Trp-Arg-dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 133) Ac-dVal-dPro-c[Aad-Trp-Arg-dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 134) Ac-dVal-dPro-c[Asp-Trp-Arg-dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 135) Ac-dVal-dPro-c[Glu-Trp-Arg-dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 136) Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 137) Dmt-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 138)Docket No.: 183B-416027-WO Ac-dAla-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 139) Ac-dAla-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 140) Ac-dAla-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 141) Ac-dAla-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 142) Ac-dAla-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 143) Ac-dAla-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 144) Ac-dAla-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 145) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 146) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 147) Ac-dAla-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 148) Ac-Nle-c[Asp-Pro-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 149) Ac-Nle-c[Glu-Pro-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 150) Ac-Nle-c[Lys-Pro-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 151) Ac-Nle-c[Orn-Pro-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 152) Ac-Nle-c[Aad-Pro-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 153) Ac-Nle-c[Asp-His-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 154) Ac-Nle-c[Glu-His-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 155) Ac-Nle-c[Lys-His-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 156) Ac-Nle-c[Orn-His-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 157) Ac-Nle-c[Orn-His-dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 158) Ac-Nle-c[Aad-His-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 159) Ac-Nle-c[Glu-Pro-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 160) Ac-Nle-c[Lys-Pro-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 161) Ac-Nle-c[Orn-Pro-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 162)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 163) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 164) Ac-Glu-c[Glu-Pro-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 165) Ac-Glu-c[Lys-Pro-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 166) Ac-Glu-c[Orn-Pro-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 167) Ac-Glu-c[Dab-Pro-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 168) Ac-Glu-c[Aad-Pro-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 169) Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 170) Ac-Glu-c[Glu-His-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 171) Ac-Glu-c[Lys-His-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 172) Ac-Glu-c[Orn-His-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 173) Ac-Glu-c[Dab-His-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 174) Ac-Glu-c[Aad-His-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 175) Ac-Nle-c[Asp-Pro-Gly-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 176) Ac-Nle-c[Lys-Pro-Gly-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 177) Ac-Nle-c[Orn-Pro-Gly-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 178) Ac-Nle-c[Aad-Pro-Gly-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 179) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 180) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 181) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 182) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 183) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 184) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 185) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 186)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 187) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 188) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 189) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 190) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 191) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 192) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 193) Ac-Nle-c[Glu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194) Ac-Nle-c[Lys-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 195) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-NH2 (SEQ ID NO: 196) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-NH2 (SEQ ID NO: 197) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-NH2 (SEQ ID NO: 198) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-NH2 (SEQ ID NO: 199) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-NH2 (SEQ ID NO: 200) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 201) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 202) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 203) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 204) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 205) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 206) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 207) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-OH (SEQ ID NO: 208) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-OH (SEQ ID NO: 209)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-OH (SEQ ID NO: 210) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-OH (SEQ ID NO: 211) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-OH (SEQ ID NO: 212) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-OH (SEQ ID NO: 213) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-OH (SEQ ID NO: 214) Ac-dGln-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215) Ac-dGln-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 216) Ac-dGln-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 217) Ac-dGln-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 218) Ac-dGln-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 219) Ac-dGln-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 220) Ac-dGln-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 221) Ac-dGln-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 222) Ac-dGln-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 223) Ac-dGln-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 224) Ac-dGln-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 225) Ac-dGln-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 226) Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 227) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 237) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 238) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 239) Ac-Glu-c[Asp-Pro-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 240) Ac-Glu-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 241) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 242)Docket No.: 183B-416027-WO Ac-Glu-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 243) Ac-Glu-c[Lys-Pro-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 244) Ac-Glu-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 245) Ac-Glu-c[Orn-Pro-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 246) Ac-Glu-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 247) Ac-Glu-c[Dab-Pro-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 248) Ac-Glu-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 249) Ac-Glu-c[Aad-Pro-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 250) Ac-Glu-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 251) Ac-Glu-c[Asp-His-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 252) Ac-Glu-c[Asp-His-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 253) Ac-Glu-c[Glu-His-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 254) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 255) Ac-Glu-c[Glu-His-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 256) Ac-Glu-c[Lys-His-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 257) Ac-Glu-c[Lys-His-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 258) Ac-Glu-c[Lys-His-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 259) Ac-Glu-c[Orn-His-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 260) Ac-Glu-c[Orn-His-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 261) Ac-Glu-c[Dab-His-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 262) Ac-Glu-c[Dab-His-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 263) Ac-Glu-c[Dab-His-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 264) Ac-Glu-c[Aad-His-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 265) Ac-Glu-c[Aad-His-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 266)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268) Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 269) Ac-Nle-c[Asp-dHis-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 271) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 272) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 273) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 274) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 275) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 276) Ac-Nle-c[Asp-Trp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 277) Ac-Nle-c[Glu-Trp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 278) Ac-Nle-c[Lys-Trp-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 279) Ac-Nle-c[Aad-Trp-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 280) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 281) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 282) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 283) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 284) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 285) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 286) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 287) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 288) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 289) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 290)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 291) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 292) Ac-dGln-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 293) Ac-dGln-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 294) Ac-dGln-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 295) Ac-dGln-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 296) Ac-dGln-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 297) Ac-dGln-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 298) Ac-dGln-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299) Ac-dGln-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 300) Ac-dGln-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 301) Ac-dGln-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 302) Ac-dGln-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 303) Ac-dGln-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 304) Ac-dAsn-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305) Ac-dAsn-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 306) Ac-dAsn-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 307) Ac-dAsn-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 308) Ac-dAsn-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 309) Ac-dAsn-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 310) Ac-dAsn-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311) Ac-dAsn-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 312) Ac-dAsn-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 313) Ac-dAsn-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 314)Docket No.: 183B-416027-WO Ac-dAsn-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 315) Ac-dAsn-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 316) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 317) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 318) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 319) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 320) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 321) Ac-Nle-c[Glu-β-Ala-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322) Ac-Nle-c[Lys-β-Ala-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 323) Ac-Nle-c[Orn-β-Ala-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 324) Ac-Nle-c[Aad-β-Ala-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 325) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 326) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 327) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 328) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 329) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 330) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 331) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 332) Ac-Nle-c[Orn-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 333) Ac-Nle-c[Dab-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 334) Ac-Nle-c[Aad-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 335) Ac-Nle-c[Aad-Mamb-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 336) Ac-Ala-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 337) Ac-Ala-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 338)Docket No.: 183B-416027-WO Ac-Ala-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 339) Ac-Ala-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 340) Ac-Ala-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 341) Ac-Ala-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 342) Ac-Ala-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 343) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 344) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 345) Ac-Ala-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 346) Ac-Nle-c[Asp-His-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 347) Ac-Nle-c[Glu-His-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 348) Ac-Nle-c[Lys-His-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 349) Ac-Nle-c[Orn-His-p(Cl)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 350) Ac-Nle-c[Dab-His-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 351) Ac-Nle-c[Aad-His-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 352) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 353) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 354) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 355) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 356) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 357) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 359) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 360) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 361) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 362)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 363) Ac-Nle-c[Asp-His-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364) Ac-Nle-c[Glu-His-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 365) Ac-Nle-c[Lys-His-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 366) Ac-Nle-c[Orn-His-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 367) Ac-Nle-c[Dab-His-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 368) Ac-Nle-c[Aad-His-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 369) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 370) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 371) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 372) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 373) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 374) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 375) Ac-Nle-c[Asp-His-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 376) Ac-Nle-c[Glu-His-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 377) Ac-Nle-c[Lys-His-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 378) Ac-Nle-c[Orn-His-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 379) Ac-Nle-c[Dab-His-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 380) Ac-Nle-c[Aad-His-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 381) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 382) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 383) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 384) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 385) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 386)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 387) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 388) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 389) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 390) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 391) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 392) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 393) Ac-dVal-dPro-c[Lys-Trp-Arg-p(Cl)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 394) Ac-dVal-dPro-c[Asp-Trp-Arg-p(Cl)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 395) Ac-dVal-dPro-c[Glu-Trp-Arg-p(Cl)dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 396) Dmt-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 397) Dmt-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 398) Dmt-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 399) Dmt-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 400) Dmt-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 401) Dmt-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 402) Ac-dAla-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 403) Ac-dAla-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 404) Ac-dAla-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 405) Ac-dAla-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 406) Ac-dAla-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 407) Ac-dAla-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 408) Ac-dAla-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 409) Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 410)Docket No.: 183B-416027-WO Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 411) Ac-dAla-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 412) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 414) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 415) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 416) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 417) Ac-Nle-c[Glu-His-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 418) Ac-Nle-c[Lys-His-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 419) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 420) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 421) Ac-Nle-c[Aad-His-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 422) Ac-Nle-c[Glu-Pro-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 423) Ac-Nle-c[Lys-Pro-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 424) Ac-Nle-c[Orn-Pro-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 425) Ac-Nle-c[Aad-Pro-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 426) Ac-Nle-c[Asp-Pro-Gly-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427) Ac-Nle-c[Glu-Pro-Gly-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 428) Ac-Nle-c[Lys-Pro-Gly-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 429) Ac-Nle-c[Orn-Pro-Gly-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 430) Ac-Nle-c[Aad-Pro-Gly-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 431) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 432) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 433) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 434)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 435) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 436) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 437) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 438) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 440) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 441) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 442) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 443) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 445) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-NH2 (SEQ ID NO: 446) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-NH2 (SEQ ID NO: 447) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 448) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-Nle-NH2 (SEQ ID NO: 449) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 450) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 451) Ac-dVal-dPro-c[Lys-Trp-Arg-p(F)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 452) Ac-dVal-dPro-c[Orn-Trp-Arg-dNal(2')-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 453) Ac-dVal-dPro-c[Orn-Trp-Arg-p(F)dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 454) Ac-dVal-dPro-c[Dab-Trp-Arg-dNal(2')-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 455) Ac-dVal-dPro-c[Dab-Trp-Arg-p(F)dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 456) Ac-dVal-dPro-c[Aad-Trp-Arg-p(F)dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 457) Ac-dVal-dPro-c[Asp-Trp-Arg-p(F)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 458)Docket No.: 183B-416027-WO Ac-dVal-dPro-c[Glu-Trp-Arg-dNal(2')-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 459) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 460) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 461) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 462) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 463) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 464) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-dPro-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 467) Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468) Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470) c[CO-cis-CH = CH-CO-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471) Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472) Ac-dGln-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 473) Ac-dAsn-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 474) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 475) Ac-Nle-c[Asp-His-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 476) Ac-Nle-c[Asp-Pro-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 477) Dmt-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 478) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 479) Ac-Nle-c[dAsp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 480) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 481) Ac-Nle-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 482)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 483) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 484) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 485) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 486) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 487) Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488) Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489) Ac-Nle-c[Asp-Pro-Gly-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 490) Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491) Ac-Nle-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492) Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493) Ac-Nle-c[Asp-Pro-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494) Ac-Nle-c[Asp-Pro-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495) Ac-Nle-c[Asp-Pro-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Lys]-dVal-dPro-NH2 (no Trp) (SEQ ID NO: 497) Ac-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 498) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 499) Ac-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 500) Ac-c[Asp-His-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 501) Ac-c[Asp-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 502) Ac-Nle-c[Glu-Trp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 503) Ac-Nle-c[Lys-Trp-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 504) Ac-Nle-c[Orn-Trp-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 505) Ac-Nle-c[Dab-Trp-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 506)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Trp-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 507) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 508) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 509) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 510) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 511) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 512) Ac-Nle-c[Asp-His-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 513) Ac-Nle-c[Glu-His-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 514) Ac-Nle-c[Lys-His-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 515) Ac-Nle-c[Orn-His-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 516) Ac-Nle-c[Dab-His-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 517) Ac-Nle-c[Aad-His-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 518) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 519) Ac-dGln-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 520) Ac-dGln-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 521) Ac-dGln-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 522) Ac-dGln-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 523) Ac-dGln-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 524) Ac-dGln-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 525) Ac-dGln-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 526) Ac-dGln-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 527) Ac-dGln-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 528) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 529) Ac-dAsn-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 530)Docket No.: 183B-416027-WO Ac-dAsn-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 531) Ac-dAsn-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 532) Ac-dAsn-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 533) Ac-dAsn-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 534) Ac-dAsn-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 535) Ac-dAsn-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 536) Ac-dAsn-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 537) Ac-dAsn-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 538) c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 539) c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 541) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 542) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 543) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 544) Ac-Nle-c[Glu-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 545) Ac-Nle-c[Orn-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 546) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 547) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 548) Ac-Nle-c[Aad-Mamb-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 549) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 550) Ac-Ala-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 551) Ac-Ala-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 552) Ac-Ala-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 553) Ac-Ala-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 554)Docket No.: 183B-416027-WO Ac-Ala-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 555) Ac-Ala-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 556) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 557) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 558) Ac-Ala-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 559) Ac-Nle-c[Asp-His-dNal(2')-Pro-Trp-Lys]-NH2 (SEQ ID NO: 560) Ac-Nle-c[Glu-His-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 561) Ac-Nle-c[Lys-His-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 562) Ac-Nle-c[Orn-His-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 563) Ac-Nle-c[Dab-His-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 564) Ac-Nle-c[Aad-His-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 565) Ac-Nle-c[Glu-Pro-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 566) Ac-Nle-c[Lys-Pro-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 567) Ac-Nle-c[Orn-Pro-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 568) Ac-Nle-c[Dab-Pro-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 569) Ac-Nle-c[Aad-Pro-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 570) Ac-Nle-c[Glu-Pro-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 571) Ac-Nle-c[Lys-Pro-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 572) Ac-Nle-c[Orn-Pro-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 573) Ac-Nle-c[Dab-Pro-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 574) Ac-Nle-c[Aad-Pro-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 575) Ac-Nle-c[Asp-His-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 576) Ac-Nle-c[Glu-His-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 577) Ac-Nle-c[Lys-His-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 578)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-His-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 579) Ac-Nle-c[Dab-His-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 580) Ac-Nle-c[Aad-His-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 581) Ac-Nle-c[Glu-Pro-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 582) Ac-Nle-c[Lys-Pro-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 583) Ac-Nle-c[Orn-Pro-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 584) Ac-Nle-c[Dab-Pro-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 585) Ac-Nle-c[Aad-Pro-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 586) Ac-Nle-c[Asp-His-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 587) Ac-Nle-c[Glu-His-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 588) Ac-Nle-c[Lys-His-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 589) Ac-Nle-c[Orn-His-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 590) Ac-Nle-c[Dab-His-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 591) Ac-Nle-c[Aad-His-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 592) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 593) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 594) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 595) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 596) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 597) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 598) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 599) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 600) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 601) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 602)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 603) Dmt-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 604) Dmt-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 605) Dmt-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 606) Dmt-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 607) Dmt-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 608) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 609) Ac-dAla-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 610) Ac-dAla-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 611) Ac-dAla-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 612) Ac-dAla-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 613) Ac-dAla-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 614) Ac-dAla-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 615) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 616) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 617) Ac-dAla-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 618) Ac-Nle-c[Glu-Pro-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 619) Ac-Nle-c[Lys-Pro-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 620) Ac-Nle-c[Orn-Pro-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 621) Ac-Nle-c[Aad-Pro-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 622) Ac-Nle-c[Asp-His-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 623) Ac-Nle-c[Glu-His-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 624) Ac-Nle-c[Lys-His-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 625) Ac-Nle-c[Orn-His-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 626)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-His-dNal(2')-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 627) Ac-Nle-c[Aad-His-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 628) Ac-Nle-c[Glu-Pro-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 629) Ac-Nle-c[Lys-Pro-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 630) Ac-Nle-c[Orn-Pro-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 631) Ac-Nle-c[Glu-Pro-Gly-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 632) Ac-Nle-c[Lys-Pro-Gly-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 633) Ac-Nle-c[Orn-Pro-Gly-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 634) Ac-Nle-c[Aad-Pro-Gly-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 635) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 636) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 637) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 638) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 639) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 640) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 641) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 642) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 643) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 644) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 645) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 646) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 647) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 648) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 649) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 650)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 651) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 652) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 653) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 654) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 655) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 656) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 657) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 658) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 659) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 660) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 661) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 662) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 663) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 664) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 665) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 666) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 667) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 668) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 669) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 670) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 671) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 672) Ac-dGln-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 673)Docket No.: 183B-416027-WO Ac-dGln-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 674) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 675) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 676) Ac-Nle-c[dAsp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 677) Ac-Nle-c[dLys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 678) Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 679) Ac-Nle-c[Asp-β-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 680) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 681) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 682) Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 683) Ac-Nle-c[Asp-dHis-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 684) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 685) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 686) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 687) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 688) Ac-Nle-c[Asp-Trp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 689) Ac-Nle-c[Glu-Trp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 690) Ac-Nle-c[Lys-Trp-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 691) Ac-Nle-c[Orn-Trp-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 692) Ac-Nle-c[Dab-Trp-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 693) Ac-Nle-c[Aad-Trp-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 694) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 695) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 696) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 697)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 698) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 699) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 700) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 701) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 702) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 703) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 704) Ac-dAsn-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 705) Ac-dAsn-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 706) Ac-dAsn-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 707) Ac-dAsn-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 708) Ac-dAsn-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 709) Ac-dAsn-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 710) Ac-dAsn-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 711) Ac-dAsn-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 712) Ac-dAsn-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 713) Ac-dAsn-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 714) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 715) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 716) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 717) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 718) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 719) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 720) Ac-Nle-c[Asp-β-Ala-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 721)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-β-Ala-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 722) Ac-Nle-c[Dab-β-Ala-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 723) Ac-Nle-c[Aad-β-Ala-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 724) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 725) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 726) Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 727) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 728) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 729) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 730) Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 731) Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 732) Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 733) Ac-Nle-c[Glu-Mamb-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 734) Ac-Nle-c[Lys-Mamb-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 735) Ac-Nle-c[Orn-Mamb-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 736) Ac-Nle-c[Dab-Mamb-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 737) Ac-Nle-c[Aad-Mamb-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 738) Ac-Nle-c[Asp-His-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 739) Ac-Nle-c[Glu-His-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 740) Ac-Nle-c[Lys-His-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 741) Ac-Nle-c[Orn-His-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 742) Ac-Nle-c[Dab-His-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 743) Ac-Nle-c[Aad-His-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 744) Ac-Nle-c[Lys-Pro-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 745)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 746) Ac-Nle-c[Glu-Pro-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 747) Ac-Nle-c[Lys-Pro-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 748) Ac-Nle-c[Orn-Pro-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 749) Ac-Nle-c[Dab-Pro-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 750) Ac-Nle-c[Aad-Pro-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 751) Ac-Nle-c[Asp-His-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 752) Ac-Nle-c[Glu-His-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 753) Ac-Nle-c[Lys-His-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 754) Ac-Nle-c[Orn-His-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 755) Ac-Nle-c[Aad-His-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 756) Ac-Nle-c[Asp-Pro-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 757) Ac-Nle-c[Glu-Pro-p(F)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 758) Ac-Nle-c[Lys-Pro-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 759) Ac-Nle-c[Orn-Pro-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 760) Ac-Nle-c[Asp-His-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 761) Ac-Nle-c[Lys-His-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 762) Ac-Nle-c[Orn-His-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 763) Ac-Nle-c[Dab-His-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 764) Ac-Nle-c[Aad-His-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 765) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 766) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 767) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 768) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 769)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 770) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 771) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 772) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 773) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 774) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 775) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 776) Ac-Nle-c[Glu-Pro-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 777) Ac-Nle-c[Orn-Pro-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 778) Ac-Nle-c[Aad-Pro-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 779) Ac-Nle-c[Glu-His-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 780) Ac-Nle-c[Lys-His-p(F)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 781) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 782) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 783) Ac-Nle-c[Aad-His-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 784) Ac-Nle-c[Asp-Pro-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 785) Ac-Nle-c[Glu-Pro-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 786) Ac-Nle-c[Lys-Pro-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 787) Ac-Nle-c[Orn-Pro-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 788) Ac-Nle-c[Aad-Pro-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 789) Ac-Nle-c[Glu-Pro-Gly-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 790) Ac-Nle-c[Lys-Pro-Gly-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 791) Ac-Nle-c[Orn-Pro-Gly-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 792) Ac-Nle-c[Aad-Pro-Gly-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 793)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 794) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 795) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 796) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 797) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 798) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 799) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 800) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 801) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 802) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 803) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 804) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 805) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 806) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 807) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-dPro-NH3 (SEQ ID NO: 808) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 809) Ac-dAsn-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 810) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 811) Ac-dAsn-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 812) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-NH2 (SEQ ID NO: 813) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 814) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-NH2 (SEQ ID NO: 815) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-NH2 (SEQ ID NO: 816) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-NH2 (SEQ ID NO: 817)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 818) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-NH2 (SEQ ID NO: 819) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 820) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 821) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 822) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 823) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 824) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 825) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 826) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 827) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-OH (SEQ ID NO: 828) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-OH (SEQ ID NO: 829) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-OH (SEQ ID NO: 830) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-OH (SEQ ID NO: 831) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-OH (SEQ ID NO: 832) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-OH (SEQ ID NO: 833) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-OH (SEQ ID NO: 834) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-OH (SEQ ID NO: 835) Ac-Nle-c[Glu-His-Trp-Arg-p(F)dPhe-Orn]-dVal-dPro-NH2 (SEQ ID NO: 836) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 837) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 838) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 839) Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 840) Ac-Nle-c[[STA-AA10333]-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 841)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-NH2 (SEQ ID NO: 842) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 843) Ac-Nle-c[Asp-Pro-d(F)Phe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 844) Ac-Nle-c[Asp-Pro-Gly-d(F)Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 845) Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 846) Ac-Ala-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 847) Ac-Ala-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 848) Ac-Ala-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 849) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 850) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 851) Ac-Ala-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 852) Ac-dAla-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 853) Ac-dAla-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 854) Ac-dAla-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 855) Ac-dAla-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 856) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 857) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 858) Ac-dAla-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 859) Ac-Ala-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 860) Ac-dAla-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 861) Ac-Ala-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 862) Ac-dAla-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 863) Ac-dGln-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 864) Ac-dGln-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 865)Docket No.: 183B-416027-WO Ac-dGln-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 866) Ac-dGln-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 867) Ac-dGln-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 868) Ac-dGln-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 869) Ac-dGln-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 870) Ac-dGln-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 871) Ac-dGln-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 872) Ac-dGln-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 873) Ac-dGln-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 874) Ac-dPro-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 875) Ac-dPro-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 876) Ac-Nle-c[Asp-Pro-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 877) Ac-Nle-c[Glu-Pro-dNal(1')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 878) and Ac-Nle-c[Asp-Pro-Gly-dNal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 879), wherein c represents cyclization through a lactam bond between R2and R7.

[0050] In some embodiments of the sequence of Formula (I), Y1is present. Accordingly, in some embodiments, the sequence of Formula (I) is a sequence of Formula (IA): X1-R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IA), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysineDocket No.: 183B-416027-WO (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu,Docket No.: 183B-416027-WO provided that: when R4is dPhe, then X1is absent, R1is absent, Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when Y3is Lys, then R1is Glu, R4is dNal(2’), and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R4is p(Cl)dPhe, then either (i) X1is dVal, R1is dPro, and R2is Orn, Dab, or Aad, or (ii) R1is Nle, Y1is dVal, and (a) R3is Mamb, and R2is not Aad; (b) R3is absent and R2is Asp; (c) R3is Trp-Pro and R2is Dab or Orn; (d) R3is Pro and either R7is dOrn or R7is Glu and R5is Pro; (e) R3is β-Ala, and R2is Asp or Dab; or (f) R3is Pro-Pro and R2is Asp; when Y1is Nle, then Y2is Nle and (i) R4is p(Cl)dPhe and R2is Orn, Dab, or Aad, (ii) R4is dNal(2’) and R2is Aad, or (iii) R4is p(F)dPhe, and R2is Glu; when R4is dNal(2’), then R5is Arg or Pro, and (i) R1is dAsn, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; (ii) R1is dGln, R2is Asp and R3is dAla, His, or dHis; (iii) R1is Glu, Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; (iv) R1is absent, and either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; (v) R1is dPro, and R2is Aad; or (vi) R1is Nle, and (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is dPro, X1is dVal, and R2is Glu, (iv) R1is Dmt and R3is Pro; or (v) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6isDocket No.: 183B-416027-WO dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn; when R4is dTrp, then R3is Pro-Pro; and when R4is dNal(1’), then R3is Pro-Pro.

[0051] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IA): X1-R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IA), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4-Docket No.: 183B-416027-WO D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is absent, Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when Y3is Lys, then R1is Glu, R4is dNal(2’), and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R4is p(Cl)dPhe, then either (i) X1is dVal, R1is dPro, and R2is Orn, Dab, or Aad, or (ii) R1is Nle, Y1is dVal, and (a) R3is Mamb, and R2is not Aad; (b) R3is absent and R2is Asp; (c) R3is Trp-Pro and R2is Dab or Orn; (d) R3is Pro and either R7is dOrn or R7is Glu and R5is Pro; (e) R3is β-Ala, and R2is Asp or Dab; or (f) R3is Pro-Pro and R2is Asp; when Y1is Nle, then Y2is Nle and (i) R4is p(Cl)dPhe and R2is Orn, Dab, or Aad, (ii) R4is dNal(2’) and R2is Aad, or (iii) R4is p(F)dPhe, and R2is Glu;Docket No.: 183B-416027-WO when R4is dNal(2’), then R5is Arg or Pro, and (i) R1is dAsn, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; (ii) R1is dGln, R2is Asp and R3is dAla, His, or dHis; (iii) R1is Glu, Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; (iv) R1is absent, and either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; (v) R1is dPro, and R2is Aad; or (vi) R1is Nle, and (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is dPro, X1is dVal, and R2is Glu, (iv) R1is Dmt and R3is Pro; or (v) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn; when R4is dTrp, then R3is Pro-Pro; and when R4is dNal(1’), then R3is Pro-Pro.

[0052] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IA), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysineDocket No.: 183B-416027-WO (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu,Docket No.: 183B-416027-WO provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4) Ac-Nle-c[Asp-His-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5) Ac-Nle-c[Asp-Pro-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 6) Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 7) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 8) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 9) Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 10) Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 11) Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 13) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 16) Ac-Nle-c[Asp-dHis-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 17) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 18) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 19) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 20) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 22)Docket No.: 183B-416027-WO Ac-Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 23) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24) Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 25) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 26) Ac-Glu-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 27) Ac-Nle-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28) Ac-Nle-c[Asp-dAla-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29) Ac-dVal-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 30) Ac-Nle-c[Glu-Trp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 32) Ac-Nle-c[Lys-Trp-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 33) Ac-Nle-c[Orn-Trp-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 34) Ac-Nle-c[Dab-Trp-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 35) Ac-Nle-c[Aad-Trp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 36) Ac-Nle-c[Glu-Pro-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 37) Ac-Nle-c[Lys-Pro-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 38) Ac-Nle-c[Dab-Pro-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 39) Ac-Nle-c[Asp-His-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 40) Ac-Nle-c[Glu-His-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 41) Ac-Nle-c[Lys-His-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 42) Ac-Nle-c[Orn-His-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 43) Ac-Nle-c[Dab-His-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 44) Ac-Nle-c[Aad-His-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 45) Ac-dAsn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 46) Ac-dAsn-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 47)Docket No.: 183B-416027-WO Ac-dAsn-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 48) Ac-dAsn-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 49) Ac-dAsn-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 50) Ac-dAsn-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 51) Ac-dAsn-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 52) Ac-dAsn-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 53) Ac-dAsn-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 54) Ac-dAsn-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 55) Ac-dAsn-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 56) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 57) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 58) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 59) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 60) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 61) Ac-Nle-c[Asp-β-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 63) Ac-Nle-c[Glu-β-Ala-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64) Ac-Nle-c[Lys-β-Ala-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 65) Ac-Nle-c[Orn-β-Ala-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 66) Ac-Nle-c[Dab-β-Ala-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 67) Ac-Nle-c[Aad-β-Ala-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 68) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 69) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 70) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 71) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 72)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 73) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 74) Ac-Nle-c[Glu-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 75) Ac-Nle-c[Lys-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 76) Ac-Nle-c[Orn-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 77) Ac-Nle-c[Dab-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 78) Ac-Nle-c[Aad-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 79) Ac-Nle-c[Glu-Mamb-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 80) Ac-Nle-c[Lys-Mamb-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 81) Ac-Nle-c[Orn-Mamb-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 82) Ac-Nle-c[Dab-Mamb-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 83) Ac-Nle-c[Aad-Mamb-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 84) Ac-Ala-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 85) Ac-Ala-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 86) Ac-Ala-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 87) Ac-Ala-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 88) Ac-Ala-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 89) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 90) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 91) Ac-Ala-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 92) Ac-Nle-c[Glu-His-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 94) Ac-Nle-c[Lys-His-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 95) Ac-Nle-c[Orn-His-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 96) Ac-Nle-c[Dab-His-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 97)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-His-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 98) Ac-Nle-c[Glu-Pro-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 99) Ac-Nle-c[Lys-Pro-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 100) Ac-Nle-c[Orn-Pro-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 101) Ac-Nle-c[Dab-Pro-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 102) Ac-Nle-c[Aad-Pro-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 103) Ac-Nle-c[Asp-His-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 104) Ac-Nle-c[Glu-His-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 105) Ac-Nle-c[Lys-His-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 106) Ac-Nle-c[Orn-His-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 107) Ac-Nle-c[Dab-His-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 108) Ac-Nle-c[Aad-His-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 109) Ac-Nle-c[Asp-Pro-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 110) Ac-Nle-c[Glu-Pro-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 111) Ac-Nle-c[Orn-Pro-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 112) Ac-Nle-c[Dab-Pro-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 113) Ac-Nle-c[Asp-His-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 114) Ac-Nle-c[Glu-His-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 115) Ac-Nle-c[Lys-His-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 116) Ac-Nle-c[Orn-His-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 117) Ac-Nle-c[Dab-His-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 118) Ac-Nle-c[Aad-His-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 119) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 120) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 121)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 122) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 123) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 124) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 125) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 126) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 127) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 128) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 129) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 130) Ac-dVal-dPro-c[Lys-Trp-Arg-dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 131) Ac-dVal-dPro-c[Orn-Trp-Arg-dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 132) Ac-dVal-dPro-c[Dab-Trp-Arg-dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 133) Ac-dVal-dPro-c[Aad-Trp-Arg-dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 134) Ac-dVal-dPro-c[Asp-Trp-Arg-dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 135) Ac-dVal-dPro-c[Glu-Trp-Arg-dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 136) Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 137) Dmt-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 138) Ac-dAla-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 139) Ac-dAla-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 140) Ac-dAla-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 141) Ac-dAla-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 142) Ac-dAla-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 143) Ac-dAla-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 144) Ac-dAla-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 145)Docket No.: 183B-416027-WO Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 146) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 147) Ac-dAla-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 148) Ac-Nle-c[Asp-Pro-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 149) Ac-Nle-c[Glu-Pro-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 150) Ac-Nle-c[Lys-Pro-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 151) Ac-Nle-c[Orn-Pro-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 152) Ac-Nle-c[Aad-Pro-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 153) Ac-Nle-c[Asp-His-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 154) Ac-Nle-c[Glu-His-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 155) Ac-Nle-c[Lys-His-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 156) Ac-Nle-c[Orn-His-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 157) Ac-Nle-c[Orn-His-dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 158) Ac-Nle-c[Aad-His-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 159) Ac-Nle-c[Glu-Pro-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 160) Ac-Nle-c[Lys-Pro-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 161) Ac-Nle-c[Orn-Pro-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 162) Ac-Nle-c[Aad-Pro-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 163) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 164) Ac-Glu-c[Glu-Pro-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 165) Ac-Glu-c[Lys-Pro-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 166) Ac-Glu-c[Orn-Pro-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 167) Ac-Glu-c[Dab-Pro-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 168) Ac-Glu-c[Aad-Pro-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 169)Docket No.: 183B-416027-WO Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 170) Ac-Glu-c[Glu-His-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 171) Ac-Glu-c[Lys-His-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 172) Ac-Glu-c[Orn-His-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 173) Ac-Glu-c[Dab-His-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 174) Ac-Glu-c[Aad-His-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 175) Ac-Nle-c[Asp-Pro-Gly-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 176) Ac-Nle-c[Lys-Pro-Gly-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 177) Ac-Nle-c[Orn-Pro-Gly-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 178) Ac-Nle-c[Aad-Pro-Gly-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 179) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 180) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 181) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 182) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 183) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 184) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 185) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 186) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 187) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 188) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 189) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 190) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 191) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 192) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 193)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194) Ac-Nle-c[Lys-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 195) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 201) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 202) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 203) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 204) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 205) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 206) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 207) Ac-dGln-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215) Ac-dGln-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 216) Ac-dGln-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 217) Ac-dGln-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 218) Ac-dGln-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 219) Ac-dGln-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 220) Ac-dGln-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 221) Ac-dGln-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 222) Ac-dGln-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 223) Ac-dGln-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 224) Ac-dGln-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 225) Ac-dGln-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 226) Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 227)Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 237)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 238) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 239) Ac-Glu-c[Asp-Pro-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 240) Ac-Glu-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 241) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 242) Ac-Glu-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 243) Ac-Glu-c[Lys-Pro-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 244) Ac-Glu-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 245) Ac-Glu-c[Orn-Pro-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 246) Ac-Glu-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 247) Ac-Glu-c[Dab-Pro-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 248) Ac-Glu-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 249) Ac-Glu-c[Aad-Pro-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 250) Ac-Glu-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 251) Ac-Glu-c[Asp-His-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 252) Ac-Glu-c[Asp-His-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 253) Ac-Glu-c[Glu-His-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 254) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 255) Ac-Glu-c[Glu-His-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 256) Ac-Glu-c[Lys-His-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 257) Ac-Glu-c[Lys-His-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 258) Ac-Glu-c[Lys-His-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 259) Ac-Glu-c[Orn-His-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 260) Ac-Glu-c[Orn-His-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 261)Docket No.: 183B-416027-WO Ac-Glu-c[Dab-His-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 262) Ac-Glu-c[Dab-His-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 263) Ac-Glu-c[Dab-His-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 264) Ac-Glu-c[Aad-His-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 265) Ac-Glu-c[Aad-His-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 266) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268) Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 269) Ac-Nle-c[Asp-dHis-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 271) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 272) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 273) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 274) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 276) Ac-Nle-c[Asp-Trp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 277) Ac-Nle-c[Glu-Trp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 278) Ac-Nle-c[Lys-Trp-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 279) Ac-Nle-c[Aad-Trp-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 280) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 281) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 282) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 283) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 284) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 285) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 286)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 287) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 288) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 289) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 290) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 291) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 292) Ac-dGln-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 293) Ac-dGln-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 294) Ac-dGln-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 295) Ac-dGln-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 296) Ac-dGln-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 297) Ac-dGln-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 298) Ac-dGln-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299) Ac-dGln-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 300) Ac-dGln-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 301) Ac-dGln-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 302) Ac-dGln-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 303) Ac-dGln-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 304) Ac-dAsn-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305) Ac-dAsn-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 306) Ac-dAsn-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 307) Ac-dAsn-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 308) Ac-dAsn-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 309) Ac-dAsn-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 310)Docket No.: 183B-416027-WO Ac-dAsn-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311) Ac-dAsn-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 312) Ac-dAsn-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 313) Ac-dAsn-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 314) Ac-dAsn-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 315) Ac-dAsn-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 316) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 317) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 318) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 319) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 320) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 321) Ac-Nle-c[Glu-β-Ala-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322) Ac-Nle-c[Lys-β-Ala-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 323) Ac-Nle-c[Orn-β-Ala-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 324) Ac-Nle-c[Aad-β-Ala-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 325) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 326) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 327) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 328) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 329) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 330) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 331) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 332) Ac-Nle-c[Orn-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 333) Ac-Nle-c[Dab-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 334)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 335) Ac-Nle-c[Aad-Mamb-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 336) Ac-Ala-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 337) Ac-Ala-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 338) Ac-Ala-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 339) Ac-Ala-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 340) Ac-Ala-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 341) Ac-Ala-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 342) Ac-Ala-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 343) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 344) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 345) Ac-Ala-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 346) Ac-Nle-c[Asp-His-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 347) Ac-Nle-c[Glu-His-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 348) Ac-Nle-c[Lys-His-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 349) Ac-Nle-c[Orn-His-p(Cl)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 350) Ac-Nle-c[Dab-His-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 351) Ac-Nle-c[Aad-His-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 352) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 353) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 354) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 355) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 356) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 357) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 359) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 360) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 361) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 362) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 363) Ac-Nle-c[Asp-His-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364) Ac-Nle-c[Glu-His-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 365) Ac-Nle-c[Lys-His-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 366) Ac-Nle-c[Orn-His-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 367) Ac-Nle-c[Dab-His-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 368) Ac-Nle-c[Aad-His-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 369) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 370) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 371) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 372) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 373) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 374) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 375) Ac-Nle-c[Asp-His-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 376) Ac-Nle-c[Glu-His-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 377) Ac-Nle-c[Lys-His-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 378) Ac-Nle-c[Orn-His-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 379) Ac-Nle-c[Dab-His-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 380) Ac-Nle-c[Aad-His-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 381) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 382)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 383) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 384) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 385) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 386) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 387) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 388) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 389) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 390) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 391) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 392) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 393) Ac-dVal-dPro-c[Lys-Trp-Arg-p(Cl)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 394) Ac-dVal-dPro-c[Asp-Trp-Arg-p(Cl)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 395) Ac-dVal-dPro-c[Glu-Trp-Arg-p(Cl)dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 396) Dmt-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 397) Dmt-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 398) Dmt-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 399) Dmt-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 400) Dmt-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 401) Dmt-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 402) Ac-dAla-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 403) Ac-dAla-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 404) Ac-dAla-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 405) Ac-dAla-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 406)Docket No.: 183B-416027-WO Ac-dAla-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 407) Ac-dAla-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 408) Ac-dAla-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 409) Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 410) Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 411) Ac-dAla-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 412) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 414) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 415) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 416) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 417) Ac-Nle-c[Glu-His-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 418) Ac-Nle-c[Lys-His-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 419) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 420) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 421) Ac-Nle-c[Aad-His-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 422) Ac-Nle-c[Glu-Pro-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 423) Ac-Nle-c[Lys-Pro-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 424) Ac-Nle-c[Orn-Pro-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 425) Ac-Nle-c[Aad-Pro-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 426) Ac-Nle-c[Asp-Pro-Gly-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427) Ac-Nle-c[Glu-Pro-Gly-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 428) Ac-Nle-c[Lys-Pro-Gly-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 429) Ac-Nle-c[Orn-Pro-Gly-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 430)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-Gly-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 431) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 432) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 433) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 434) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 435) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 436) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 437) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 438) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 440) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 441) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 442) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 443) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 445) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-NH2 (SEQ ID NO: 446) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-NH2 (SEQ ID NO: 447) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 448) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-Nle-NH2 (SEQ ID NO: 449) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 450) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 451) Ac-dVal-dPro-c[Lys-Trp-Arg-p(F)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 452) Ac-dVal-dPro-c[Orn-Trp-Arg-dNal(2')-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 453) Ac-dVal-dPro-c[Orn-Trp-Arg-p(F)dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 454)Docket No.: 183B-416027-WO Ac-dVal-dPro-c[Dab-Trp-Arg-dNal(2')-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 455) Ac-dVal-dPro-c[Dab-Trp-Arg-p(F)dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 456) Ac-dVal-dPro-c[Aad-Trp-Arg-p(F)dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 457) Ac-dVal-dPro-c[Asp-Trp-Arg-p(F)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 458) Ac-dVal-dPro-c[Glu-Trp-Arg-dNal(2')-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 459) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 460) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 461) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 462) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 463) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 464) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-dPro-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 467) Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468) Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470) c[CO-cis-CH = CH-CO-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471) Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472) Ac-dGln-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 473) Ac-dAsn-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 474) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 475) Ac-Nle-c[Asp-His-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 476) Ac-Nle-c[Asp-Pro-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 477) Dmt-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 478)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 479) Ac-Nle-c[dAsp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 480) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 481) Ac-Nle-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 482) Ac-Nle-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 483) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 484) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 485) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 486) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 487) Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488) Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489) Ac-Nle-c[Asp-Pro-Gly-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 490) Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491) Ac-Nle-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492) Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493) Ac-Nle-c[Asp-Pro-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494) Ac-Nle-c[Asp-Pro-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495) Ac-Nle-c[Asp-Pro-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Lys]-dVal-dPro-NH2 (SEQ ID NO: 497) Ac-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 498) Ac-Nle-c[Glu-Trp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 503) Ac-Nle-c[Lys-Trp-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 504) Ac-Nle-c[Orn-Trp-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 505) Ac-Nle-c[Dab-Trp-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 506)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Trp-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 507) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 508) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 509) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 510) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 511) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 512) Ac-Nle-c[Asp-His-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 513) Ac-Nle-c[Glu-His-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 514) Ac-Nle-c[Lys-His-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 515) Ac-Nle-c[Orn-His-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 516) Ac-Nle-c[Dab-His-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 517) Ac-Nle-c[Aad-His-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 518) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 519) Ac-dGln-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 520) Ac-dGln-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 521) Ac-dGln-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 522) Ac-dGln-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 523) Ac-dGln-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 524) Ac-dGln-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 525) Ac-dGln-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 526) Ac-dGln-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 527) Ac-dGln-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 528) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 529) Ac-dAsn-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 530)Docket No.: 183B-416027-WO Ac-dAsn-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 531) Ac-dAsn-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 532) Ac-dAsn-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 533) Ac-dAsn-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 534) Ac-dAsn-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 535) Ac-dAsn-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 536) Ac-dAsn-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 537) Ac-dAsn-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 538) c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 539) c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 541) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 542) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 543) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 544) Ac-Nle-c[Glu-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 545) Ac-Nle-c[Orn-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 546) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 547) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 548) Ac-Nle-c[Aad-Mamb-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 549) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 550) Ac-Ala-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 551) Ac-Ala-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 552) Ac-Ala-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 553) Ac-Ala-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 554)Docket No.: 183B-416027-WO Ac-Ala-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 555) Ac-Ala-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 556) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 557) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 558) Ac-Ala-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 559) Ac-Nle-c[Glu-His-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 561) Ac-Nle-c[Lys-His-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 562) Ac-Nle-c[Orn-His-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 563) Ac-Nle-c[Dab-His-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 564) Ac-Nle-c[Aad-His-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 565) Ac-Nle-c[Glu-Pro-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 566) Ac-Nle-c[Lys-Pro-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 567) Ac-Nle-c[Orn-Pro-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 568) Ac-Nle-c[Dab-Pro-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 569) Ac-Nle-c[Aad-Pro-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 570) Ac-Nle-c[Glu-Pro-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 571) Ac-Nle-c[Lys-Pro-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 572) Ac-Nle-c[Orn-Pro-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 573) Ac-Nle-c[Dab-Pro-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 574) Ac-Nle-c[Aad-Pro-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 575) Ac-Nle-c[Asp-His-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 576) Ac-Nle-c[Glu-His-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 577) Ac-Nle-c[Lys-His-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 578) Ac-Nle-c[Orn-His-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 579)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-His-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 580) Ac-Nle-c[Aad-His-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 581) Ac-Nle-c[Glu-Pro-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 582) Ac-Nle-c[Lys-Pro-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 583) Ac-Nle-c[Orn-Pro-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 584) Ac-Nle-c[Dab-Pro-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 585) Ac-Nle-c[Aad-Pro-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 586) Ac-Nle-c[Asp-His-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 587) Ac-Nle-c[Glu-His-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 588) Ac-Nle-c[Lys-His-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 589) Ac-Nle-c[Orn-His-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 590) Ac-Nle-c[Dab-His-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 591) Ac-Nle-c[Aad-His-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 592) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 593) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 594) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 595) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 596) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 597) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 598) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 599) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 600) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 601) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 602) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 603)Docket No.: 183B-416027-WO Dmt-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 604) Dmt-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 605) Dmt-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 606) Dmt-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 607) Dmt-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 608) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 609) Ac-dAla-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 610) Ac-dAla-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 611) Ac-dAla-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 612) Ac-dAla-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 613) Ac-dAla-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 614) Ac-dAla-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 615) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 616) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 617) Ac-dAla-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 618) Ac-Nle-c[Glu-Pro-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 619) Ac-Nle-c[Lys-Pro-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 620) Ac-Nle-c[Orn-Pro-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 621) Ac-Nle-c[Aad-Pro-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 622) Ac-Nle-c[Asp-His-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 623) Ac-Nle-c[Glu-His-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 624) Ac-Nle-c[Lys-His-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 625) Ac-Nle-c[Orn-His-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 626) Ac-Nle-c[Orn-His-dNal(2')-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 627)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-His-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 628) Ac-Nle-c[Glu-Pro-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 629) Ac-Nle-c[Lys-Pro-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 630) Ac-Nle-c[Orn-Pro-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 631) Ac-Nle-c[Glu-Pro-Gly-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 632) Ac-Nle-c[Lys-Pro-Gly-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 633) Ac-Nle-c[Orn-Pro-Gly-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 634) Ac-Nle-c[Aad-Pro-Gly-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 635) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 636) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 637) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 638) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 639) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 640) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 641) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 642) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 643) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 644) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 645) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 646) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 647) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 648) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 649) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 650) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 651)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 652) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 653) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 654) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 655) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 656) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 657) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 658) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 659) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 660) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 661) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 662) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 663) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 664) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 665) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 666) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 667) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 668) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 669) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 670) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 671) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 672) Ac-dGln-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 673) Ac-dGln-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 674)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-dNal(2')-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 675) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 676) Ac-Nle-c[dAsp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 677) Ac-Nle-c[dLys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 678) Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 679) Ac-Nle-c[Asp-β-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 680) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 681) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 682) Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 683) Ac-Nle-c[Asp-dHis-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 684) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 685) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 686) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 687) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 688) Ac-Nle-c[Asp-Trp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 689) Ac-Nle-c[Glu-Trp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 690) Ac-Nle-c[Lys-Trp-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 691) Ac-Nle-c[Orn-Trp-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 692) Ac-Nle-c[Dab-Trp-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 693) Ac-Nle-c[Aad-Trp-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 694) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 695) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 696) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 697) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 698)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 699) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 700) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 701) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 702) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 703) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 704) Ac-dAsn-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 705) Ac-dAsn-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 706) Ac-dAsn-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 707) Ac-dAsn-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 708) Ac-dAsn-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 709) Ac-dAsn-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 710) Ac-dAsn-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 711) Ac-dAsn-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 712) Ac-dAsn-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 713) Ac-dAsn-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 714) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 715) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 716) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 717) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 718) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 719) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 720) Ac-Nle-c[Asp-β-Ala-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 721) Ac-Nle-c[Lys-β-Ala-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 722)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-β-Ala-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 723) Ac-Nle-c[Aad-β-Ala-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 724) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 725) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 726) Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 727) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 728) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 729) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 730) Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 731) Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 732) Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 733) Ac-Nle-c[Glu-Mamb-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 734) Ac-Nle-c[Lys-Mamb-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 735) Ac-Nle-c[Orn-Mamb-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 736) Ac-Nle-c[Dab-Mamb-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 737) Ac-Nle-c[Aad-Mamb-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 738) Ac-Nle-c[Asp-His-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 739) Ac-Nle-c[Glu-His-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 740) Ac-Nle-c[Lys-His-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 741) Ac-Nle-c[Orn-His-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 742) Ac-Nle-c[Dab-His-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 743) Ac-Nle-c[Aad-His-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 744) Ac-Nle-c[Lys-Pro-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 745) Ac-Nle-c[Asp-Pro-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 746)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 747) Ac-Nle-c[Lys-Pro-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 748) Ac-Nle-c[Orn-Pro-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 749) Ac-Nle-c[Dab-Pro-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 750) Ac-Nle-c[Aad-Pro-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 751) Ac-Nle-c[Asp-His-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 752) Ac-Nle-c[Glu-His-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 753) Ac-Nle-c[Lys-His-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 754) Ac-Nle-c[Orn-His-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 755) Ac-Nle-c[Aad-His-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 756) Ac-Nle-c[Asp-Pro-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 757) Ac-Nle-c[Glu-Pro-p(F)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 758) Ac-Nle-c[Lys-Pro-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 759) Ac-Nle-c[Orn-Pro-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 760) Ac-Nle-c[Asp-His-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 761) Ac-Nle-c[Lys-His-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 762) Ac-Nle-c[Orn-His-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 763) Ac-Nle-c[Dab-His-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 764) Ac-Nle-c[Aad-His-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 765) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 766) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 767) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 768) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 769) Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 770)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 771) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 772) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 773) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 774) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 775) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 776) Ac-Nle-c[Glu-Pro-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 777) Ac-Nle-c[Orn-Pro-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 778) Ac-Nle-c[Aad-Pro-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 779) Ac-Nle-c[Glu-His-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 780) Ac-Nle-c[Lys-His-p(F)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 781) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 782) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 783) Ac-Nle-c[Aad-His-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 784) Ac-Nle-c[Asp-Pro-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 785) Ac-Nle-c[Glu-Pro-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 786) Ac-Nle-c[Lys-Pro-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 787) Ac-Nle-c[Orn-Pro-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 788) Ac-Nle-c[Aad-Pro-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 789) Ac-Nle-c[Glu-Pro-Gly-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 790) Ac-Nle-c[Lys-Pro-Gly-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 791) Ac-Nle-c[Orn-Pro-Gly-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 792) Ac-Nle-c[Aad-Pro-Gly-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 793) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 794)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 795) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 796) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 797) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 798) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 799) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 800) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 801) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 802) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 803) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 804) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 805) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 806) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 807) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-dPro-NH3 (SEQ ID NO: 808) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 809) Ac-dAsn-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 810) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 811) Ac-dAsn-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 812) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 820) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 821) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 822) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 823) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 824) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 825)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 826) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 827) Ac-Nle-c[Glu-His-Trp-Arg-p(F)dPhe-Orn]-dVal-dPro-NH2 (SEQ ID NO: 836) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 837) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 838) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 839) Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 840) Ac-Nle-c[Das-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 841) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 843) Ac-Nle-c[Asp-Pro-d(F)Phe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 844) Ac-Nle-c[Asp-Pro-Gly-d(F)Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 845) Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 846) Ac-Ala-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 847) Ac-Ala-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 848) Ac-Ala-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 849) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 850) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 851) Ac-Ala-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 852) Ac-dAla-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 853) Ac-dAla-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 854) Ac-dAla-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 855) Ac-dAla-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 856) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 857) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 858)Docket No.: 183B-416027-WO Ac-dAla-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 859) Ac-Ala-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 860) Ac-dAla-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 861) Ac-Ala-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 862) Ac-dAla-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 863) Ac-dGln-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 864) Ac-dGln-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 865) Ac-dGln-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 866) Ac-dGln-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 867) Ac-dGln-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 868) Ac-dGln-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 869) Ac-dGln-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 870) Ac-dGln-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 871) Ac-dGln-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 872) Ac-dGln-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 873) Ac-dGln-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 874) Ac-dPro-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 875) Ac-dPro-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 876) Ac-Nle-c[Asp-Pro-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 877) Ac-Nle-c[Glu-Pro-dNal(1')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 878) and Ac-Nle-c[Asp-Pro-Gly-dNal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 879), wherein c represents cyclization through a lactam bond between R2and R7.

[0053] In some embodiments of the sequence of Formula (I) or (IA), R4is dNal(2’). Accordingly, in some embodiments, the sequence of Formula (I) or (IA) is a sequence of Formula (IB):Docket No.: 183B-416027-WO R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IB), wherein: R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D- glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D-histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is 2’-D-naphthylalanine (dNal(2’)); R5is arginine (Arg), or Pro; R6is absent, Trp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), and dPro; Y2is absent, or dPro; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap,Docket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when Y3is Lys, then R1is Glu, and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R1is dAsn, then, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; when R1is dGln, then R2is Asp and R3is dAla, His, or dHis; when R1is Glu, then Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; when R1is absent, then either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; and when R1is Nle, then (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab.

[0054] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IB): R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IB), wherein: R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D- glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das);Docket No.: 183B-416027-WO R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D-histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is 2’-D-naphthylalanine (dNal(2’)); R5is arginine (Arg), or Pro; R6is absent, Trp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), and dPro; Y2is absent, or dPro; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when Y3is Lys, then R1is Glu, and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R1is dAsn, then, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; when R1is dGln, then R2is Asp and R3is dAla, His, or dHis;Docket No.: 183B-416027-WO when R1is Glu, then Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; when R1is absent, then either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; and when R1is Nle, then (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab.

[0055] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IB), wherein: R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D- glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D-histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is 2’-D-naphthylalanine (dNal(2’)); R5is arginine (Arg), or Pro; R6is absent, Trp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab;Docket No.: 183B-416027-WO Y1is selected from the group consisting of dVal, D-arginine (dArg), and dPro; Y2is absent, or dPro; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of: Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 238) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 239) Ac-Glu-c[Glu-His-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 254) Ac-Glu-c[Lys-His-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 257) Ac-Glu-c[Dab-His-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 262) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-NH2 (SEQ ID NO: 446) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-NH2 (SEQ ID NO: 447) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 448) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-Nle-NH2 (SEQ ID NO: 449) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 450) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 451) Ac-dVal-dPro-c[Orn-Trp-Arg-dNal(2')-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 453)Docket No.: 183B-416027-WO Ac-dVal-dPro-c[Dab-Trp-Arg-dNal(2')-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 455) Ac-dVal-dPro-c[Glu-Trp-Arg-dNal(2')-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 459) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 460) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 461) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 462) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 463) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 464) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-dPro-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 467) Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468) Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470) c[CO-cis-CH = CH-CO-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471) Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472) Ac-dGln-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 473) Ac-dAsn-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 474) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 475) Ac-Nle-c[Asp-His-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 476) Ac-Nle-c[Asp-Pro-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 477) Dmt-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 478) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 479) Ac-Nle-c[dAsp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 480) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 481)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 482) Ac-Nle-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 483) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 484) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 485) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 486) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 487) Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488) Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489) Ac-Nle-c[Asp-Pro-Gly-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 490) Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491) Ac-Nle-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492) Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493) Ac-Nle-c[Asp-Pro-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494) Ac-Nle-c[Asp-Pro-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495) Ac-Nle-c[Asp-Pro-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Lys]-dVal-dPro-NH2 (SEQ ID NO: 497) Ac-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 498) Ac-Nle-c[Glu-Trp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 503) Ac-Nle-c[Lys-Trp-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 504) Ac-Nle-c[Orn-Trp-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 505) Ac-Nle-c[Dab-Trp-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 506) Ac-Nle-c[Aad-Trp-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 507) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 508) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 509)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 510) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 511) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 512) Ac-Nle-c[Asp-His-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 513) Ac-Nle-c[Glu-His-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 514) Ac-Nle-c[Lys-His-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 515) Ac-Nle-c[Orn-His-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 516) Ac-Nle-c[Dab-His-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 517) Ac-Nle-c[Aad-His-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 518) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 519) Ac-dGln-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 520) Ac-dGln-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 521) Ac-dGln-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 522) Ac-dGln-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 523) Ac-dGln-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 524) Ac-dGln-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 525) Ac-dGln-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 526) Ac-dGln-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 527) Ac-dGln-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 528) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 529) Ac-dAsn-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 530) Ac-dAsn-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 531) Ac-dAsn-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 532) Ac-dAsn-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 533)Docket No.: 183B-416027-WO Ac-dAsn-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 534) Ac-dAsn-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 535) Ac-dAsn-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 536) Ac-dAsn-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 537) Ac-dAsn-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 538) c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 539) c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 541) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 542) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 543) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 544) Ac-Nle-c[Glu-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 545) Ac-Nle-c[Orn-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 546) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 547) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 548) Ac-Nle-c[Aad-Mamb-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 549) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 550) Ac-Ala-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 551) Ac-Ala-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 552) Ac-Ala-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 553) Ac-Ala-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 554) Ac-Ala-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 555) Ac-Ala-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 556) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 557)Docket No.: 183B-416027-WO Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 558) Ac-Ala-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 559) Ac-Nle-c[Glu-His-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 561) Ac-Nle-c[Lys-His-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 562) Ac-Nle-c[Orn-His-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 563) Ac-Nle-c[Dab-His-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 564) Ac-Nle-c[Aad-His-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 565) Ac-Nle-c[Glu-Pro-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 566) Ac-Nle-c[Lys-Pro-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 567) Ac-Nle-c[Orn-Pro-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 568) Ac-Nle-c[Dab-Pro-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 569) Ac-Nle-c[Aad-Pro-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 570) Ac-Nle-c[Glu-Pro-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 571) Ac-Nle-c[Lys-Pro-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 572) Ac-Nle-c[Orn-Pro-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 573) Ac-Nle-c[Dab-Pro-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 574) Ac-Nle-c[Aad-Pro-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 575) Ac-Nle-c[Asp-His-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 576) Ac-Nle-c[Glu-His-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 577) Ac-Nle-c[Lys-His-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 578) Ac-Nle-c[Orn-His-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 579) Ac-Nle-c[Dab-His-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 580) Ac-Nle-c[Aad-His-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 581) Ac-Nle-c[Glu-Pro-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 582)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 583) Ac-Nle-c[Orn-Pro-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 584) Ac-Nle-c[Dab-Pro-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 585) Ac-Nle-c[Aad-Pro-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 586) Ac-Nle-c[Asp-His-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 587) Ac-Nle-c[Glu-His-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 588) Ac-Nle-c[Lys-His-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 589) Ac-Nle-c[Orn-His-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 590) Ac-Nle-c[Dab-His-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 591) Ac-Nle-c[Aad-His-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 592) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 593) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 594) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 595) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 596) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 597) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 598) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 599) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 600) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 601) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 602) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 603) Dmt-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 604) Dmt-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 605) Dmt-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 606)Docket No.: 183B-416027-WO Dmt-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 607) Dmt-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 608) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 609) Ac-dAla-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 610) Ac-dAla-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 611) Ac-dAla-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 612) Ac-dAla-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 613) Ac-dAla-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 614) Ac-dAla-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 615) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 616) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 617) Ac-dAla-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 618) Ac-Nle-c[Glu-Pro-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 619) Ac-Nle-c[Lys-Pro-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 620) Ac-Nle-c[Orn-Pro-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 621) Ac-Nle-c[Aad-Pro-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 622) Ac-Nle-c[Asp-His-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 623) Ac-Nle-c[Glu-His-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 624) Ac-Nle-c[Lys-His-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 625) Ac-Nle-c[Orn-His-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 626) Ac-Nle-c[Orn-His-dNal(2')-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 627) Ac-Nle-c[Aad-His-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 628) Ac-Nle-c[Glu-Pro-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 629) Ac-Nle-c[Lys-Pro-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 630)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 631) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 636) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 637) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 638) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 639) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 640) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 641) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 642) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 643) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 644) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 645) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 646) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 647) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 648) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 649) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 650) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 651) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 652) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 653) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 654) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 655) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 656) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 657)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 658) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 659) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 660) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 661) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 662) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 663) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 664) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 665) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 666) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 667) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 668) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 669) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 670) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 671) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 672) Ac-dGln-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 673) Ac-dGln-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 674) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 675) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 676) Ac-Nle-c[dAsp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 677) Ac-Nle-c[dLys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 678) Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 679); and Ac-Nle-c[Asp-β-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 680), wherein c represents cyclization through a lactam bond between R2and R7.Docket No.: 183B-416027-WO

[0056] In some embodiments of the sequence of Formula (I) or (IA), R4is dPhe or p(F)dPhe. Accordingly, in some embodiments, the sequence of Formula (I) or (IA) is a sequence of Formula (IC): R1-R2-R3-R4-R5-R6-R7-Y1-Y2(IC), wherein: R1is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-glycine (Pro-Gly), proline (Pro), histidine (His), and 3-aminomethylbenzoic acid (Mamb); R4is D-phenylalanine (dPhe) or para-fluoro-D-phenylalanine (p(F)dPhe); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, or dTrp; R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is dVal; Y2is dPro; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap,Docket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is Dmt and R3is Pro; or (iv) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn.

[0057] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IC): R1-R2-R3-R4-R5-R6-R7-Y1-Y2(IC), wherein: R1is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β-dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-glycine (Pro-Gly), proline (Pro), histidine (His), and 3-aminomethylbenzoic acid (Mamb);Docket No.: 183B-416027-WO R4is D-phenylalanine (dPhe) or para-fluoro-D-phenylalanine (p(F)dPhe); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, or dTrp; R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is dVal; Y2is dPro; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is Dmt and R3is Pro; or (iv) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2isDocket No.: 183B-416027-WO Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, or (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab.

[0058] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of Formula (IC), wherein: R1is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β-dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-glycine (Pro-Gly), proline (Pro), histidine (His), and 3-aminomethylbenzoic acid (Mamb); R4is D-phenylalanine (dPhe) or para-fluoro-D-phenylalanine (p(F)dPhe); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, or dTrp; R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is dVal; Y2is dPro; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap,Docket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4) Ac-Nle-c[Asp-His-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5) Ac-Nle-c[Asp-Pro-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 6) Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 7) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 8) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 9) Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 10) Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 11) Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 16) Ac-Nle-c[Asp-dHis-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 17) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 22) Ac-Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 23)Docket No.: 183B-416027-WO Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 25) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 26) Ac-Glu-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 27) Ac-Nle-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28) Ac-Nle-c[Asp-dAla-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29) Ac-dVal-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 30) Ac-Nle-c[Glu-Trp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 32) Ac-Nle-c[Lys-Trp-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 33) Ac-Nle-c[Orn-Trp-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 34) Ac-Nle-c[Dab-Trp-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 35) Ac-Nle-c[Aad-Trp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 36) Ac-Nle-c[Glu-Pro-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 37) Ac-Nle-c[Lys-Pro-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 38) Ac-Nle-c[Dab-Pro-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 39) Ac-Nle-c[Asp-His-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 40) Ac-Nle-c[Glu-His-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 41) Ac-Nle-c[Lys-His-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 42) Ac-Nle-c[Orn-His-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 43) Ac-Nle-c[Dab-His-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 44) Ac-Nle-c[Aad-His-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 45) Ac-dAsn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 46) Ac-dAsn-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 47) Ac-dAsn-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 48) Ac-dAsn-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 49)Docket No.: 183B-416027-WO Ac-dAsn-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 50) Ac-dAsn-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 51) Ac-dAsn-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 52) Ac-dAsn-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 53) Ac-dAsn-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 54) Ac-dAsn-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 55) Ac-dAsn-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 56) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 57) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 58) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 59) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 60) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 61) Ac-Nle-c[Asp-β-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 63) Ac-Nle-c[Glu-β-Ala-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64) Ac-Nle-c[Lys-β-Ala-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 65) Ac-Nle-c[Orn-β-Ala-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 66) Ac-Nle-c[Dab-β-Ala-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 67) Ac-Nle-c[Aad-β-Ala-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 68) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 69) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 70) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 71) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 72) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 73) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 74)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 75) Ac-Nle-c[Lys-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 76) Ac-Nle-c[Orn-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 77) Ac-Nle-c[Dab-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 78) Ac-Nle-c[Aad-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 79) Ac-Nle-c[Glu-Mamb-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 80) Ac-Nle-c[Lys-Mamb-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 81) Ac-Nle-c[Orn-Mamb-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 82) Ac-Nle-c[Dab-Mamb-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 83) Ac-Nle-c[Aad-Mamb-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 84) Ac-Ala-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 85) Ac-Ala-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 86) Ac-Ala-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 87) Ac-Ala-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 88) Ac-Ala-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 89) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 90) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 91) Ac-Ala-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 92) Ac-Nle-c[Glu-His-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 94) Ac-Nle-c[Lys-His-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 95) Ac-Nle-c[Orn-His-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 96) Ac-Nle-c[Dab-His-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 97) Ac-Nle-c[Aad-His-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 98) Ac-Nle-c[Glu-Pro-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 99)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 100) Ac-Nle-c[Orn-Pro-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 101) Ac-Nle-c[Dab-Pro-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 102) Ac-Nle-c[Aad-Pro-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 103) Ac-Nle-c[Asp-His-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 104) Ac-Nle-c[Glu-His-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 105) Ac-Nle-c[Lys-His-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 106) Ac-Nle-c[Orn-His-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 107) Ac-Nle-c[Dab-His-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 108) Ac-Nle-c[Aad-His-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 109) Ac-Nle-c[Asp-Pro-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 110) Ac-Nle-c[Glu-Pro-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 111) Ac-Nle-c[Orn-Pro-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 112) Ac-Nle-c[Dab-Pro-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 113) Ac-Nle-c[Asp-His-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 114) Ac-Nle-c[Glu-His-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 115) Ac-Nle-c[Lys-His-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 116) Ac-Nle-c[Orn-His-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 117) Ac-Nle-c[Dab-His-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 118) Ac-Nle-c[Aad-His-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 119) Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 137) Dmt-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 138) Ac-dAla-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 139) Ac-dAla-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 140)Docket No.: 183B-416027-WO Ac-dAla-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 141) Ac-dAla-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 142) Ac-dAla-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 143) Ac-dAla-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 144) Ac-dAla-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 145) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 146) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 147) Ac-dAla-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 148) Ac-Nle-c[Asp-Pro-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 149) Ac-Nle-c[Glu-Pro-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 150) Ac-Nle-c[Lys-Pro-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 151) Ac-Nle-c[Orn-Pro-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 152) Ac-Nle-c[Aad-Pro-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 153) Ac-Nle-c[Asp-His-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 154) Ac-Nle-c[Glu-His-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 155) Ac-Nle-c[Lys-His-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 156) Ac-Nle-c[Orn-His-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 157) Ac-Nle-c[Orn-His-dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 158) Ac-Nle-c[Aad-His-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 159) Ac-Nle-c[Asp-Pro-Gly-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 176) Ac-Nle-c[Lys-Pro-Gly-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 177) Ac-Nle-c[Orn-Pro-Gly-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 178) Ac-Nle-c[Aad-Pro-Gly-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 179) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 180)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 181) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 182) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 183) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 184) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 185) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 186) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 187) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 188) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 189) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 190) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 191) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 192) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 193) Ac-Nle-c[Glu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194) Ac-Nle-c[Lys-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 195) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 201) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 202) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 203) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 204) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 205) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 206) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 207) Ac-dGln-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215)Docket No.: 183B-416027-WO Ac-dGln-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 216) Ac-dGln-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 217) Ac-dGln-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 218) Ac-dGln-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 219) Ac-dGln-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 220) Ac-dGln-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 221) Ac-dGln-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 222) Ac-dGln-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 223) Ac-dGln-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 224) Ac-dGln-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 225) Ac-dGln-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 226) Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 227) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 681) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 682) Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 683) Ac-Nle-c[Asp-dHis-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 684) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 685) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 686) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 687) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 688) Ac-Nle-c[Asp-Trp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 689) Ac-Nle-c[Glu-Trp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 690) Ac-Nle-c[Lys-Trp-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 691) Ac-Nle-c[Orn-Trp-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 692)Docket No.: 183B-416027-WO Ac-Nle-c[Dab-Trp-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 693) Ac-Nle-c[Aad-Trp-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 694) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 695) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 696) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 697) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 698) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 699) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 700) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 701) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 702) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 703) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 704) Ac-dAsn-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 705) Ac-dAsn-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 706) Ac-dAsn-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 707) Ac-dAsn-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 708) Ac-dAsn-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 709) Ac-dAsn-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 710) Ac-dAsn-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 711) Ac-dAsn-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 712) Ac-dAsn-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 713) Ac-dAsn-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 714) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 725) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 726)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 727) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 728) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 729) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 730) Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 731) Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 732) Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 733) Ac-Nle-c[Glu-Mamb-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 734) Ac-Nle-c[Lys-Mamb-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 735) Ac-Nle-c[Orn-Mamb-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 736) Ac-Nle-c[Dab-Mamb-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 737) Ac-Nle-c[Aad-Mamb-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 738) Ac-Nle-c[Asp-His-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 739) Ac-Nle-c[Glu-His-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 740) Ac-Nle-c[Lys-His-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 741) Ac-Nle-c[Orn-His-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 742) Ac-Nle-c[Dab-His-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 743) Ac-Nle-c[Aad-His-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 744) Ac-Nle-c[Lys-Pro-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 745) Ac-Nle-c[Asp-Pro-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 746) Ac-Nle-c[Glu-Pro-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 747) Ac-Nle-c[Lys-Pro-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 748) Ac-Nle-c[Orn-Pro-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 749) Ac-Nle-c[Dab-Pro-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 750)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 751) Ac-Nle-c[Asp-His-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 752) Ac-Nle-c[Glu-His-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 753) Ac-Nle-c[Lys-His-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 754) Ac-Nle-c[Orn-His-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 755) Ac-Nle-c[Aad-His-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 756) Ac-Nle-c[Asp-Pro-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 757) Ac-Nle-c[Glu-Pro-p(F)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 758) Ac-Nle-c[Lys-Pro-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 759) Ac-Nle-c[Orn-Pro-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 760) Ac-Nle-c[Asp-His-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 761) Ac-Nle-c[Lys-His-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 762) Ac-Nle-c[Orn-His-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 763) Ac-Nle-c[Dab-His-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 764) Ac-Nle-c[Aad-His-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 765) Ac-Nle-c[Glu-Pro-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 777) Ac-Nle-c[Orn-Pro-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 778) Ac-Nle-c[Aad-Pro-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 779) Ac-Nle-c[Glu-His-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 780) Ac-Nle-c[Lys-His-p(F)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 781) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 782) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 783) Ac-Nle-c[Aad-His-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 784) Ac-Nle-c[Glu-Pro-Gly-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 790)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-Gly-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 791) Ac-Nle-c[Orn-Pro-Gly-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 792) Ac-Nle-c[Aad-Pro-Gly-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 793) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 794) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 795) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 796) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 797) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 798) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 799) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 800) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 801) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 802) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 803) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 804) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 805) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 806) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 807) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 809) Ac-dAsn-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 810) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 811) Ac-dAsn-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 812) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 820) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 821) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 822)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 823) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 824) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 825) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 826) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 827); Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 837) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 838) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 839) Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 840) Ac-Nle-c[Das-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 841) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 843) Ac-Nle-c[Asp-Pro-d(F)Phe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 844) Ac-Nle-c[Asp-Pro-Gly-d(F)Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 845) Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 846) Ac-Ala-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 847) Ac-Ala-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 848) Ac-Ala-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 849) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 850) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 851) Ac-Ala-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 852) Ac-dAla-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 853) Ac-dAla-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 854) Ac-dAla-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 855) Ac-dAla-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 856)Docket No.: 183B-416027-WO Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 857) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 858) Ac-dAla-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 859) Ac-Ala-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 860) Ac-dAla-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 861) Ac-Ala-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 862) Ac-dAla-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 863) Ac-dGln-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 864) Ac-dGln-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 865) Ac-dGln-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 866) Ac-dGln-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 867) Ac-dGln-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 868) Ac-dGln-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 869) Ac-dGln-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 870) Ac-dGln-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 871) Ac-dGln-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 872) Ac-dGln-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 873); and Ac-dGln-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 874). wherein c represents cyclization through a lactam bond between R2and R7.

[0059] In some embodiments, the non-naturally occurring melanocortin analog has one or more beta hairpin (β-hairpin) and / or beta turn (β-turn) structures. In some embodiments, R3of the sequence according to any one of Formulae (I)-(IC) provides the β-hairpin and / or β-turn structures of the non-naturally occurring melanocortin analogs.

[0060] As will be appreciated by the skilled artisan, non-naturally occurring melanocortin analogs comprising a sequence of any one of Formulae (I)-(IC), have an N-Docket No.: 183B-416027-WO terminus and a C-terminus. The melanocortin analogs of the present technology are written beginning with the N-terminus at the left-most amino acid residue and ending with the C- terminus at the right most residue. Accordingly, the N-terminus of a non-naturally melanocortin analog comprising a sequence of any one of Formulae (I)-(IC) may be at any one of X1, X2, X3, or R1. Similarly, the C-terminus of a non-naturally occurring melanocortin analog comprising a sequence of any one of Formulae (I)-(IB(ii)) may be at Y2, Y3, or Y4.

[0061] In some embodiments, the N-terminus of the non-naturally occurring melanocortin analog, if present, is modified by an acyl group. In some embodiments, the acyl group is acetyl ).

[0062] Alternatively,N-terminus of the non-naturally occurring melanocortin analog, if present, is not modified.

[0063] The moiety Y1Y2Y3Y4represents a C-terminus of the non-naturally occurring melanocortin analog. In some embodiments, the most C-terminal residues of the melanocortin analog are dVal-dPro. The C-terminal dVal-dPro moiety may confer improved properties on the melanocortin analog, such as increased plasma duration and improved transport across the blood-brain-barrier, the epithelium, and / or gastrointestinal tract.

[0064] In some embodiments, Y1is present and Y2-Y4are absent. In some embodiments when Y1is present and Y2-Y4are absent, then Y1is dArg.

[0065] In some embodiments, Y1and Y2are present and Y3and Y4are absent. In some embodiments, when Y1and Y2are present and Y3and Y4are absent , then Y1is dVal and Y2is dPro.

[0066] In some embodiments, Y1-Y4are present. In some embodiments, when Y1-Y4are present, then Y1is dVal, Y2is dVal, Y3is dVal, and Y4is dPro. In some embodiments, when Y1-Y4are present, then Y1is dPro, Y2is dPro, Y3is Lys, and Y4is Asp.Docket No.: 183B-416027-WO

[0067] In some embodiments, the C-terminus of the non-naturally occurring melanocortin analog is modified an amide ). In the sequence of any one of Formulae (I)-(IC), a non- analog with a C-terminus modified by an amide may be -

[0068] In some embodiments of any one of Formulae (I)-(IC), the C-terminus of the non-naturally occurring melanocortin analog is not modified. In the sequence of any one of Formulae (I)-(IC), a non-naturally occurring melanocortin analog with an unmodified C- terminus may be represented by -OH.

[0069] Non-naturally occurring melanocortin analogs comprising a sequence of any one of Formulae (I)-(IC) may be cyclized. For example, the non-naturally occurring melanocortin analog may be cyclized through a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu.

[0070] In some embodiments, the non-naturally occurring melanocortin analogs is cyclized through a side-chain lactam bridge. In some embodiments, the non-naturally occurring melanocortin analog is cyclized through a lactam bond between Asp at R2and Lys at R7. In other embodiments, the non-naturally occurring melanocortin analogs is cyclized through a lactam bond between Lys at R2and Asp at R7. In other embodiments, the non- naturally occurring melanocortin analog is cyclized through a lactam bond between Glu at R2and Orn at R7. In yet other embodiments, the non-naturally occurring melanocortin analogs is cyclized through a lactam bond between Orn at R2and Glu at R7. In still other embodiments, the non-naturally occurring melanocortin analog is cyclized through a lactam bond between Aad at R2and Dab at R7. In still other embodiments, the non-naturallyDocket No.: 183B-416027-WO occurring melanocortin analog is cyclized through a lactam bond between Dab at R2and Aad at R7.

[0071] In some embodiments, X1is absent. Alternatively, in some embodiments, X1is present. In such embodiments, X1is dVal and R1is dPro. In further embodiments, Y1and Y2are each Nle. In still further embodiments, R3is Trp-Arg, R4is dNal(2’), p(Cl)dPhe, or p(F)dPhe, R5is Pro and R6is absent. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-dVal-dPro-c[Orn-Trp-Arg-p(Cl)dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 880); Ac-dVal-dPro-c[Dab-Trp-Arg-p(Cl)dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 881); Ac-dVal-dPro-c[Aad-Trp-Arg-dNal(2')-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 882); Ac-dVal-dPro-c[Aad-Trp-Arg-p(Cl)dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 883); and Ac-dVal-dPro-c[Glu-Trp-Arg-p(F)dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 884), wherein c represents cyclization through R2and R7via a lactam bond.

[0072] In some embodiments, R1is Nle. Alternatively, in some embodiments, R1is an amino acid other than Nle. In some embodiments, R1is dAsn or dGln. In further embodiments, R3is selected from Pro, His, dHis, dAla, Ala, and Lys. In still further embodiments, R4is dNal(2’), dPhe, or p(F)dPhe. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-dGln-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 885); Ac-dGln-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 886); Ac-dAsn-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 887); Ac-dAsn-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 888); Ac-dGln-c[Asp-dHis-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 889); Ac-dGln-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 890); Ac-dAsn-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 891); Ac-dAsn-c[Asp-dHis-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 892);Docket No.: 183B-416027-WO Ac-dAsn-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 893); and Ac-dAsn-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 894), wherein c represents cyclization through R2and R7via a lactam bond.

[0073] In some embodiments, R3is a dipeptide. In some embodiments, R3is Trp-Pro. In further embodiments, R4is dNal(2’) or p(Cl)dPhe. In still further embodiments, R1is absent or Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 895); Ac-Nle-c[Orn-Trp-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 896); and Ac-Nle-c[Dab-Trp-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 897), wherein c represents cyclization through R2and R7via a lactam bond.

[0074] In some embodiments, R3is Pro-Pro. In further embodiments, R4is selected from p(Cl)dPhe, dNal(2’), Trp, dTrp, dNal(1’), and Nal(1’). In still further embodiments, R1is Nle and Y1-Y2is dVal-dPro or absent. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 898); Ac-Nle-c[Aad-Pro-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 899); Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 900); Ac-Nle-c[Asp-Pro-Pro-Trp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 901); Ac-Nle-c[Asp-Pro-Pro-dNal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 902); Ac-Nle-c[Asp-Pro-Pro-Nal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 903); and Ac-Nle-c[Asp-Pro-Pro-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 904), wherein c represents cyclization through R2and R7via a lactam bond.

[0075] In some embodiments, R3is Pro-Gly. In further embodiments, R4is dPhe, Trp, dTrp, or Nal(1’). In still further embodiments, R1is Nle and Y1-Y2is dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of:Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-Gly-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 905); Ac-Nle-c[Asp-Pro-Gly-Trp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 906); Ac-Nle-c[Asp-Pro-Gly-Nal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 907); Ac-Nle-c[Asp-Pro-Gly-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 908), wherein c represents cyclization through R2and R7via a lactam bond.

[0076] In some embodiments, R3is a non-canonical amino acid. In some embodiments, R3is β-Ala. In further embodiments, R4is p(Cl)dPhe, p(F)dPhe, or dNal(2’). In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Asp-β-Ala-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 909); Ac-Nle-c[Asp-β-Ala-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 910); Ac-Nle-c[Glu-β-Ala-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 911); Ac-Nle-c[Glu-β-Ala-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 912); Ac-Nle-c[Lys-β-Ala-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 913); Ac-Nle-c[Orn-β-Ala-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 914); Ac-Nle-c[Orn-β-Ala-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 915); Ac-Nle-c[Dab-β-Ala-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 916); Ac-Nle-c[Dab-β-Ala-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 917); and Ac-Nle-c[Aad-β-Ala-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 918), wherein c represents cyclization through R2and R7via a lactam bond.

[0077] In some embodiments, R3is Mamb. In further embodiments, R4is p(Cl)dPhe, dPhe, or dNal(2’). In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Asp-Mamb-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 919);Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 920); Ac-Nle-c[Asp-Mamb-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 921); Ac-Nle-c[Asp-Mamb-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 922); Ac-Nle-c[Glu-Mamb-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 923); Ac-Nle-c[Glu-Mamb-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 924); Ac-Nle-c[Lys-Mamb-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 925); Ac-Nle-c[Lys-Mamb-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 926); Ac-Nle-c[Orn-Mamb-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 927); Ac-Nle-c[Orn-Mamb-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 928); Ac-Nle-c[Dab-Mamb-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 929); and Ac-Nle-c[Dab-Mamb-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 930), wherein c represents cyclization through R2and R7via a lactam bond.

[0078] In some embodiments, R3is His or Pro.

[0079] In some embodiments, R1is Ala or dAla. In further embodiments, R4is p(F)dPhe or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In yet further embodiments, R3is Pro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Ala-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 931); Ac-Ala-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 932); Ac-Ala-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 933); and Ac-dAla-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 934), wherein c represents cyclization through R2and R7via a lactam bond.

[0080] In some embodiments, R1is Dmt. In further embodiments, R4is p(F)dPhe or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of:Docket No.: 183B-416027-WO Dmt-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 935); Dmt-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 936); Dmt-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 937); Dmt-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 938); Dmt-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 939); Dmt-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 940); Dmt-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 941); Dmt-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 942); Dmt-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 943); and Dmt-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 944), wherein c represents cyclization through R2and R7via a lactam bond.

[0081] In some embodiments, R3is His or Pro and R5is Arg. Alternatively, in some embodiments, R3is His or Pro and R5is absent or an amino acid other than Arg.

[0082] In some embodiments, R5is Pro, dPro, or Hyp. In further embodiments, R4is p(F)dPhe, p(Cl)dPhe, or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 945); Ac-Nle-c[Glu-Pro-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 946); Ac-Nle-c[Glu-Pro-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 947); Ac-Nle-c[Lys-Pro-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 948); Ac-Nle-c[Orn-Pro-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 949); Ac-Nle-c[Orn-Pro-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 950); Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 951); Ac-Nle-c[Dab-Pro-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 952);Docket No.: 183B-416027-WO Ac-Nle-c[Dab-Pro-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 953); Ac-Nle-c[Aad-Pro-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2; (SEQ ID NO: 954) Ac-Nle-c[Aad-Pro-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 955); Ac-Nle-c[Asp-His-dPhe-Hyp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 956); and Ac-Nle-c[Asp-His-dPhe-dPro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 957), wherein c represents cyclization through R2and R7via a lactam bond.

[0083] In some embodiments, R5is Gly. In further embodiments, R4is p(F)dPhe or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is: Ac-Nle-c[Asp-Pro-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 958); or Ac-Nle-c[Dab-His-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 959), wherein c represents cyclization through R2and R7via a lactam bond.

[0084] In some embodiments, R5is Asp. In further embodiments, R4is p(F)dPhe or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Lys-Pro-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 960); Ac-Nle-c[Dab-Pro-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 961); Ac-Nle-c[Aad-Pro-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 962); and Ac-Nle-c[Aad-Pro-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 963), wherein c represents cyclization through R2and R7via a lactam bond.

[0085] In some embodiments, R5is absent. In further embodiments, R4is p(F)dPhe. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Lys-Pro-p(F)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 964), wherein c represents cyclization through R2and R7via a lactam bond.Docket No.: 183B-416027-WO

[0086] In some embodiments, R3is His or Pro and R6is Trp. Alternatively, in some embodiments, R3is His or Pro and R6is an amino acid other than Trp. In some embodiments, R6is dTrp. In further embodiments, R4is p(F)dPhe or dPhe. In still further embodiments, R1is Nle and Y1-Y2is absent or dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Orn-Pro-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 965); Ac-Nle-c[Aad-Pro-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 966); and Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 967), wherein c represents cyclization through R2and R7via a lactam bond.

[0087] In some embodiments, R3is His or Pro and Y2-Y4are absent. In some embodiments, Y1is dArg. In still further embodiments, R4is p(F)dPhe,. In some embodiments, the sequence of any one of Formulae (I)-(IC) is: Ac-Nle-c[Dab-Pro-p(F)dPhe- Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 968), wherein c represents cyclization through R2and R7via a lactam bond.

[0088] In some embodiments, R3is His or Pro and Y1-Y4are present. In some embodiments, Y1is dPro, Y2is dPro, Y3is Lys, and Y4is Asp. In further embodiments, R1is Glu, R2is Asp, Glu, Lys, Orn, Dab, or Aad, R4is dNal(2’), R5is Arg, R6is Trp, and R7is Lys, Orn, Asp, Glu, Aad, or Dab. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Glu-c[Glu-Pro-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 969); Ac-Glu-c[Lys-Pro-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 970); Ac-Glu-c[Orn-Pro-dNal(2')-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 971); Ac-Glu-c[Dab-Pro-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 972); Ac-Glu-c[Aad-Pro-dNal(2')-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 973); Ac-Glu-c[Asp-His-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 974); Ac-Glu-c[Orn-His-dNal(2')-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 975); and Ac-Glu-c[Aad-His-dNal(2')-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 976),Docket No.: 183B-416027-WO wherein c represents cyclization through R2and R7via a lactam bond.

[0089] In some embodiments, when R3is His or Pro, then the non-naturally occurring melanocortin analog is cyclized through a lactam bond between Asp at R2and dOrn at R7. In further embodiments, R1is Nle, R4is dNal(2’) or p(Cl)dPhe, R5is Arg, R6is Trp, and Y1- Y2is dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is: Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 977); or Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 978), wherein c represents cyclization through R2and R7via a lactam bond.

[0090] In some embodiments, when R3is His or Pro, then the non-naturally occurring melanocortin analog is cyclized through a lactam bond between CO-cis-CH=CH-CO at R2and Lys, Dab, or Orn at R7. In further embodiments, R1is absent, R4is dNal(2’) or dPhe, R5is Arg, R6is Trp, and Y1-Y2is dVal-dPro or absent. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 979); c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 980); c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 981); c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 982); and c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 983), wherein c represents cyclization through R2and R7via a lactam bond.

[0091] In some embodiments, R3is absent. In some embodiments, when R3is absent, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond. In other embodiments, when R3is absent, then the non-naturally occurring melanocortin analog is cyclized through a side chain lactam bond. In further embodiments, when R3is absent, then R1is Nle, R4is dNal(2’), p(Cl)dPhe, or p(F)dPhe, R5is Arg, R6is Trp, and Y1- Y2is dVal-dPro. In some embodiments, the sequence of any one of Formulae (I)-(IC) is selected from the group consisting of: Ac-Nle-c[Asp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 984); Ac-Nle-c[Lys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 985);Docket No.: 183B-416027-WO Ac-Nle-c[Asp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 986); Ac-Nle-c[Glu-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 987); Ac-Nle-c[Apm-dNal(2')-Arg-Trp-dDap]-dVal-dPro-NH2 (SEQ ID NO: 988); Ac-Nle-c[Lys-dNal(2')-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 989); Ac-Nle-c[Orn-dNal(2')-Arg-Trp-dGlu]-dVal-dPro-NH2 (SEQ ID NO: 990); Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 991); Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 992); Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-dDap]-dVal-dPro-NH2 (SEQ ID NO: 993); Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-dGlu]-dVal-dPro-NH2 (SEQ ID NO: 994); Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[dAsp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[dLys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 230); Ac-Nle-c[Das-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 231); and Ac-Nle-c[hLys-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 232), wherein c represents cyclization through R2and R7via a lactam bond.

[0092] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence selected from any one of SEQ ID NOs: 228–230, 231–232, and 880– 994. Non-Naturally Occurring Melanocortin Analog Synthesis

[0093] The non-naturally occurring melanocortin analogs of the present technology may be readily synthesized by any known conventional procedure for the formation of a peptide linkage between amino acids. Such conventional procedures include, for example, any solution phase procedure permitting a condensation between the free alpha amino group of an amino acid or residue thereof having the carboxyl group or other reactive groups protected and the free primary carboxyl group of another amino acid or residue thereof having the amino group or other reactive groups protected. In an exemplary procedure, theDocket No.: 183B-416027-WO non-naturally occurring melanocortin analogs of the present technology may be synthesized by solid-phase synthesis and purified according to methods known in the art. Any of a number of well-known procedures utilizing a variety of resins and reagents may be used to prepare the non-naturally occurring melanocortin analogs of the present technology.

[0094] The process for synthesizing the non-naturally occurring melanocortin analogs may be carried out by a procedure whereby each amino acid in the desired sequence is added one at a time in succession to another amino acid or residue thereof or by a procedure whereby peptide fragments with the desired amino acid sequence are first synthesized conventionally and then condensed to provide the desired peptide. The resulting peptide is then cyclized to yield a cyclic peptide.

[0095] Solid phase peptide synthesis methods are well known and practiced in the art. In such methods, the synthesis of peptides can be carried out by sequentially incorporating the desired amino acid residues one at a time into the growing peptide chain according to the general principles of solid phase methods. These methods are disclosed in numerous references, including Merrifield, Angew Chem.24:799-810 (1985) and Barany et al., The Peptides, Analysis, Synthesis and Biology, Vol. 2, Gross E. and Meienhofer J., Eds. Academic Press 1-284 (1980), each incorporated herein by reference in their entireties.

[0096] In chemical syntheses of peptides, reactive side chain groups of the various amino acid residues are protected with suitable protecting groups, which prevent a chemical reaction from occurring at that site until the protecting group is removed. Also common is the protection of the alpha amino group of an amino acid residue or fragment while that entity reacts at the carboxyl group, followed by the selective removal of the alpha amino protecting group to allow a subsequent reaction to take place at that site. Specific protecting for solid phase synthesis methods and solution phase synthesis methods groups are known to those having ordinary skill in the art.

[0097] Alpha amino groups may be protected by a suitable protecting group, including a urethane-type protecting group, such as benzyloxycarbonyl (Z) and substituted benzyloxycarbonyl, such as p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p- bromobenzyloxycarbonyl, p-biphenyl-isopropoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc) and p-methoxybenzyloxycarbonyl (Moz); aliphatic urethane-type protecting groups,Docket No.: 183B-416027-WO such as t-butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropoxycarbonyl, and allyloxycarbonyl. Fmoc is useful for alpha amino protection.

[0098] Guanidino groups may be protected by a suitable protecting group, such as nitro, p-toluenesulfonyl (Tosyl), Z, pentamethylchromanesulfonyl (Pmc), adamantyloxycarbonyl, pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) and Boc. Pmc is a useful protecting group for Arg.

[0099] Solid phase synthesis is commenced from the C-terminal end of the peptide by coupling a protected alpha amino acid to a suitable resin. Such starting material is prepared by attaching an alpha amino-protected amino acid by an ester linkage to a p- benzyloxybenzyl alcohol (Wang) resin or a 2-chlorotrityl chloride resin, by an amide bond between an Fmoc-Linker, such as p-[(R,S)-α-[1-(9H-fluor-en-9-yl)-methoxyformamido]-2,4- dimethyloxybenzyl]-phenoxyacetic acid (Rink linker) to a benzhydrylamine (BHA) resin, or by other means well known in the art. Fmoc-Linker-BHA resin supports are commercially available and generally used when feasible. The resins are carried through repetitive cycles as necessary to add amino acids sequentially. The alpha amino Fmoc protecting groups are removed under basic conditions. Piperidine, piperazine, diethylamine, or morpholine (20- 40% v / v) in N,N-dimethylformamide (DMF) may be used for this purpose.

[0100] Following removal of the alpha amino protecting group, the subsequent protected amino acids are coupled stepwise in the desired order to obtain an intermediate, protected peptide-resin. The activating reagents used for coupling of the amino acids in the solid phase synthesis of the non-naturally occurring melanocortin analogs are well known in the art. After the peptide is synthesized, if desired, the orthogonally protected side chain protecting groups may be removed using methods well known in the art for further derivatization of the peptide.

[0101] Reactive groups in a peptide may be selectively modified, either during solid phase synthesis or after removal from the resin. For example, peptides may be modified to obtain N-terminus modifications, such as acetylation, while on resin, or may be removed from the resin by use of a cleaving reagent and then modified. Methods for N-terminus modification, such as acetylation, and for C-terminus modification, such as amidation, are known in the art. Similarly, methods for modifying side chains of amino acids are well knownDocket No.: 183B-416027-WO to those skilled in the art of peptide synthesis. The choice of modifications made to reactive groups present on the peptide will be determined, in part, by the characteristics that are desired in the peptide.

[0102] The peptide may be cyclized prior to cleavage from the peptide resin. For cyclization through reactive side chain moieties, the desired side chains are deprotected, and the peptide suspended in a suitable solvent and a cyclic coupling agent added. Suitable solvents include, for example DMF, dichloromethane (DCM) or 1-methyl-2-pyrrolidone (NMP). Suitable cyclic coupling reagents include, for example, 2-(1H-benzotriazol-1-yl)- 1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 2-(1H-benzotriazol-1-yl)-1,1,3,3- tetramethyluronium hexafluorophosphate (HBTU), benzotriazole-1-yl-oxy- tris(dimethylamino)phosphoniumhexafluorophosphate (BOP), benzotriazole-1-yl-oxy- tris(pyrrolidino)phosphoniumhexafluorophosphate (PyBOP), 2-(7-aza-1H-benzotriazol-1- yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TATU), 2-(2-oxo-1 (2H)-pyridyl)-1,1,3,3- tetramethyluronium tetrafluoroborate (TPTU) or N,N′-dicyclohexylcarbodiimide / 1- hydroxybenzotriazole (DCCl / HOBt). Coupling is convention initiated by use of a suitable base, such as N,N-diispropylethylamine (DIPEA), sym-collidine or N-methylmorpholine (NMM).

[0103] Following cleavage of peptides from the solid phase following their synthesis, the peptide can be purified by any number of methods, such as reverse phase high performance liquid chromatography (RP-HPLC), using a suitable column, such as a C18 column. Other methods of separation or purification, such as methods based on the size or charge of the peptide, can also be employed. Once purified, the peptide can be characterized by any number of methods, such as high-performance liquid chromatograph (HPLC), amino acid analysis, mass spectrometry, and the like. Salt Forms of Non-Naturally Occurring Melanocortin Analogs

[0104] The non-naturally occurring melanocortin analogs of the present technology may be in the form of any salt. The term “pharmaceutically acceptable salts” refers to salts prepared from non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium,Docket No.: 183B-416027-WO sodium, zinc, and the like. Exemplary salts are the ammonium, calcium, lithium, magnesium, potassium, and sodium salts. Salts derived from organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

[0105] When the non-naturally occurring melanocortin analogs of the present technology are basic, acid addition salts may be prepared from non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, carboxylic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p-toluenesulfonic acid, trifluoroacetic acid, and the like. Acid addition salts of the non- naturally occurring melanocortin analogs of the present technology are prepared in a suitable solvent from the peptide and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, citric, tartaric, maleic, succinic or methanesulfonic acid. The acetate salt form is especially useful. Where the non-naturally occurring melanocortin analogs of the present technology include an acidic moiety, suitable salts may include alkali metal salts, such as sodium or potassium salts, or alkaline earth metal salts, such as calcium or magnesium salts. Pharmaceutical Compositions

[0106] The non-naturally occurring melanocortin analogs of the present technology may be formulated in a pharmaceutical composition. Pharmaceutical compositions may comprise one or more carriers and / or excipients. The carriers and excipients may facilitate delivery of the non-naturally occurring melanocortin analog.

[0107] In some embodiments, the non-naturally occurring melanocortin analog is present in a pharmaceutical composition in a therapeutically effective amount. TheDocket No.: 183B-416027-WO therapeutically effective amount may be an amount sufficient to elicit a desired response in the subject, such as, for example, weight gain.

[0108] In some embodiments, the non-naturally occurring melanocortin analog is present in the composition in a concentration of 0.1 mg / mL to 500 mg / mL, relative to a total volume of the composition. For example, the non-naturally occurring melanocortin analog is present in the composition in a concentration of 0.1 mg / mL to 500 mg / mL, 0.5 mg / mL to 250 mg / mL, 1 mg / mL to 100 mg / mL, 2.5 mg / mL to 50 mg / mL, or 5 mg / mL to 25 mg / mL, relative to a total volume of the composition. In some embodiments, the non-naturally occurring melanocortin analog is present in the composition in a concentration of 5 mg / mL to 100 mg / mL, or about 50 mg / mL, relative to a total volume of the composition.

[0109] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of any one of Formulae (I)-(IC) and the non-naturally occurring melanocortin analog is present in the composition in a concentration of 5 mg / mL to 100 mg / mL, relative to a total volume of the composition. For example, the non-naturally occurring melanocortin analog comprising a sequence of any one of Formulae (I)-(IC) is present in the composition in a concentration of 5 mg / mL to 100 mg / mL, 10 mg / mL to 75 mg / mL, 15 mg / mL to 50 mg / mL, 20 mg / mL to 40 mg / mL, or 25 mg / mL to 30 mg / mL, relative to a total volume of the composition. In some embodiments, the non-naturally occurring melanocortin analog comprising a sequence of any one of Formulae (I)-(IC) is present in the composition in a concentration of about 50 mg / mL, relative to a total volume of the composition.

[0110] In some embodiments, the pharmaceutical composition comprising the non- naturally occurring melanocortin analog is formulated for intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration. In some embodiments, the composition comprising the non-naturally occurring melanocortin analog is administered to the subject parenterally. In some embodiments, the composition comprising the non-naturally occurring melanocortin analog is administered to the subject subcutaneously. In some embodiments, the composition comprising the non-naturally occurring melanocortin analog is administered to the subject orally.Docket No.: 183B-416027-WO

[0111] Pharmaceutical compositions disclosed herein formulated for parenteral administration may be in the form of an aqueous or non-aqueous isotonic sterile injection solution or suspension. The term “parenteral”, as used herein, includes subcutaneous, intravenous, intraperitoneal, intramuscular, and intralesional, or infusion techniques. Pharmaceutical compositions disclosed herein formulated for oral administration may be in the form of tablet, capsule, lozenge, pill, sachet, or any other orally deliverable form know in the art.

[0112] In some embodiments, the composition formulated for parenteral administration (e.g., subcutaneous administration) comprises the non-naturally occurring melanocortin analog of formula (I) at a concentration at about 0.001 nmol, 0.005 nmol, 0.01 nmol, 0.02 nmol, 0.05 nmol, 0.1 nmol, 0.25 nmol, 0.5 nmol, 1 nmol, 2.5 nmol, 5 nmol, 10 nmol, 20 nmol, 25 nmol, 50 nmol, 100 nmol, 250 nmol, 500 nmol, or 1000 nmol, or even more, depending on the specific peptide selected, the desired response, the route of administration, the formulation and other factors known to those of skill in the art. In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence of any one of Formulae (I)-(IC).

[0113] In some embodiments, the non-naturally occurring melanocortin analog crosses blood-brain-barrier (BBB) of the subject.

[0114] In some embodiments, the subject is a mammal, including but not limited to a human, a non-human primate such as a chimpanzee, a domestic livestock or a farm animal such as a cow, a bison, sheep, a pig, a goat, a horse, a chicken, and a rooster, a domestic pet animal such as a dog, a cat, a rat, a mouse, and a rabbit, and a laboratory subject such as a rodent, including a rat, a mouse, and a guinea pig. In some embodiments, the subject is a human. In some embodiments, the subject is an animal such as a rat or a dog.

[0115] The pharmaceutical composition comprising the carriers and / or excipients disclosed in the present technology facilitate delivery (e.g., parenteral administration, in particular subcutaneous injection) of the non-naturally occurring melanocortin analog disclosed herein in any of its embodiments to a subject. Other purposes of the compositions comprising the carriers and / or excipients are to enhance dispersion, solubility, and stabilityDocket No.: 183B-416027-WO of the non-naturally occurring melanocortin analog, and to reduce adverse injection site reactions.

[0116] The carriers and / or excipients of the pharmaceutical composition can generally include one or more of the following components: a pH buffered aqueous solution comprising (a) sodium acetate, (b) Tris, and (c) water. In some embodiments, all components are compatible with the non-naturally occurring melanocortin analog (i.e., do not react or cause the non-naturally occurring melanocortin analog to react) and are homogeneously dispersed or dissolved uniformly in the composition.

[0117] In some embodiments, the carrier and / or excipient is isotonic.

[0118] In order to achieve a desirable tonicity, the composition of the present technology can further include a salt such as sodium chloride, sodium succinate, sodium sulfate, potassium chloride, magnesium chloride, magnesium sulfate, and calcium chloride. In some embodiments, the salt is present in the composition in a concentration of 0.1 mg / mL to 50 mg / mL, 1 mg / mL to 25 mg / mL, or 5 mg / mL to 10 mg / mL, relative to a total volume of the composition.

[0119] The carriers and / or excipients of the composition may also include a pH buffered aqueous solution which comprises (a) sodium acetate, (b) Tris, and (c) water.

[0120] The water used herein can act as a diluent and include, without limitation, water for injection (WFI), sterile water, bacteriostatic water for injection (BWFI), distilled water, bidistilled water, deionized water, deionized distilled water, and reverse osmosis water. In some embodiments, the water present in the pH buffered aqueous solution is water for injection.

[0121] In some embodiments, the pharmaceutical composition further includes water in an amount of about 1 wt% to about 90 wt%, about 10 wt% to about 75 wt%, or about 25 wt% to about 50 wt%, relative to a total weight of the composition.

[0122] In some embodiments, sodium acetate is present in the pharmaceutical composition in a concentration of 0.5 mg / mL to 50 mg / mL, relative to a total volume of the composition. For example, sodium acetate is present in the composition in a concentration of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20Docket No.: 183B-416027-WO mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL, relative to a total volume of the composition. In some embodiments, sodium acetate is present in the composition in a concentration of about 6 mg / mL to about 8 mg / mL, relative to a total volume of the composition. For example, sodium acetate is present in the composition in a concentration of 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.1 mg / mL, 7.5 mg / mL, or 8 mg / mL, relative to a total volume of the composition.

[0123] In some embodiments, sodium acetate is present in the composition in a molar concentration of 5 mM to 700 mM, relative to a total volume of the composition. For example, sodium acetate is present in the composition in a molar concentration of 5 mM to 700 mM, 10 mM to 600 mM, 20 mM to 500 mM, 30 mM to 400 mM, 40 mM to 300 mM, 50 mM to 200 mM, 60 mM to 100 mM, or 70 mM to 80 mM, relative to a total volume of the composition. In some embodiments, sodium acetate is present in the composition in a molar concentration of about 80 mM to about 100 mM, relative to a total volume of the composition. For example, sodium acetate is present in the composition in a molar concentration of 80 mM, 85 mM, 87 mM, 90 mM, 95 mM, or 100 mM, relative to a total volume of the composition.

[0124] The term “Tris” represents tris(hydroxymethyl)aminomethane also known as Tris buffer, Tris base, TRIS, tromethamine, tromethamine buffer, Trizma®, Trisamine, Trometamol, Tromethane, Trisaminol, or THAM. In some embodiments, Tris is present in the composition in a concentration of 0.5 mg / mL to 50 mg / mL, relative to a total volume of the composition. For example, Tris is present in the composition in a concentration of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20 mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL, relative to a total volume of the composition. In some embodiments, Tris is present in the composition in a concentration of about 6 mg / mL to about 8 mg / mL, relative to a total volume of the composition. For example, Tris is present in the composition in a concentration of 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.3 mg / mL, 7.6 mg / mL, or 8 mg / mL, relative to a total volume of the composition.

[0125] In some embodiments, Tris is present in the composition in a molar concentration of 2 mM to 500 mM, relative to a total volume of the composition. For example, Tris is present in the composition in a molar concentration of 2 mM to 500 mM, 5 mM to 400Docket No.: 183B-416027-WO mM, 10 mM to 300 mM, 20 mM to 200 mM, 30 mM to 150 mM, 40 mM to 100 mM, 50 mM to 80 mM, or 60 mM to 70 mM, relative to a total volume of the composition. In some embodiments, Tris is present in the composition in a molar concentration of about 50 mM to about 70 mM, relative to a total volume of the composition. For example, Tris is present in the composition in a molar concentration of 50 mM, 55 mM, 60 mM, 65 mM, or 70 mM, relative to a total volume of the composition.

[0126] In some embodiments, the pH buffered aqueous solution provides the composition with a pH equivalent or close to the physiological pH levels. This may reduce adverse injection site reactions and also provide the non-naturally occurring melanocortin analog with enhanced stability and resistance to aggregation and degradation.

[0127] In addition to sodium acetate and Tris, the composition may further include other buffering agents. Non-limiting examples of additional buffering agents include saline, phosphate, phosphoric acid, citrate, succinate, gluconate, histidine, acetic acid, ascorbate, tartartic acid, maleic acid, glycine, lactate, lactic acid, ascorbic acid, imidazole, bicarbonate, carbonic acid, succinic acid, sodium benzoate, benzoic acid, gluconate, edetate, malate, imidazole, and mixtures thereof. In some embodiments, the composition comprises acetic acid as an additional buffering agent.

[0128] In some embodiments, a weight ratio of sodium acetate to Tris is 1:4 to 4:1, 2:7 to 7:2, 1:3 to 3:1, 2:5 to 5:2, 1:2 to 2:1, 2:3 to 3:2, or about 1:1. In some embodiments, the weight ratio of sodium acetate to Tris is about 1:1.

[0129] In some embodiments, a weight ratio of the non-naturally occurring melanocortin analog to sodium acetate is 1:1 to 20:1, 3:2 to 15:1, 2:1 to 12:1, 3:1 to 10:1, 4:1 to 9:1, 5:1 to 8:1, or 6:1 to 7:1. In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to sodium acetate is about 7:1.

[0130] In some embodiments, a weight ratio of the non-naturally occurring melanocortin analog to Tris is 1:1 to 20:1, 3:2 to 15:1, 2:1 to 12:1, 3:1 to 10:1, 4:1 to 9:1, 5:1 to 8:1, or 6:1 to 7:1. In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to Tris is about 7:1.Docket No.: 183B-416027-WO

[0131] The pharmaceutical composition may further comprise a preservative agent. Exemplary preservative agents include, but are not limited to, ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, phenol, m-cresol, benzyl alcohol, alpha-tocopherol, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, benzalkonium chloride, phenoxyethanol, and methyl paraben.

[0132] If present, the concentration of the preservative agent can range from 0.001 mg / mL to 50 mg / mL, 0.01 mg / mL to 25 mg / mL, 0.1 mg / mL to 10 mg / mL, or 1 mg / mL to 5 mg / mL, relative to a total volume of the composition.

[0133] In some embodiments, the composition is in the form of an aqueous solution or a suspension. In some embodiments, the composition is in the form of an emulsion. In some embodiments, the composition is in the form of an aqueous solution. In some embodiments, the composition is in the form of an aqueous solution which is clear, colorless, and / or free of visible foreign matter.

[0134] The active ingredient(s) (e.g., the non-naturally occurring melanocortin analog) may be dissolved or suspended in the aforementioned carrier and / or excipient. Additional aqueous or non-aqueous carriers that may facilitate dissolution of the active ingredient include, but are not limited to, ethanol, benzyl alcohol, DMSO, polyethylene glycol, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, and / or various buffers.

[0135] In some embodiments, the composition has a pH ranging from 6.5 to 8.5. In some embodiments, the composition has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5.

[0136] In some embodiments, the composition is basic and has a pH of about 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the composition has a pH ranging from about 7.3 to about 7.4. In some embodiments, the composition has a pH of 7.3 or 7.4.

[0137] In some embodiments, the composition has an osmolality ranging from 250 mOsm / kg to 350 mOsm / kg. For example, the composition has an osmolality ranging fromDocket No.: 183B-416027-WO 250 mOsm / kg to 360 mOsm / kg, 260 mOsm / kg to 340 mOsm / kg, 270 mOsm / kg to 330 mOsm / kg, 280 mOsm / kg to 320 mOsm / kg, 290 mOsm / kg to 310 mOsm / kg, or about 300 mOsm / kg. In some embodiments, the composition has an osmolarity of about 250 mOsm / kg, about 260 mOsm / kg, about 270 mOsm / kg, about 280 mOsm / kg, about 290 mOsm / kg, about 300 mOsm / kg, about 310 mOsm / kg, about 320 mOsm / kg, about 330 mOsm / kg, about 340 mOsm / kg, about 350 mOsm / kg, or about 360 mOsm / kg. In some embodiments, the composition has an osmolality ranging from about 275 mOsm / kg to about 330 mOsm / kg. In some embodiments, the composition has an osmolality of about 279 mOsm / kg, about 314 mOsm / kg, or about 329 mOsm / kg.

[0138] In some embodiments, the composition has a viscosity ranging from 0.5 cP to 5 cP. For example, the composition has a viscosity ranging from 0.5 cP to 5 cP, 0.75 cP to 4.5 cP, 1.0 cP to 4 cP, 1.2 cP to 3.5 cP, 1.3 cP to 3 cP, 1.4 cP to 2.5 cP, 1.5 cP to 2 cP, or 1.6 cP to 1.8 cP. In some embodiments, the composition has a viscosity of about 0.5 cP, 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, or 2.0 cP. In some embodiments, the composition has a viscosity of about 1.4 cP or 1.6 cP.

[0139] In some embodiments, the pharmaceutical composition further comprises one or more antioxidants. For example, the pharmaceutical composition may comprise ascorbic acid, cysteine, sodium metabisulfite, propyl gallate, butylated hydroxytoluene, and / or butylated hydroxyanisole.

[0140] In some embodiments, the pharmaceutical composition further comprises a surfactant, such as a sorbitan ester.

[0141] In some embodiments, the pharmaceutical composition further comprises a flavoring or scent, such as an aromatic oil. Use of non-naturally occurring melanocortin analogs

[0142] The non-naturally occurring melanocortin analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including the non-naturally occurring melanocortin analogs of the present technology are useful to treat, reduce, or prevent conditions associated with (i) full MC4R antagonism and full, partial, or no MC3R agonism;Docket No.: 183B-416027-WO (ii) partial MC4R antagonism and no MC3R activity; or (iii) full MC4R agonism and full MC3R antagonism. The non-naturally occurring melanocortin analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including the non-naturally occurring melanocortin analogs of the present technology are also useful to stimulate appetite, increase body weight and / or increase food consumption. Examples of conditions associated with (i) full MC4R antagonism and full, partial, or no MC3R agonism; (ii) partial MC4R antagonism and no MC3R activity; or (iii) full MC4R agonism and full MC3R antagonism include, but are not limited to, psychological diseases and conditions, allergies, intolerances, gastrointestinal diseases and conditions, side-effects from a medication, substance abuse, viral infections, bacterial infections, food poisoning, dehydration, fatigue, hormonal imbalances, pain, cardiovascular diseases and conditions, anemia, autoimmune diseases and conditions, respiratory diseases and conditions, and inflammatory diseases and conditions. Dosing and Administration

[0143] The non-naturally occurring melanocortin analog may be formulated for delivery to a subject in need thereof. In some embodiments, the non-naturally occurring melanocortin analog is formulated for intraperitoneal, intravenous, parenteral, depot, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration. In some embodiments, the pharmaceutical composition comprising the non-naturally occurring melanocortin analog is formulated for subcutaneous administration. In some embodiments, the pharmaceutical composition comprising the non-naturally occurring melanocortin analog is formulated for oral administration. In some embodiments, the pharmaceutical composition comprising the non-naturally occurring melanocortin analog is formulated for depot administration.

[0144] In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 0.001 mg / kg to about 1000 mg / kg per body weight of the subject once daily. In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 10 mg / kg to about 250 mg / kg per body weight of the subject once daily. In some embodiments, non-naturally occurring melanocortin receptor analog is administered at a dose of about 15 mg / kg to about 100Docket No.: 183B-416027-WO mg / kg per body weight of the subject once daily. In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 20 mg / kg to about 75 mg / kg per body weight of the subject once daily.

[0145] In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 0.001 mg / kg to about 25 mg / kg per body weight of the subject. In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 0.5 mg / kg to about 10 mg / kg per body weight of the subject. In some embodiments, the amount administered is a therapeutically effective amount.

[0146] In some embodiments, the non-naturally occurring melanocortin receptor analog is administered at a dose of about 0.001 mg / kg, about 0.01 mg / kg, about 0.10 mg.kg, about 0.5 mg / kg, about 1.0 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 50 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, about 100 mg / kg, about 125 mg / kg, about 150 mg / kg, about 175 mg / kg, about 200 mg / kg, about 250 mg / kg, about 300 mg / kg, about 350 mg / kg, about 400 mg / kg, about 450 mg / kg, or about 500 mg / kg per body weight of the subject once daily or twice daily.

[0147] In some embodiments, the non-naturally occurring melanocortin analog is administered to the subject for at least about 1 day, about 1 week, about 1 month, about 3 months, about 6 months, about 1 year, or about 5 years.

[0148] In some embodiments, the non-naturally occurring melanocortin analog is administered to the subject for at least about 1 day, about 5 days, about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, about 40 days, about 45 days, about 50 days, about 60 days, about 75 days, about 90 days, about 100 days, about 110 days, or about 120 days. EXAMPLES

[0149] The following examples are intended to illustrate various embodiments of the present technology. As such, the specific embodiments discussed are not to be construedDocket No.: 183B-416027-WO as limitations on the scope of the present technology. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of present technology, and it is understood that such equivalent embodiments, are to be included herein. Further, all references cited herein are hereby incorporated by reference in their entirety, as if fully set forth herein. Example 1: Non-Naturally Occurring Melanocortin Analog Synthesis-Generic

[0150] The non-naturally occurring melanocortin analogs of the present technology were synthesized by conventional procedures (e.g., solution-phase procedure, solid-phase synthesis) for the formation of a peptide linkage between amino acids. The solution-phase procedure involved a condensation between the free alpha amino group of an amino acid or derivative thereof having the carboxyl group or other reactive groups protected and the free primary carboxyl group of another amino acid or derivative thereof having the amino group or other reactive groups protected. The solid-phase synthesis utilized a variety of resins and reagents and may involve additional purification steps.

[0151] The process for synthesizing the non-naturally occurring melanocortin analogs was generally performed by a procedure as follows. Each amino acid in the desired sequence of the non-naturally occurring melanocortin analogs was added one at a time in succession to another amino acid or derivative thereof or by a procedure whereby peptide fragments with the desired amino acid sequence were first synthesized conventionally and then condensed to provide the desired peptide. In most cases, the resulting peptide was then cyclized to yield a cyclic peptide.

[0152] Solid-phase peptide synthesis was carried out by sequentially incorporating the desired amino acid residues one at a time into the growing peptide chain coupled to a solid- phase support according to the general principles of solid phase methods (see Merrifield, Angew Chem.24:799-810 (1985) and Barany et al., The Peptides, Analysis, Synthesis and Biology, Vol. 2, Gross E. and Meienhofer J., Eds. Academic Press 1-284 (1980)), the disclosure of which is incorporated herein by reference in its entirety. An exemplary solid-phase synthesis of non-naturally occurring melanocortin analogs is provided below.Docket No.: 183B-416027-WO

[0153] Initially, the C-terminal amino acid residue of the non-naturally occurring melanocortin analog was coupled to a solid-phase support, e.g., a solid-phase resin. Coupling of the C-terminal amino acid residue and the solid-phase support may be carried out according to any method know in the art. Depending on the coupling method, the alpha- amine of the C-terminal amino acid residue may or may not be protected with an amine protecting group, as described below. Likewise, the carboxyl group of the amino acid residue may or may not be activated prior to coupling to the solid-phase support in order to increase its electrophilicity. Some methods of coupling rely on the formation of an ester bond between the carboxyl group of the amino acid and a reactive handle on the solid-phase resin. For example, an amino acid residue may be coupled to a p-benzyloxybenzyl alcohol resin (Wang) or a 2-chlorotrityl chloride resin via an ester linkage. Some methods of coupling rely on the formation of an aminde bond between the carboxyl group of the amino acid and a reactive handle on the solid-phase resin For example, an amino acid residue may be coupled to a benzhydrylamine (BHA) resin through an Fmoc-linker such as, for example, p- [(R,S)-α-[1-(9H-fluor-en-9-yl)-methoxyformamido]-2,4-dimethyloxybenzyl]-phenoxyacetic acid (Rink linker) via an amide linkage.

[0154] The non-naturally occurring melanocortin analog was then synthesized by sequential amino acid addition or combination of peptide fragments. Subsequently, the peptide was cleaved from the solid-phase support and purified by methods known in the art, such as, for example, reverse phase high performance liquid chromatography (RP-HPLC) using a suitable column, such as a C18 column. Additionally, or alternatively, other methods of separation or purification were employed, including, but not limited to, methods based on the size or charge of the peptide. Once purified, the peptide was characterized by methods such as high-performance liquid chromatograph (HPLC), amino acid analysis, mass spectrometry, and the like. Example 2: Non-Naturally Occurring Melanocortin Analog Synthesis-Protecting Groups

[0155] During synthesis of the non-naturally occurring melanocortin analogs, reactive side chain groups of the various amino acid residues were protected with suitable protectingDocket No.: 183B-416027-WO groups, which prevented undesirable chemical reaction from occurring at that site until the protecting group was removed.

[0156] Additionally, protection of the alpha amino group of an amino acid residue or fragment was performed while that entity reacting with the carboxyl group, followed by the selective removal of the alpha amino protecting group to allow a subsequent reaction to take place at that site. Specific protecting groups for solid phase synthesis methods and solution phase synthesis methods are known to those having ordinary skill in the art. Alpha amino groups were protected by a suitable protecting group, including a urethane-type protecting group, such as benzyloxycarbonyl (Z) and substituted benzyloxycarbonyl, such as p- chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p- biphenyl-isopropoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc) and p- methoxybenzyloxycarbonyl (Moz); aliphatic urethane-type protecting groups, such as t- butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropoxycarbonyl, and allyloxycarbonyl. Fmoc was also used for alpha amino protection. Guanidino groups, if present, were protected by a suitable protecting group, such as nitro, p-toluenesulfonyl (Tos), Z, pentamethylchromanesulfonyl (Pmc), adamantyloxycarbonyl, pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) and Boc. Pmc was used as a protecting group for Arg.

[0157] Alpha aminoprotecting groups may be removed under basic conditions, such as, for example, using a solution of piperidine, piperazine, diethylamine, or morpholine (20- 40% v / v) in N,N-dimethylformamide (DMF). In synthesis methods in which alpha amino protecting groups were used, protecting groups were removed after synthesis of the peptide and before or after cleavage of the solid-phase support. Example 3: Non-Naturally Occurring Melanocortin Analog Synthesis-Additional Modifications

[0158] If necessary, the non-naturally occurring melanocortin analogs were further modified to obtain N-terminus modifications, such as acetylation, while on resin, or were removed from the resin by use of a cleaving reagent and then modified. Likewise, C-terminus modification (e.g., amidation), was performed if needed.Docket No.: 183B-416027-WO

[0159] Additionally, cyclized peptide structures were obtained prior to cleavage from the peptide resin. For cyclization through reactive side chain moieties, the desired side chains were deprotected, and the peptide suspended in a suitable solvent and a cyclic coupling agent added. Suitable solvents, for example DMF, dichloromethane (DCM) or 1- methyl-2-pyrrolidone (NMP), were used for the cyclization. Suitable cyclic coupling reagents (e.g., 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 2-(1H- benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), benzotriazole- 1-yl-oxy-tris(dimethylamino)phosphoniumhexafluorophosphate (BOP), benzotriazole-1-yl- oxy-tris(pyrrolidino)phosphoniumhexafluorophosphate (PyBOP), 2-(7-aza-1H-benzotriazol- 1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TATU), 2-(2-oxo-1 (2H)-pyridyl)-1,1,3,3- tetramethyluronium tetrafluoroborate (TPTU), N,N′-dicyclohexylcarbodiimide / 1- hydroxybenzotriazole (DCCl / HOBt)) were also used for the cyclization. Coupling was initiated by a suitable base, such as N,N-diispropylethylamine (DIPEA), sym-collidine or N- methylmorpholine (NMM). Example 4: Biological Data

[0001] The agonist and antagonist activity of exemplary non-naturally occurring melanocortin analogs at the melanocortin receptors (e.g., MC1R, MC3R, MC4R, and MC5R) were measured via cAMP accumulation assay, according to the following procedure. Experimental design and execution were conducted by Epics Therapeutics S.A. EuroscreenFast (Bruxelles, Belgium). Compound Handing

[0002] Compounds were delivered as powder (1 mg) or 10 mM solutions (100 μl) in 100% DMSO. Powders were solubilized in 100% DMSO at a concentration of 10 mM (master solution) in a solvent volume defined. Serial dilutions were performed from master solution in 100% DMSO to obtain intermediate concentrations 200-, 300- or 400-fold higher than the concentrations to be tested, depending on the assay. Each sample was diluted 100- fold in the assay buffer and dispensed in a test plate. Amounts, solvents, and dilutions were estimated based on standard small-molecule drugs. Cell lines used for functional assays are shown in Table 1.Docket No.: 183B-416027-WO Table 1. Cell lines Receptor Cell Line Reference agonist Reference antagonist MC1R CHO-K1 NDP-α-MSH N / A Comp

[0003] Compounds were tested for (i) agonist and / or antagonist activity at the human MC3 (FAST-0232C) and MC4 (FAST-0233C) receptors, (ii) agonist activity at the human MC1 (FAST-0230C) receptor, and / or (iii) agonist activity at the human MC5 (FAST-0233C) receptor at the following nanomolar concentrations, in duplicate: 0.0001, 0.001, 0.01, 0.03, 0.1, 0.3, 1, 10, 100, and 1,000. Testing Protocol

[0004] Cyclic AMP (cAMP) Homogenous Time-Resolved Fluorescence (HTRF) assay for Gs coupled receptor:

[0005] CHO-K1 cells expressing recombinant human receptor grown prior to the test in media without antibiotic were detached by gentle flushing with PBS-EDTA (5 mM EDTA), recovered by centrifugation and resuspended in assay buffer (KRH: 5 mM KCl, 1.25 mM MgSO4, 124 mM NaCl, 25 mM HEPES, 13.3 mM Glucose, 1.25 mM KH2PO4, 1.45 mM CaCl2, 0.5 g / l BSA, supplemented with 1mM IBMX or 25μM Rolipram).

[0006] Dose response curves were performed in parallel with the reference compounds.

[0007] For agonist test (384well): 5 μl of cells were mixed with 5 μl of the test compound at increasing concentrations and then incubated 30 min at room temperature. After addition of the lysis buffer containing cAMP-d2 and anti-cAMP cryptate detection reagents, plates were incubated 1-hour at room temperature, and fluorescence ratios were measured according to the manufacturer specification, with the HTRF kit. Reference agonist NDP-α- MSH was also tested as a comparator.

[0008] For antagonist test (384well): 5 μl of cells were mixed in the wells of an assay plate with 5 μl of a mix of the test compound at increasing concentrations for a finalDocket No.: 183B-416027-WO concentration corresponding to the historical EC80. The plates were then incubated 30 min at room temperature. After addition of the lysis buffer containing cAMP-d2 and anti-cAMP cryptate detection reagents, plates were incubated 1-hour at room temperature, and fluorescence ratios were measured according to the manufacturer specification, with the HTRF kit. Reference antagonist SHU9119 was also tested as a comparator. Quality Control for Compound Testing

[0009] On each day of experimentation and prior to the testing of compounds, reference compounds were tested at several concentrations in duplicate (n=2) to obtain a dose-response curve and an estimated EC50 and / or IC50 values.

[0010] Reference values thus obtained for the test were compared to historical values obtained from the same receptor and used to validate the experimental session.

[0011] A session was considered as valid only if the reference value was found to be within a 0.5 logs interval from the historical value.

[0012] For replicate determinations, the maximum variability tolerated in the test was of + / -20% around the average of the replicates. Non-naturally occurring melanocortin analog grouping

[0160] Group A included non-naturally occurring melanocortin analogs A1 to A9, all of which are cyclic peptides comprising the motif His-dNal(2’)-Arg-Trp, or a derivative thereof. Derivatives of the motif His-dNal(2’)-Arg-Trp may include substitution of His for another basic amino acid such as, for example, Dap, Dab, or Gln, or for a small aliphatic amino acid, such as, for example, Gly or Ala and of substitution of dNal(2’) for another aromatic amino acid, such as, for example, p(F)dPhe. Group A melanocortin analogs also comprise dGln or dAsn at the N-terminus and dVal-dPro at the C-terminus. Group A non-naturally occurring melanocortin analogs are provided in Table 2. Table 2. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID FormulaDocket No.: 183B-416027-WO A3 891 Ac-dAsn-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 A4 892 Ac-dAsn-c[Asp-dHis-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 allof which are cyclic peptides comprising the motif β-Ala-dNal(2')-Arg-Trp, or a derivative thereof. Derivatives of the motif β-Ala-dNal(2')-Arg-Trp may include substitution of dNal(2’) for another aromatic amino acid such as, for example, p(F)dPhe or p(Cl)dPhe. Group B melanocortin analogs also comprise Nle at the N-terminus and dVal-dPro at the C-terminus. Group B non-naturally occurring melanocortin analogs are provided in Table 3. Table 3. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID Formula analog NOall of which are cyclic peptides comprising the motif Mamb-dPhe-Arg-Trp, or a derivative thereof. Derivatives of the motif Pro-dPhe-Arg may include substitution of dPhe for another aromatic amino acid such as, for example, p(F)dPhe, p(Cl)dPhe, or dNal(2’). Group C melanocortin analogs also comprise Nle at the N-terminus and dVal-dPro at the C-terminus. Group C non-naturally occurring melanocortin analogs are provided in Table 4. Table 4. Non-naturally occurring melanocortin analogsDocket No.: 183B-416027-WO Melanocortin SEQ ID Formula analog NO allof which are cyclic peptides comprising the motif dNal(2’)-Arg-Trp, or a derivative thereof. Derivatives of the motif dNal(2’)-Arg-Trp may include substitution of dNal(2’) for another aromatic amino acid such as, for example, p(F)dPhe, or p(Cl)dPhe. Group D melanocortin analogs also comprise Nle at the N-terminus and dVal-dPro at the C-terminus. Group D non- naturally occurring melanocortin analogs are provided in Table 5. Table 5. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID n l NO FormulaDocket No.: 183B-416027-WO D15 231 Ac-Nle-c[Das-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 D16 232 Ac-Nle-c[hLys-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 allof which are cyclic peptides comprising the motif Pro-Pro-dNal(2)-Arg-Trp (SEQ ID NO: 233) or a derivative thereof. Derivatives of SEQ ID NO: 233 may include substitution of Pro for another amino acid such as, for example, Gly or Trp, and / or substitution of dNal(2’) for another aromatic amino acid such as, for example, dPhe, p(Cl)dPhe, Trp, dTrp, dNal(1’) or Nal(1’). Group E melanocortin analogs also comprise Nle at the N-terminus and dVal-dPro at the C-terminus. Group E non-naturally occurring melanocortin analogs are provided in Table 6. Table 6. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID Formula analog NOl of which are cyclic peptides comprising the motif Trp-Arg-dNal(2’)-Pro, or a derivative thereof. Derivatives of the motif Trp-Arg-dNal(2’)-Pro may include substitution of dNal(2’) for another aromatic amino acid such as, for example, p(Cl)dPhe. Group F melanocortin analogs also comprise Glu or Nle at the N-terminus and dVal-dPro at the C-terminus. Group F non- naturally occurring melanocortin analogs are provided in Table 7. Table 7. Non-naturally occurring melanocortin analogsDocket No.: 183B-416027-WO Melanocortin SEQ ID Formula analog NO allof which are cyclic peptides comprising derivatives of the motif Pro-p(F)dPhe-Arg-Trp (SEQ ID NO: 234), or a derivative thereof. Derivatives of SEQ ID NO: 234 may include substitution of Trp for another aromatic amino acid, such as, for example, dTrp, substitution of p(F)dPhe for another small aromatic amino acid, such as, for example, dPhe, and / or deletion of one of the residues, such as, for example, Arg. Group G melanocortin analogs also comprise dVal-dPro or dArg at the C-terminus. Group G non-naturally occurring melanocortin analogs are provided in Table 8. Table 8. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID Formula analog NODocket No.: 183B-416027-WO

[0167] Group H included non-naturally occurring melanocortin analogs H1 to H7, all of which are cyclic peptides comprising the motif Pro-dNal(2’)-Arg-Trp, or a derivative thereof. Derivatives of the motif Pro-dNal(2’)-Arg-Trp may include substitution of dNal(2’) for another aromatic amino acid, such as, for example, p(Cl)dPhe. Group H melanocortin analogs may comprise Nle at the N-terminus and an dVal-dPro at the C-terminus. Group H non-naturally occurring melanocortin analogs are provided in Table 9. Table 9. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID Formula analog NO 2 2 2 l ofwhich are cyclic peptides comprising derivatives of the motif Pro-p(F)dPhe-Pro-Trp (SEQ ID NO: 235), or a derivative thereof. Derivatives of SEQ ID NO: 235 may include substitution of Pro for another amino acid, such as, for example, dPro, Gly, or Hyp, or substitution of p(F)dPhe for another small aromatic amino acid, such as, for example, dPhe. Group I melanocortin analogs also comprise dVal-dPro at the C-terminus. Group I non-naturally occurring melanocortin analogs are provided in Table 10. Table 10. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID FormulaDocket No.: 183B-416027-WO I9 953 Ac-Nle-c[Dab-Pro-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 I10 954 Ac-Nle-c[Aad-Pro-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 l ofwhich are cyclic peptides comprising derivatives of the motif Pro-dNal(2’)-Arg-Trp, or a derivative thereof. Derivatives of the motif Pro-dNal(2’)-Arg-Trp may include substitution of Pro for another amino acid, such as, for example, His. Group J melanocortin analogs also comprise Glu at the N-terminus and dPro-dPro-Lys-Asp (SEQ ID NO: 236) at the C- terminus. Group J non-naturally occurring melanocortin analogs are provided in Table 11. Table 11. Non-naturally occurring melanocortin analogs Melanocortin SEQ ID Formula analog NO - p- - p- p- - - p-n 5 receptorDocket No.: 183B-416027-WO

[0013] Administration of some of the exemplary non-naturally occurring melanocortin analogs activated melanocortin 1 receptor (MC1R) and / or melanocortin 5 receptor (MC5R) activity, as measured by cAMP levels (Table 12). Table 12. Dose-response results of melanocortin analogs and control against the melanocortin 1 receptor (MC1R) and the melanocortin 5 receptor (MC5R) MC1R MC5R Compound ID Max Activation Max ActivationDocket No.: 183B-416027-WO C10 ** A ** A C11 ** A * ADocket No....

Claims

1. Docket No.: 183B-416027-WO CLAIMS I / We claim:

1. A non-naturally occurring melanocortin analog comprising a sequence of Formula (I): X1-R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IA), wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab;Docket No.: 183B-416027-WO Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is absent, Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when Y3is Lys, then R1is Glu, R4is dNal(2’), and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R4is p(Cl)dPhe, then either (i) X1is dVal, R1is dPro, and R2is Orn, Dab, or Aad, or (ii) R1is Nle, Y1is dVal, and (a) R3is Mamb, and R2is not Aad; (b) R3is absent and R2is Asp; (c) R3is Trp-Pro and R2is Dab or Orn; (d) R3is Pro and either R7is dOrn or R7is Glu and R5is Pro; (e) R3is β-Ala, and R2is Asp or Dab; or (f) R3is Pro-Pro and R2is Asp; when Y1is Nle, then Y2is Nle and (i) R4is p(Cl)dPhe and R2is Orn, Dab, or Aad, (ii) R4is dNal(2’) and R2is Aad, or (iii) R4is p(F)dPhe, and R2is Glu; when R4is dNal(2’), then R5is Arg or Pro, and (i) R1is dAsn, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; (ii) R1is dGln, R2is Asp and R3is dAla, His, or dHis; (iii) R1is Glu,Docket No.: 183B-416027-WO Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; (iv) R1is absent, and either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; (v) R1is dPro, and R2is Aad; or (vi) R1is Nle, and (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is dPro, X1is dVal, and R2is Glu, (iv) R1is Dmt and R3is Pro; or (v) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab, or (d) R3is β-Ala, and R2is Glu or Orn; when R4is dTrp, then R3is Pro-Pro; and when R4is dNal(1’), then R3is Pro-Pro.

2. The non-naturally occurring melanocortin analog of claim 1, wherein: X1is absent or D-valine (dVal); R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das);Docket No.: 183B-416027-WO R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), prolyl-glycine (Pro-Gly), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D- histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is selected from the group consisting of tryptophan (Trp), D-tryptophan (dTrp), D- phenylalanine (dPhe), para-chloro-D-phenylalanine (p(Cl)dPhe), para-fluoro-D- phenylalanine (p(F)dPhe), 2’-D-naphthylalanine (dNal(2’)), 1’-D-naphthylalanine (dNal(1’)), and 1’-naphthylalanine ((Nal(1’)); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, dTrp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), Nle, and dPro; Y2is absent, dPro, or Nle; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of:Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4) Ac-Nle-c[Asp-His-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5) Ac-Nle-c[Asp-Pro-dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 6) Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 7) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 8) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 9) Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 10) Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 11) Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12) Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 13) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 16) Ac-Nle-c[Asp-dHis-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 17) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 18) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 19) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 20) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 22) Ac-Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 23) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24)Docket No.: 183B-416027-WO Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 25) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 26) Ac-Glu-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 27) Ac-Nle-c[Asp-Lys-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28) Ac-Nle-c[Asp-dAla-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29) Ac-dVal-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 30) Ac-Nle-c[Glu-Trp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 32) Ac-Nle-c[Lys-Trp-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 33) Ac-Nle-c[Orn-Trp-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 34) Ac-Nle-c[Dab-Trp-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 35) Ac-Nle-c[Aad-Trp-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 36) Ac-Nle-c[Glu-Pro-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 37) Ac-Nle-c[Lys-Pro-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 38) Ac-Nle-c[Dab-Pro-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 39) Ac-Nle-c[Asp-His-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 40) Ac-Nle-c[Glu-His-dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 41) Ac-Nle-c[Lys-His-dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 42) Ac-Nle-c[Orn-His-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 43) Ac-Nle-c[Dab-His-dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 44) Ac-Nle-c[Aad-His-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 45) Ac-dAsn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 46) Ac-dAsn-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 47) Ac-dAsn-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 48) Ac-dAsn-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 49)Docket No.: 183B-416027-WO Ac-dAsn-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 50) Ac-dAsn-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 51) Ac-dAsn-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 52) Ac-dAsn-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 53) Ac-dAsn-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 54) Ac-dAsn-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 55) Ac-dAsn-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 56) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 57) c[CO-cis-CH=CH-CO-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 58) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 59) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 60) c[CO-cis-CH=CH-CO-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 61) Ac-Nle-c[Asp-β-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 63) Ac-Nle-c[Glu-β-Ala-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64) Ac-Nle-c[Lys-β-Ala-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 65) Ac-Nle-c[Orn-β-Ala-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 66) Ac-Nle-c[Dab-β-Ala-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 67) Ac-Nle-c[Aad-β-Ala-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 68) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 69) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 70) Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 71) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 72) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 73) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 74)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 75) Ac-Nle-c[Lys-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 76) Ac-Nle-c[Orn-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 77) Ac-Nle-c[Dab-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 78) Ac-Nle-c[Aad-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 79) Ac-Nle-c[Glu-Mamb-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 80) Ac-Nle-c[Lys-Mamb-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 81) Ac-Nle-c[Orn-Mamb-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 82) Ac-Nle-c[Dab-Mamb-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 83) Ac-Nle-c[Aad-Mamb-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 84) Ac-Ala-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 85) Ac-Ala-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 86) Ac-Ala-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 87) Ac-Ala-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 88) Ac-Ala-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 89) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 90) Ac-Ala-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 91) Ac-Ala-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 92) Ac-Nle-c[Glu-His-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 94) Ac-Nle-c[Lys-His-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 95) Ac-Nle-c[Orn-His-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 96) Ac-Nle-c[Dab-His-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 97) Ac-Nle-c[Aad-His-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 98) Ac-Nle-c[Glu-Pro-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 99)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 100) Ac-Nle-c[Orn-Pro-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 101) Ac-Nle-c[Dab-Pro-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 102) Ac-Nle-c[Aad-Pro-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 103) Ac-Nle-c[Asp-His-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 104) Ac-Nle-c[Glu-His-dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 105) Ac-Nle-c[Lys-His-dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 106) Ac-Nle-c[Orn-His-dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 107) Ac-Nle-c[Dab-His-dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 108) Ac-Nle-c[Aad-His-dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 109) Ac-Nle-c[Asp-Pro-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 110) Ac-Nle-c[Glu-Pro-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 111) Ac-Nle-c[Orn-Pro-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 112) Ac-Nle-c[Dab-Pro-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 113) Ac-Nle-c[Asp-His-dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 114) Ac-Nle-c[Glu-His-dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 115) Ac-Nle-c[Lys-His-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 116) Ac-Nle-c[Orn-His-dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 117) Ac-Nle-c[Dab-His-dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 118) Ac-Nle-c[Aad-His-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 119) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 120) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 121) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 122) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 123)Docket No.: 183B-416027-WO Ac-Nle-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 124) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 125) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 126) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 127) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 128) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 129) Ac-Nle-c[Aad-His-dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 130) Ac-dVal-dPro-c[Lys-Trp-Arg-dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 131) Ac-dVal-dPro-c[Orn-Trp-Arg-dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 132) Ac-dVal-dPro-c[Dab-Trp-Arg-dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 133) Ac-dVal-dPro-c[Aad-Trp-Arg-dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 134) Ac-dVal-dPro-c[Asp-Trp-Arg-dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 135) Ac-dVal-dPro-c[Glu-Trp-Arg-dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 136) Dmt-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 137) Dmt-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 138) Ac-dAla-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 139) Ac-dAla-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 140) Ac-dAla-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 141) Ac-dAla-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 142) Ac-dAla-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 143) Ac-dAla-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 144) Ac-dAla-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 145) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 146) Ac-dAla-c[Orn-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 147)Docket No.: 183B-416027-WO Ac-dAla-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 148) Ac-Nle-c[Asp-Pro-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 149) Ac-Nle-c[Glu-Pro-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 150) Ac-Nle-c[Lys-Pro-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 151) Ac-Nle-c[Orn-Pro-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 152) Ac-Nle-c[Aad-Pro-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 153) Ac-Nle-c[Asp-His-dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 154) Ac-Nle-c[Glu-His-dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 155) Ac-Nle-c[Lys-His-dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 156) Ac-Nle-c[Orn-His-dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 157) Ac-Nle-c[Orn-His-dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 158) Ac-Nle-c[Aad-His-dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 159) Ac-Nle-c[Glu-Pro-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 160) Ac-Nle-c[Lys-Pro-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 161) Ac-Nle-c[Orn-Pro-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 162) Ac-Nle-c[Aad-Pro-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 163) Ac-Glu-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 164) Ac-Glu-c[Glu-Pro-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 165) Ac-Glu-c[Lys-Pro-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 166) Ac-Glu-c[Orn-Pro-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 167) Ac-Glu-c[Dab-Pro-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 168) Ac-Glu-c[Aad-Pro-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 169) Ac-Glu-c[Asp-His-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 170) Ac-Glu-c[Glu-His-dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 171)Docket No.: 183B-416027-WO Ac-Glu-c[Lys-His-dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 172) Ac-Glu-c[Orn-His-dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 173) Ac-Glu-c[Dab-His-dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 174) Ac-Glu-c[Aad-His-dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 175) Ac-Nle-c[Asp-Pro-Gly-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 176) Ac-Nle-c[Lys-Pro-Gly-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 177) Ac-Nle-c[Orn-Pro-Gly-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 178) Ac-Nle-c[Aad-Pro-Gly-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 179) Ac-Nle-c[Dab-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 180) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 181) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 182) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 183) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 184) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 185) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 186) Ac-Nle-c[Dab-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 187) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 188) Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 189) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 190) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 191) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 192) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 193) Ac-Nle-c[Glu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194) Ac-Nle-c[Lys-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 195)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 201) Ac-Nle-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 202) Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 203) Ac-Nle-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 204) Ac-Nle-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 205) Ac-Nle-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 206) Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 14) Ac-Nle-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 207) Ac-dGln-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215) Ac-dGln-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 216) Ac-dGln-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 217) Ac-dGln-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 218) Ac-dGln-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 219) Ac-dGln-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 220) Ac-dGln-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 221) Ac-dGln-c[Glu-His-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 222) Ac-dGln-c[Lys-His-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 223) Ac-dGln-c[Orn-His-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 224) Ac-dGln-c[Dab-His-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 225) Ac-dGln-c[Aad-His-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 226) Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 227)Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 237) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 238) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 239)Docket No.: 183B-416027-WO Ac-Glu-c[Asp-Pro-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 240) Ac-Glu-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 241) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 242) Ac-Glu-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 243) Ac-Glu-c[Lys-Pro-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 244) Ac-Glu-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 245) Ac-Glu-c[Orn-Pro-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 246) Ac-Glu-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 247) Ac-Glu-c[Dab-Pro-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 248) Ac-Glu-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 249) Ac-Glu-c[Aad-Pro-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 250) Ac-Glu-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 251) Ac-Glu-c[Asp-His-p(F)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 252) Ac-Glu-c[Asp-His-p(Cl)dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 253) Ac-Glu-c[Glu-His-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 254) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 255) Ac-Glu-c[Glu-His-p(Cl)dPhe-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 256) Ac-Glu-c[Lys-His-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 257) Ac-Glu-c[Lys-His-p(F)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 258) Ac-Glu-c[Lys-His-p(Cl)dPhe-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 259) Ac-Glu-c[Orn-His-p(F)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 260) Ac-Glu-c[Orn-His-p(Cl)dPhe-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 261) Ac-Glu-c[Dab-His-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 262) Ac-Glu-c[Dab-His-p(F)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 263)Docket No.: 183B-416027-WO Ac-Glu-c[Dab-His-p(Cl)dPhe-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 264) Ac-Glu-c[Aad-His-p(F)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 265) Ac-Glu-c[Aad-His-p(Cl)dPhe-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 266) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268) Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 269) Ac-Nle-c[Asp-dHis-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 271) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 272) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 273) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 274) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 276) Ac-Nle-c[Asp-Trp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 277) Ac-Nle-c[Glu-Trp-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 278) Ac-Nle-c[Lys-Trp-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 279) Ac-Nle-c[Aad-Trp-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 280) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 281) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 282) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 283) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 284) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 285) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 286) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 287) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 288)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 289) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 290) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 291) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 292) Ac-dGln-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 293) Ac-dGln-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 294) Ac-dGln-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 295) Ac-dGln-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 296) Ac-dGln-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 297) Ac-dGln-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 298) Ac-dGln-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299) Ac-dGln-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 300) Ac-dGln-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 301) Ac-dGln-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 302) Ac-dGln-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 303) Ac-dGln-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 304) Ac-dAsn-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305) Ac-dAsn-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 306) Ac-dAsn-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 307) Ac-dAsn-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 308) Ac-dAsn-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 309) Ac-dAsn-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 310) Ac-dAsn-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311) Ac-dAsn-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 312)Docket No.: 183B-416027-WO Ac-dAsn-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 313) Ac-dAsn-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 314) Ac-dAsn-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 315) Ac-dAsn-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 316) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 317) c[CO-cis-CH=CH-CO-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 318) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 319) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 320) c[CO-cis-CH=CH-CO-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 321) Ac-Nle-c[Glu-β-Ala-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322) Ac-Nle-c[Lys-β-Ala-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 323) Ac-Nle-c[Orn-β-Ala-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 324) Ac-Nle-c[Aad-β-Ala-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 325) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 326) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 327) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 328) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 329) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 330) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 331) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 332) Ac-Nle-c[Orn-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 333) Ac-Nle-c[Dab-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 334) Ac-Nle-c[Aad-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 335) Ac-Nle-c[Aad-Mamb-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 336)Docket No.: 183B-416027-WO Ac-Ala-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 337) Ac-Ala-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 338) Ac-Ala-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 339) Ac-Ala-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 340) Ac-Ala-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 341) Ac-Ala-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 342) Ac-Ala-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 343) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 344) Ac-Ala-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 345) Ac-Ala-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 346) Ac-Nle-c[Asp-His-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 347) Ac-Nle-c[Glu-His-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 348) Ac-Nle-c[Lys-His-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 349) Ac-Nle-c[Orn-His-p(Cl)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 350) Ac-Nle-c[Dab-His-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 351) Ac-Nle-c[Aad-His-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 352) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 353) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 354) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 355) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 356) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 357) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 359) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 360)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 361) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 362) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 363) Ac-Nle-c[Asp-His-p(Cl)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364) Ac-Nle-c[Glu-His-p(Cl)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 365) Ac-Nle-c[Lys-His-p(Cl)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 366) Ac-Nle-c[Orn-His-p(Cl)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 367) Ac-Nle-c[Dab-His-p(Cl)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 368) Ac-Nle-c[Aad-His-p(Cl)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 369) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 370) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 371) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 372) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 373) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 374) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 375) Ac-Nle-c[Asp-His-p(Cl)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 376) Ac-Nle-c[Glu-His-p(Cl)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 377) Ac-Nle-c[Lys-His-p(Cl)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 378) Ac-Nle-c[Orn-His-p(Cl)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 379) Ac-Nle-c[Dab-His-p(Cl)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 380) Ac-Nle-c[Aad-His-p(Cl)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 381) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 382) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 383) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 384)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 385) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 386) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 387) Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 388) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 389) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 390) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 391) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 392) Ac-Nle-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 393) Ac-dVal-dPro-c[Lys-Trp-Arg-p(Cl)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 394) Ac-dVal-dPro-c[Asp-Trp-Arg-p(Cl)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 395) Ac-dVal-dPro-c[Glu-Trp-Arg-p(Cl)dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 396) Dmt-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 397) Dmt-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 398) Dmt-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 399) Dmt-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 400) Dmt-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 401) Dmt-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 402) Ac-dAla-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 403) Ac-dAla-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 404) Ac-dAla-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 405) Ac-dAla-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 406) Ac-dAla-c[Aad-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 407) Ac-dAla-c[Glu-His-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 408)Docket No.: 183B-416027-WO Ac-dAla-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 409) Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 410) Ac-dAla-c[Orn-His-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 411) Ac-dAla-c[Aad-His-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 412) Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413) Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 414) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 415) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 416) Ac-Nle-c[Aad-Pro-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 417) Ac-Nle-c[Glu-His-p(Cl)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 418) Ac-Nle-c[Lys-His-p(Cl)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 419) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 420) Ac-Nle-c[Orn-His-p(Cl)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 421) Ac-Nle-c[Aad-His-p(Cl)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 422) Ac-Nle-c[Glu-Pro-Pro-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 423) Ac-Nle-c[Lys-Pro-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 424) Ac-Nle-c[Orn-Pro-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 425) Ac-Nle-c[Aad-Pro-Pro-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 426) Ac-Nle-c[Asp-Pro-Gly-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427) Ac-Nle-c[Glu-Pro-Gly-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 428) Ac-Nle-c[Lys-Pro-Gly-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 429) Ac-Nle-c[Orn-Pro-Gly-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 430) Ac-Nle-c[Aad-Pro-Gly-p(Cl)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 431) Ac-Nle-c[Dab-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 432)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 433) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 434) Ac-Nle-c[Lys-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 435) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 436) Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 437) Ac-Nle-c[Dab-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 438) Ac-Nle-c[Glu-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 440) Ac-Nle-c[Lys-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 441) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 442) Ac-Nle-c[Orn-His-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 443) Ac-Nle-c[Glu-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444) Ac-Nle-c[Lys-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 445) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-NH2 (SEQ ID NO: 446) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-NH2 (SEQ ID NO: 447) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 448) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-Nle-NH2 (SEQ ID NO: 449) Ac-dVal-dPro-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 450) Ac-dVal-dPro-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 451) Ac-dVal-dPro-c[Lys-Trp-Arg-p(F)dPhe-Pro-Asp]-Nle-Nle-NH2 (SEQ ID NO: 452) Ac-dVal-dPro-c[Orn-Trp-Arg-dNal(2')-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 453) Ac-dVal-dPro-c[Orn-Trp-Arg-p(F)dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 454) Ac-dVal-dPro-c[Dab-Trp-Arg-dNal(2')-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 455) Ac-dVal-dPro-c[Dab-Trp-Arg-p(F)dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 456)Docket No.: 183B-416027-WO Ac-dVal-dPro-c[Aad-Trp-Arg-p(F)dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 457) Ac-dVal-dPro-c[Asp-Trp-Arg-p(F)dPhe-Pro-Lys]-Nle-Nle-NH2 (SEQ ID NO: 458) Ac-dVal-dPro-c[Glu-Trp-Arg-dNal(2')-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 459) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 460) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 461) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 462) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 463) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 464) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-dPro-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 467) Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468) Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470) c[CO-cis-CH = CH-CO-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471) Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472) Ac-dGln-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 473) Ac-dAsn-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 474) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 475) Ac-Nle-c[Asp-His-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 476) Ac-Nle-c[Asp-Pro-dNal(2')-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 477) Dmt-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 478) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 479) Ac-Nle-c[dAsp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 480)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 481) Ac-Nle-c[Asp-Trp-Arg-dNal(2')-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 482) Ac-Nle-c[Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 483) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 484) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 485) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 486) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 487) Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488) Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489) Ac-Nle-c[Asp-Pro-Gly-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 490) Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491) Ac-Nle-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492) Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493) Ac-Nle-c[Asp-Pro-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494) Ac-Nle-c[Asp-Pro-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495) Ac-Nle-c[Asp-Pro-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Lys]-dVal-dPro-NH2 (SEQ ID NO: 497) Ac-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 498) Ac-Nle-c[Glu-Trp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 503) Ac-Nle-c[Lys-Trp-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 504) Ac-Nle-c[Orn-Trp-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 505) Ac-Nle-c[Dab-Trp-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 506) Ac-Nle-c[Aad-Trp-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 507) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 508)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 509) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 510) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 511) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 512) Ac-Nle-c[Asp-His-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 513) Ac-Nle-c[Glu-His-dNal(2')-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 514) Ac-Nle-c[Lys-His-dNal(2')-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 515) Ac-Nle-c[Orn-His-dNal(2')-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 516) Ac-Nle-c[Dab-His-dNal(2')-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 517) Ac-Nle-c[Aad-His-dNal(2')-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 518) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 519) Ac-dGln-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 520) Ac-dGln-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 521) Ac-dGln-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 522) Ac-dGln-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 523) Ac-dGln-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 524) Ac-dGln-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 525) Ac-dGln-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 526) Ac-dGln-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 527) Ac-dGln-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 528) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 529) Ac-dAsn-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 530) Ac-dAsn-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 531) Ac-dAsn-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 532)Docket No.: 183B-416027-WO Ac-dAsn-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 533) Ac-dAsn-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 534) Ac-dAsn-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 535) Ac-dAsn-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 536) Ac-dAsn-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 537) Ac-dAsn-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 538) c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 539) c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 541) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 542) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 543) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 544) Ac-Nle-c[Glu-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 545) Ac-Nle-c[Orn-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 546) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 547) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 548) Ac-Nle-c[Aad-Mamb-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 549) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 550) Ac-Ala-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 551) Ac-Ala-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 552) Ac-Ala-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 553) Ac-Ala-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 554) Ac-Ala-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 555) Ac-Ala-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 556)Docket No.: 183B-416027-WO Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 557) Ac-Ala-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 558) Ac-Ala-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 559) Ac-Nle-c[Glu-His-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 561) Ac-Nle-c[Lys-His-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 562) Ac-Nle-c[Orn-His-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 563) Ac-Nle-c[Dab-His-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 564) Ac-Nle-c[Aad-His-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 565) Ac-Nle-c[Glu-Pro-dNal(2')-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 566) Ac-Nle-c[Lys-Pro-dNal(2')-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 567) Ac-Nle-c[Orn-Pro-dNal(2')-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 568) Ac-Nle-c[Dab-Pro-dNal(2')-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 569) Ac-Nle-c[Aad-Pro-dNal(2')-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 570) Ac-Nle-c[Glu-Pro-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 571) Ac-Nle-c[Lys-Pro-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 572) Ac-Nle-c[Orn-Pro-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 573) Ac-Nle-c[Dab-Pro-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 574) Ac-Nle-c[Aad-Pro-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 575) Ac-Nle-c[Asp-His-dNal(2')-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 576) Ac-Nle-c[Glu-His-dNal(2')-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 577) Ac-Nle-c[Lys-His-dNal(2')-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 578) Ac-Nle-c[Orn-His-dNal(2')-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 579) Ac-Nle-c[Dab-His-dNal(2')-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 580) Ac-Nle-c[Aad-His-dNal(2')-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 581)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 582) Ac-Nle-c[Lys-Pro-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 583) Ac-Nle-c[Orn-Pro-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 584) Ac-Nle-c[Dab-Pro-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 585) Ac-Nle-c[Aad-Pro-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 586) Ac-Nle-c[Asp-His-dNal(2')-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 587) Ac-Nle-c[Glu-His-dNal(2')-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 588) Ac-Nle-c[Lys-His-dNal(2')-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 589) Ac-Nle-c[Orn-His-dNal(2')-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 590) Ac-Nle-c[Dab-His-dNal(2')-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 591) Ac-Nle-c[Aad-His-dNal(2')-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 592) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 593) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 594) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 595) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 596) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 597) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 598) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 599) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 600) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 601) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 602) Ac-Nle-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 603) Dmt-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 604) Dmt-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 605)Docket No.: 183B-416027-WO Dmt-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 606) Dmt-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 607) Dmt-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 608) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 609) Ac-dAla-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 610) Ac-dAla-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 611) Ac-dAla-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 612) Ac-dAla-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 613) Ac-dAla-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 614) Ac-dAla-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 615) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 616) Ac-dAla-c[Orn-His-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 617) Ac-dAla-c[Aad-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 618) Ac-Nle-c[Glu-Pro-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 619) Ac-Nle-c[Lys-Pro-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 620) Ac-Nle-c[Orn-Pro-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 621) Ac-Nle-c[Aad-Pro-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 622) Ac-Nle-c[Asp-His-dNal(2')-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 623) Ac-Nle-c[Glu-His-dNal(2')-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 624) Ac-Nle-c[Lys-His-dNal(2')-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 625) Ac-Nle-c[Orn-His-dNal(2')-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 626) Ac-Nle-c[Orn-His-dNal(2')-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 627) Ac-Nle-c[Aad-His-dNal(2')-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 628) Ac-Nle-c[Glu-Pro-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 629)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 630) Ac-Nle-c[Orn-Pro-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 631) Ac-Nle-c[Glu-Pro-Gly-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 632) Ac-Nle-c[Lys-Pro-Gly-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 633) Ac-Nle-c[Orn-Pro-Gly-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 634) Ac-Nle-c[Aad-Pro-Gly-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 635) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 636) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 637) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 638) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 639) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 640) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 641) Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 642) Ac-Nle-c[Dab-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 643) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 644) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 645) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 646) Ac-Nle-c[Lys-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 647) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 648) Ac-Nle-c[Orn-His-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 649) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 650) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 651) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 465) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 652)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 653) Ac-Nle-c[Glu-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 654) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Dab]-dArg-dPro-NH2 (SEQ ID NO: 655) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 656) Ac-Nle-c[Aad-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 657) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 658) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 659) Ac-Nle-c[Dab-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 660) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 661) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 662) Ac-Nle-c[Orn-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 663) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Asp]-dArg-dPro-NH2 (SEQ ID NO: 664) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Glu]-dArg-dPro-NH2 (SEQ ID NO: 665) Ac-Nle-c[Lys-Pro-dNal(2')-Arg-Trp-Aad]-dArg-dPro-NH2 (SEQ ID NO: 666) Ac-Nle-c[Glu-His-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 667) Ac-Ala-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 668) Ac-dAla-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 669) Ac-dGln-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 670) Ac-dAsn-c[Glu-Pro-dNal(2')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 671) Ac-Glu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 672) Ac-dGln-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 673) Ac-dGln-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 674) Ac-Nle-c[Aad-dNal(2')-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 675) Ac-Nle-c[Dab-dNal(2')-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 676)Docket No.: 183B-416027-WO Ac-Nle-c[dAsp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 677) Ac-Nle-c[dLys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 678) Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 679) Ac-Nle-c[Asp-β-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 680) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 681) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 682) Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 683) Ac-Nle-c[Asp-dHis-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 684) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 685) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 686) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 687) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 688) Ac-Nle-c[Asp-Trp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 689) Ac-Nle-c[Glu-Trp-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 690) Ac-Nle-c[Lys-Trp-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 691) Ac-Nle-c[Orn-Trp-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 692) Ac-Nle-c[Dab-Trp-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 693) Ac-Nle-c[Aad-Trp-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 694) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 695) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 696) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 697) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 698) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 699) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-dTrp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 700)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-His-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 701) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 702) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-dTrp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 703) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 704) Ac-dAsn-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 705) Ac-dAsn-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 706) Ac-dAsn-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 707) Ac-dAsn-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 708) Ac-dAsn-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 709) Ac-dAsn-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 710) Ac-dAsn-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 711) Ac-dAsn-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 712) Ac-dAsn-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 713) Ac-dAsn-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 714) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 715) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 716) c[CO-cis-CH=CH-CO-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 717) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 718) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 719) c[CO-cis-CH=CH-CO-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 720) Ac-Nle-c[Asp-β-Ala-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 721) Ac-Nle-c[Lys-β-Ala-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 722) Ac-Nle-c[Dab-β-Ala-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 723) Ac-Nle-c[Aad-β-Ala-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 724)Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 725) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 726) Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 727) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 728) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 729) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 730) Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 731) Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 732) Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 733) Ac-Nle-c[Glu-Mamb-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 734) Ac-Nle-c[Lys-Mamb-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 735) Ac-Nle-c[Orn-Mamb-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 736) Ac-Nle-c[Dab-Mamb-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 737) Ac-Nle-c[Aad-Mamb-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 738) Ac-Nle-c[Asp-His-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 739) Ac-Nle-c[Glu-His-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 740) Ac-Nle-c[Lys-His-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 741) Ac-Nle-c[Orn-His-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 742) Ac-Nle-c[Dab-His-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 743) Ac-Nle-c[Aad-His-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 744) Ac-Nle-c[Lys-Pro-p(F)dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 745) Ac-Nle-c[Asp-Pro-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 746) Ac-Nle-c[Glu-Pro-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 747) Ac-Nle-c[Lys-Pro-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 748)Docket No.: 183B-416027-WO Ac-Nle-c[Orn-Pro-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 749) Ac-Nle-c[Dab-Pro-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 750) Ac-Nle-c[Aad-Pro-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 751) Ac-Nle-c[Asp-His-p(F)dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 752) Ac-Nle-c[Glu-His-p(F)dPhe-Gly-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 753) Ac-Nle-c[Lys-His-p(F)dPhe-Gly-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 754) Ac-Nle-c[Orn-His-p(F)dPhe-Gly-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 755) Ac-Nle-c[Aad-His-p(F)dPhe-Gly-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 756) Ac-Nle-c[Asp-Pro-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 757) Ac-Nle-c[Glu-Pro-p(F)dPhe-Asp-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 758) Ac-Nle-c[Lys-Pro-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 759) Ac-Nle-c[Orn-Pro-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 760) Ac-Nle-c[Asp-His-p(F)dPhe-Asp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 761) Ac-Nle-c[Lys-His-p(F)dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 762) Ac-Nle-c[Orn-His-p(F)dPhe-Asp-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 763) Ac-Nle-c[Dab-His-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 764) Ac-Nle-c[Aad-His-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 765) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 766) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 767) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 768) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 769) Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 770) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 771) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dArg-NH2 (SEQ ID NO: 772)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dArg-NH2 (SEQ ID NO: 773) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dArg-NH2 (SEQ ID NO: 774) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dArg-NH2 (SEQ ID NO: 775) Ac-Nle-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dArg-NH2 (SEQ ID NO: 776) Ac-Nle-c[Glu-Pro-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 777) Ac-Nle-c[Orn-Pro-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 778) Ac-Nle-c[Aad-Pro-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 779) Ac-Nle-c[Glu-His-p(F)dPhe-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 780) Ac-Nle-c[Lys-His-p(F)dPhe-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 781) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 782) Ac-Nle-c[Orn-His-p(F)dPhe-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 783) Ac-Nle-c[Aad-His-p(F)dPhe-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 784) Ac-Nle-c[Asp-Pro-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 785) Ac-Nle-c[Glu-Pro-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 786) Ac-Nle-c[Lys-Pro-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 787) Ac-Nle-c[Orn-Pro-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 788) Ac-Nle-c[Aad-Pro-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 789) Ac-Nle-c[Glu-Pro-Gly-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 790) Ac-Nle-c[Lys-Pro-Gly-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 791) Ac-Nle-c[Orn-Pro-Gly-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 792) Ac-Nle-c[Aad-Pro-Gly-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 793) Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 794) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 795) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 796)Docket No.: 183B-416027-WO Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 797) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 798) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 799) Ac-Nle-c[Dab-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 800) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 801) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 802) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 803) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 804) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 805) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 806) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 807) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dArg-dPro-NH3 (SEQ ID NO: 808) Ac-Glu-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 809) Ac-dAsn-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 810) Ac-Glu-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 811) Ac-dAsn-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 812) Ac-Nle-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 820) Ac-Nle-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 821) Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 822) Ac-Nle-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 823) Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-OH (SEQ ID NO: 824) Ac-Nle-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-OH (SEQ ID NO: 825) Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 826) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-OH (SEQ ID NO: 827)Docket No.: 183B-416027-WO Ac-Nle-c[Glu-His-Trp-Arg-p(F)dPhe-Orn]-dVal-dPro-NH2 (SEQ ID NO: 836) Ac-Nle-c[Asp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 837) Ac-Nle-c[Glu-p(F)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 838) Ac-Nle-c[Lys-p(F)dPhe-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 839) Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 840) Ac-Nle-c[Das-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 841) Ac-Nle-c[Lys-Pro-p(F)dPhe-Arg-dTrp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 843) Ac-Nle-c[Asp-Pro-d(F)Phe-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 844) Ac-Nle-c[Asp-Pro-Gly-d(F)Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 845) Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 846) Ac-Ala-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 847) Ac-Ala-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 848) Ac-Ala-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 849) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 850) Ac-Ala-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 851) Ac-Ala-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 852) Ac-dAla-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 853) Ac-dAla-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 854) Ac-dAla-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 855) Ac-dAla-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 856) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 857) Ac-dAla-c[Orn-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 858) Ac-dAla-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 859) Ac-Ala-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 860)Docket No.: 183B-416027-WO Ac-dAla-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 861) Ac-Ala-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 862) Ac-dAla-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 863) Ac-dGln-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 864) Ac-dGln-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 865) Ac-dGln-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 866) Ac-dGln-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 867) Ac-dGln-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 868) Ac-dGln-c[Lys-His-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 869) Ac-dGln-c[Orn-His-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 870) Ac-dGln-c[Dab-His-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 871) Ac-dGln-c[Aad-His-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 872) Ac-dGln-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 873) Ac-dGln-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 874) Ac-dPro-c[Glu-His-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 875) Ac-dPro-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 876) Ac-Nle-c[Asp-Pro-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 877) Ac-Nle-c[Glu-Pro-dNal(1')-Arg-Trp-Orn]-dArg-dPro-NH2 (SEQ ID NO: 878) and Ac-Nle-c[Asp-Pro-Gly-dNal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 879), wherein c represents cyclization through a lactam bond between R2and R7.

3. The non-naturally occurring melanocortin analog of claim 1 or 2, wherein the sequence of Formula (IA) is a sequence of Formula (IB): R1-R2-R3-R4-R5-R6-R7-Y1-Y2Y3-Y4(IB), wherein:Docket No.: 183B-416027-WO R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D- glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D-histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is 2’-D-naphthylalanine (dNal(2’)); R5is arginine (Arg), or Pro; R6is absent, Trp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), and dPro; Y2is absent, or dPro; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, andDocket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when Y3is Lys, then R1is Glu, and either R3is His and R2is notGlu, Lys, or Dab, or R3is Pro and R2is not Asp; when R1is dAsn, then, R2is Asp and R3is Ala, dAla, dHis, His, or Lys; when R1is dGln, then R2is Asp and R3is dAla, His, or dHis; when R1is Glu, then Y4is Asp, and either (a) R3is His and R2is Aad, Asp, or Orn, or (b) R3is Pro and R2is not Asp; when R1is absent, then either (a) R3is Trp-Pro, or (b) R2is CO-cis-CH=CH-CO and R3is His or Pro, wherein when R3is His, then R7is Dab or Orn, and when R3is Pro, then R7is Dab and Y1-Y2is dVal-dPro; and when R1is Nle, then (a) R3is absent and R2is Das, Apm, Asp, Glu, hLys, Lys, or Orn, wherein when R2is Apm, then R7is Dap or dDap, when R2is Asp, then R7is dLys, when R2is Glu, then R7is dOrn, when if R2is Lys, then R7is Asp or dAsp, and when R2is Orn, then R7is dGlu; (b) R3is Pro-Pro, and R2is Aad, (c) R3is His, R2is Asp, and R7is dOrn; or (d) R3is Mamb, and R2is Glu, Lys, Orn or Dab.

4. The non-naturally occurring melanocortin analog of any one of claims 1-3, wherein: R1is absent or is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), D-asparagine (dAsn), D-proline (dPro), glutamic acid (Glu), and D- glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das);Docket No.: 183B-416027-WO R3is absent or is selected from the group consisting of prolyl-proline (Pro-Pro), tryptyl-proline (Trp-Pro), tryptyl-arginine (Trp-Arg), proline (Pro), lysine (Lys), histidine (His), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), D-histidine (dHis), alanine (Ala), and D-alanine (dAla); R4is 2’-D-naphthylalanine (dNal(2’)); R5is arginine (Arg), or Pro; R6is absent, Trp, or tryptyl-glycine (Trp-Gly); R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is selected from the group consisting of dVal, D-arginine (dArg), and dPro; Y2is absent, or dPro; Y3is absent or Lys; Y4is absent or Asp; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of SEQ ID NOs: 238–239, 254, 257, 262, 446– 451, 453, 455, 459-498, 503-556, 561–580, 593–631, and 636–680.

5. The non-naturally occurring melanocortin analog of claim 1 or 2, wherein the sequence of Formula (IA) is a sequence of Formula (IC):Docket No.: 183B-416027-WO R1-R2-R3-R4-R5-R6-R7-Y1-Y2(IC), wherein: R1is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), CO-cis-CH=CH-CO, lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β- dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-glycine (Pro-Gly), proline (Pro), histidine (His), and 3-aminomethylbenzoic acid (Mamb); R4is D-phenylalanine (dPhe) or para-fluoro-D-phenylalanine (p(F)dPhe); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, or dTrp; R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is dVal; Y2is dPro; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, andDocket No.: 183B-416027-WO a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that: when R4is dPhe, then X1is absent, R1is Nle, Dmt, dAsn, or Ala and (i) R3is Mamb, and R2is Asp; (ii) R3is His, and R5is Hyp or dPro; (iii) R3is Pro-Gly, andR2is Glu; or (iv) R3is Pro, R5is not absent, R6is not Trp-Gly, and either and (a) R1is dAsn and R2is Lys, (b) R1is Dmt and R2is Orn, Dab, Glu, or Aad, (c) R1is Ala and R2is Orn or Aad, or (d) R1is Nle and either R5is Pro and R2is not Asp, R5is Asp, and R2is Lys or Aad; R5is Gly and R2is Asp, or R6is dTrp and R2is Aad or Orn; when R4is p(F)dPhe, then either (i) R1is Ala or dAla, R2is Orn, and R3is Pro, (ii) R1is dGln, R2is Dab, and R3is Pro, (iii) R1is Dmt and R3is Pro; or (iv) R1is Nle and (a) R3is absent and R2is Aad, Apm, Dab, dAsp, dLys, or Orn, wherein when R2is Aad, then R6is dDab; when R2is Apm, then R7is dDap, when R2is Dab, then R7is dAad, and when R2is Orn, then R7is dGlu; (b) R3is Pro and either (i) R6is dTrp and R2is Aad, (ii) R6is absent and R2is Lys, (iii) R5is Asp and R2is Aad or Dab; or (iv) R5is Pro, and R2is not Lys; (c) R3is His, R5is Gly, and R2is Dab.

6. The non-naturally occurring melanocortin analog of any one of claims 1, 2, and 5, wherein: R1is selected from the group consisting of dimethyltyrosine (Dmt), norleucine (Nle), alanine (Ala), D-alanine (dAla), D-asparagine (dAsn), glutamic acid (Glu), and D-glutamine (dGln); R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), Glu, aspartame (Apm), homolysine (hLys), lysine (Lys), D-lysine (dLys), ornithine (Orn), aminoadipic acid (Aad), 2,4-diaminobutyric acid (Dab), and β-dimethylaspartic acid (Das); R3is absent or is selected from the group consisting of prolyl-glycine (Pro-Gly), proline (Pro), histidine (His), and 3-aminomethylbenzoic acid (Mamb); R4is D-phenylalanine (dPhe) or para-fluoro-D-phenylalanine (p(F)dPhe); R5is absent or is selected from the group consisting of arginine (Arg), hydroxyproline (Hyp), D-proline (dPro), Asp, glycine (Gly), and Pro; R6is absent, Trp, or dTrp;Docket No.: 183B-416027-WO R7is selected from the group consisting of Lys, dLys, Orn, D-ornithine (dOrn), Asp, D-aspartic acid (dAsp), Glu, D-glutamic acid (dGlu), Aad, aminoadipic acid (dAad), Dab, 2,4- D-diaminobutyric acid (dDab), 2,3-diaminopropionic acid (Dap), 2,3-D-diaminopropionic acid (dDap), and Dab; Y1is dVal; Y2is dPro; and the non-naturally occurring melanocortin analog is cyclized via a moiety selected from the group consisting of: a lactam bond between R2and R7, when R2is CO-cis-CH=CH-CO, Glu, Asp, dAsp, Aad, or Das, and R7is Lys, dLys, Orn, dOrn, Dab, dDab, or dDab; a lactam bond between R2and R7, when R2is Apm, R3is absent, and R7is Dap or dDap, a lactam bond between R2and R7, when R2is hLys, R3is absent, R3is dNal(2’), and R7is Aad or dDap, and a lactam bond between R2and R7, when R2is Orn, Dab, Dap, Lys, dLys, and R7is Asp, dAsp, Aad, dAad, Glu, or dGlu, provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of SEQ ID NOs: 2–12, 14–17, 21–23, 25–30, 32–61, 63–92, 94–119, 137–159, 176–195, 201–207, 215–227, 681–714, 725–765, 777– 784, 790–812, 820–827, 837–841, and 843–874.

7. The non-naturally occurring melanocortin analog of any one of claims 1-6, wherein the N-terminus of the sequence of Formula (I) is acylated.

8. The non-naturally occurring melanocortin analog of any one of claims 1-7, wherein the N-terminus of the sequence of Formula (I) is acetylated.

9. The non-naturally occurring melanocortin analog of any one of claims 1-6, wherein the N-terminus of the sequence of Formula (I) is not modified.Docket No.: 183B-416027-WO 10. The non-naturally occurring melanocortin analog of any one of claims 1-9, wherein the C-terminus of the sequence of Formula (I) is amidated.

11. The non-naturally occurring melanocortin analog of any one of claims 1-9, wherein the C-terminus of the sequence of Formula (I) is not modified.

12. The non-naturally occurring melanocortin analog of claim 1 or 2, wherein X1is dVal and R1is dPro.

13. The non-naturally occurring melanocortin analog of any one of claims 1, 2 and 12, wherein the sequence of Formula (IA) is selected from the group consisting of: Ac-dVal-dPro-c[Orn-Trp-Arg-p(Cl)dPhe-Pro-Glu]-Nle-Nle-NH2 (SEQ ID NO: 880); Ac-dVal-dPro-c[Dab-Trp-Arg-p(Cl)dPhe-Pro-Aad]-Nle-Nle-NH2 (SEQ ID NO: 881); Ac-dVal-dPro-c[Aad-Trp-Arg-dNal(2')-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 882); Ac-dVal-dPro-c[Aad-Trp-Arg-p(Cl)dPhe-Pro-Dab]-Nle-Nle-NH2 (SEQ ID NO: 883); and Ac-dVal-dPro-c[Glu-Trp-Arg-p(F)dPhe-Pro-Orn]-Nle-Nle-NH2 (SEQ ID NO: 884), wherein c represents cyclization through R2and R7via a lactam bond.

14. The non-naturally occurring melanocortin analog of any one of claims 1-11, wherein R1is dAsn or dGln.

15. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 14, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-dGln-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 885); Ac-dGln-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 886); Ac-dAsn-c[Lys-Pro-dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 887); Ac-dAsn-c[Asp-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 888); Ac-dGln-c[Asp-dHis-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 889);Docket No.: 183B-416027-WO Ac-dGln-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 890); Ac-dAsn-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 891); Ac-dAsn-c[Asp-dHis-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 892); Ac-dAsn-c[Asp-dAla-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 893); and Ac-dAsn-c[Asp-Lys-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 894), wherein c represents cyclization through R2and R7via a lactam bond.

16. The non-naturally occurring melanocortin analog of any one of claims 1-11, wherein R3is a dipeptide.

17. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 16, wherein R3is Trp-Pro, Pro-Pro, or Pro-Gly.

18. The non-naturally occurring melanocortin analog of any one of claims 1-11, 16, and 17, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Orn-Trp-Pro-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 896); Ac-Nle-c[Dab-Trp-Pro-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 897); Ac-Nle-c[Asp-Pro-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 898); Ac-Nle-c[Aad-Pro-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 899); Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 900); Ac-Nle-c[Asp-Pro-Pro-Trp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 901); Ac-Nle-c[Asp-Pro-Pro-dNal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 902); Ac-Nle-c[Asp-Pro-Pro-Nal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 903); Ac-Nle-c[Asp-Pro-Pro-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 904); Ac-Nle-c[Glu-Pro-Gly-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 905); Ac-Nle-c[Asp-Pro-Gly-Trp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 906);Docket No.: 183B-416027-WO Ac-Nle-c[Asp-Pro-Gly-Nal(1')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 907); Ac-Nle-c[Asp-Pro-Gly-dTrp-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 908), wherein c represents cyclization through R2and R7via a lactam bond.

19. The non-naturally occurring melanocortin analog of any one of claims 1-11, wherein R3is a noncanonical amino acid.

20. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 19, wherein R3is Mamb.

21. The non-naturally occurring melanocortin analog of any one of claims 1-11, 19, and 20, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Asp-Mamb-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 919); Ac-Nle-c[Asp-Mamb-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 920); Ac-Nle-c[Asp-Mamb-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 921); Ac-Nle-c[Asp-Mamb-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 922); Ac-Nle-c[Glu-Mamb-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 923); Ac-Nle-c[Glu-Mamb-p(Cl)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 924); Ac-Nle-c[Lys-Mamb-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 925); Ac-Nle-c[Lys-Mamb-p(Cl)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 926); Ac-Nle-c[Orn-Mamb-dNal(2')-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 927); Ac-Nle-c[Orn-Mamb-p(Cl)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 928); Ac-Nle-c[Dab-Mamb-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 929); and Ac-Nle-c[Dab-Mamb-p(Cl)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 930), wherein c represents cyclization through R2and R7via a lactam bond.Docket No.: 183B-416027-WO 22. The non-naturally occurring melanocortin analog of any one of claims 1-11, wherein R3is His or Pro.

23. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R1is Ala or dAla.

24. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 23, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Ala-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 931); Ac-Ala-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 932); Ac-Ala-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 933); and Ac-dAla-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 934), wherein c represents cyclization through R2and R7via a lactam bond.

25. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R1is Dmt.

26. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 25, wherein the sequence of Formula (I) is selected from the group consisting of: Dmt-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 935); Dmt-c[Glu-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 936); Dmt-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 937); Dmt-c[Lys-Pro-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 938); Dmt-c[Orn-Pro-dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 939); Dmt-c[Orn-Pro-p(F)dPhe-Arg-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 940); Dmt-c[Dab-Pro-dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 941); Dmt-c[Dab-Pro-p(F)dPhe-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 942); Dmt-c[Aad-Pro-dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 943); andDocket No.: 183B-416027-WO Dmt-c[Aad-Pro-p(F)dPhe-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 944), wherein c represents cyclization through R2and R7via a lactam bond.

27. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R5is Pro, dPro, or Hyp.

28. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 27, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 945); Ac-Nle-c[Glu-Pro-dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 946); Ac-Nle-c[Glu-Pro-p(F)dPhe-Pro-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 947); Ac-Nle-c[Lys-Pro-dPhe-Pro-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 948); Ac-Nle-c[Orn-Pro-dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 949); Ac-Nle-c[Orn-Pro-p(F)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 950); Ac-Nle-c[Orn-Pro-p(Cl)dPhe-Pro-Trp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 951); Ac-Nle-c[Dab-Pro-dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 952); Ac-Nle-c[Dab-Pro-p(F)dPhe-Pro-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 953); Ac-Nle-c[Aad-Pro-dPhe-Pro-Trp-Dab]-dVal-dPro-NH2; (SEQ ID NO: 954) Ac-Nle-c[Aad-Pro-p(F)dPhe-Pro-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 955); Ac-Nle-c[Asp-His-dPhe-Hyp-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 956); and Ac-Nle-c[Asp-His-dPhe-dPro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 957), wherein c represents cyclization through R2and R7via a lactam bond.

29. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R5is Gly or Asp.Docket No.: 183B-416027-WO 30. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 29, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Gly-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 958); Ac-Nle-c[Dab-His-p(F)dPhe-Gly-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 959); Ac-Nle-c[Lys-Pro-dPhe-Asp-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 960); Ac-Nle-c[Dab-Pro-p(F)dPhe-Asp-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 961); Ac-Nle-c[Aad-Pro-dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 962); and Ac-Nle-c[Aad-Pro-p(F)dPhe-Asp-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 963), wherein c represents cyclization through R2and R7via a lactam bond.

31. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R5is absent.

32. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 31, wherein the sequence of Formula (I) is: Ac-Nle-c[Lys-Pro-p(F)dPhe-Trp-Asp]- dVal-dPro-NH2 (SEQ ID NO: 964), wherein c represents cyclization through R2and R7via a lactam bond.

33. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R6is dTrp.

34. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 33, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Orn-Pro-dPhe-Arg-dTrp-Glu]-dVal-dPro-NH2 (SEQ ID NO: 965); Ac-Nle-c[Aad-Pro-dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 966); and Ac-Nle-c[Aad-Pro-p(F)dPhe-Arg-dTrp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 967), wherein c represents cyclization through R2and R7via a lactam bond.Docket No.: 183B-416027-WO 35. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein Y1is dArg.

36. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 31, wherein the sequence of Formula (I) is: Ac-Nle-c[Dab-Pro-p(F)dPhe-Arg-Trp- Aad]-dArg-NH2 (SEQ ID NO: 968), wherein c represents cyclization through R2and R7via a lactam bond.

37. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein Y1is dPro, Y2is dPro, Y3is Lys, and Y4is Asp.

38. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 37, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Glu-c[Glu-Pro-dNal(2')-Arg-Trp-Gly-Orn]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 969); Ac-Glu-c[Lys-Pro-dNal(2')-Arg-Trp-Gly-Asp]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 970); Ac-Glu-c[Orn-Pro-dNal(2')-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 971); Ac-Glu-c[Dab-Pro-dNal(2')-Arg-Trp-Gly-Aad]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 972); Ac-Glu-c[Aad-Pro-dNal(2')-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 973); Ac-Glu-c[Asp-His-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 974); Ac-Glu-c[Orn-His-dNal(2')-Arg-Trp-Gly-Glu]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 975); and Ac-Glu-c[Aad-His-dNal(2')-Arg-Trp-Gly-Dab]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 976), wherein c represents cyclization through R2and R7via a lactam bond.

39. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein the non-naturally occurring melanocortin analog is cyclized through a lactam bond between Asp at R2and dOrn at R7.Docket No.: 183B-416027-WO 40. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 37, wherein the sequence of Formula (I) is: Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 977); or Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 978), wherein c represents cyclization through R2and R7via a lactam bond.

41. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein the non-naturally occurring melanocortin analog is cyclized through a lactam bond between CO-cis-CH=CH-CO at R2and Lys, Dab, or Orn at R7.

42. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 37, wherein the sequence of Formula (I) is selected from the group consisting of: c[CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 981); c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Dab]-dVal-dPro-NH2 (SEQ ID NO: 982); and c[CO-cis-CH=CH-CO-His-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 983), wherein c represents cyclization through R2and R7via a lactam bond.

43. The non-naturally occurring melanocortin analog of any one of claims 1-11 and 22, wherein R3is absent.

44. The non-naturally occurring melanocortin analog of any one of claims 1-11, 22, and 33, wherein the sequence of Formula (I) is selected from the group consisting of: Ac-Nle-c[Asp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 984); Ac-Nle-c[Lys-dNal(2')-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 985); Ac-Nle-c[Asp-dNal(2')-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 986); Ac-Nle-c[Glu-dNal(2')-Arg-Trp-dOrn]-dVal-dPro-NH2 (SEQ ID NO: 987); Ac-Nle-c[Apm-dNal(2')-Arg-Trp-dDap]-dVal-dPro-NH2 (SEQ ID NO: 988); Ac-Nle-c[Lys-dNal(2')-Arg-Trp-dAsp]-dVal-dPro-NH2 (SEQ ID NO: 989);Docket No.: 183B-416027-WO Ac-Nle-c[Orn-dNal(2')-Arg-Trp-dGlu]-dVal-dPro-NH2 (SEQ ID NO: 990); Ac-Nle-c[Apm-dNal(2')-Arg-Trp-Dap]-dVal-dPro-NH2 (SEQ ID NO: 991); Ac-Nle-c[Aad-p(F)dPhe-Arg-Trp-dDab]-dVal-dPro-NH2 (SEQ ID NO: 992); Ac-Nle-c[Apm-p(F)dPhe-Arg-Trp-dDap]-dVal-dPro-NH2 (SEQ ID NO: 993); Ac-Nle-c[Orn-p(F)dPhe-Arg-Trp-dGlu]-dVal-dPro-NH2 (SEQ ID NO: 994); Ac-Nle-c[Dab-p(F)dPhe-Arg-Trp-dAad]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[dAsp-p(F)dPhe-Arg-Trp-dLys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[dLys-p(F)dPhe-Arg-Trp-Asp]-dVal-dPro-NH2 (SEQ ID NO: 230); Ac-Nle-c[Das-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 231); and Ac-Nle-c[hLys-dNal(2')-Arg-Trp-Aad]-dVal-dPro-NH2 (SEQ ID NO: 232), wherein c represents cyclization through R2and R7via a lactam bond.

45. The non-naturally occurring melanocortin analog of any one of claims 1-44, wherein the non-naturally occurring melanocortin analog is present in a pharmaceutical composition.

46. The non-naturally occurring melanocortin analog of claim 45, wherein the pharmaceutical composition further comprises a pharmaceutical salt.

47. The non-naturally occurring melanocortin analog of claim 45, wherein the pharmaceutical composition further comprises a pharmaceutical carrier.

48. The non-naturally occurring melanocortin analog of claim 47, wherein the pharmaceutical carrier comprises water.

49. The non-naturally occurring melanocortin analog of claim 45, wherein the non- naturally occurring melanocortin analog is present in the composition in a concentration of 0.1 mg / mL to 500 mg / mL, relative to a total volume of the composition.Docket No.: 183B-416027-WO 50. The non-naturally occurring melanocortin analog of claim 45, wherein the non- naturally occurring melanocortin analog is present in the composition in a concentration of 5 mg / mL to 100 mg / mL, relative to a total volume of the composition.

51. The non-naturally occurring melanocortin analog of claim 45, wherein the non- naturally occurring melanocortin analog is present in the composition in a concentration of about 50 mg / mL, relative to a total volume of the composition.

52. The non-naturally occurring melanocortin analog of any one of claims 1-51, wherein the non-naturally occurring melanocortin analog is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration to a subject in need thereof.

53. The non-naturally occurring melanocortin analog of any one of claims 45-52, wherein the composition comprising the non-naturally occurring melanocortin analog is administered to the subject parenterally.

54. The non-naturally occurring melanocortin analog of claim 53, wherein the composition comprising the non-naturally occurring melanocortin analog is administered to the subject subcutaneously.

55. The non-naturally occurring melanocortin analog of claim 53, wherein the non- naturally occurring melanocortin analog crosses the blood-brain-barrier of the subject.

56. The non-naturally occurring melanocortin analog of any one of claims 52-55, wherein a therapeutically effective amount of the non-naturally occurring melanocortin analog is from 0.001 mg / kg to 25 mg / kg per body weight of a subject.Docket No.: 183B-416027-WO 57. The non-naturally occurring melanocortin analog of claim 56, wherein the therapeutically effective amount of the non-naturally occurring melanocortin analog is from 0.5 mg / kg to 10 mg / kg per body weight of a subject.

58. The non-naturally occurring melanocortin analog of any one of claims 52-57, wherein the non-naturally occurring melanocortin analog is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg per body weight of a subject.

59. The non-naturally occurring melanocortin analog of any one of claims 52-57, wherein the non-naturally occurring melanocortin analog is administered at least once daily in an amount ranging from about 0.5 mg / kg to about 10 mg / kg per body weight of a subject.

60. The non-naturally occurring melanocortin analog of any one of claims 52-59, wherein the non-naturally occurring melanocortin analog is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

61. The non-naturally occurring melanocortin analog of any one of claims 52-59, wherein the non-naturally occurring melanocortin analog is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.

Images